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2-­‐AG      2-­‐arachidonoylglycerol  
ABHD12   a/b-­‐hydrolase  domain  contain  12  
ABHD6     a/b-­‐hydrolase  domain  contain  6  
AEA      N-­‐arachidonoylethanolamine;  anandamide  
AMPA      a-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic  acid  
ATP      Adenosine  triphosphate  
BBB      Brain  blood  barrier  
BDNF      Brain  Derived  Neurotrophic  Factor  
BrdU      nucleoside  5-­‐bromo-­‐2'-­‐deoxyuridine  
cAMP      Cyclic  adenosine  monophosphate  
CB1      Cannabinoid  Receptor  1  
CB2      Cannabinoid  Receptor  2  
CBD      Cannabidiol  
CBF      Cerebral  blood  flow  
COX2      Cyclooxygenase  2  
CP      Cerebral  Palsy  
CRT      Cylinder  Rearing  Test  
DAGL      Diacylglycerol-­‐lipase  
ECS      Endocannabinoid  System  
FAAH      Fatty  acid  amide  hydrolase  
FABPs      Fatty  acid  binding  proteins  
GABA      Gamma-­‐aminobutyric  acid  
GAPDH   Glyceraldehyde  3-­‐phosphate  dehydrogenase  
GDNF      Glial  Cell-­‐derived  Neurotrophic  Factor  
Glu/NAA   Glutamate/N-­‐acetylaspartate  
GPCR      G  protein-­‐coupled  receptor  
H+-­‐MRS   Magnetic  Resonance  Spectroscopy  
HI      Hypoxia-­‐Ischemia  
IGF-­‐1      Insulin-­‐like  growth  factor  1  
IL      Interleukine  
iNOS      inducible  NO  synthase  
IP3      1,4,5-­‐  triphosphate  
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Lac/NAA   Lactate/N-­‐acetylaspartate  
MAGL      Monoacylglycerol  lipase  
MCAO     Temporary  middle  cerebral  artery  occlusion  
MCP1      Monocyte  chemoattractant  protein-­‐1  
mI/Cr      Myoinositol/Creatine  
MRI      Magnetic  Resonance  Imaging  
NAAA      NAE-­‐hydrolyzing  acidamidase  
NADPH   Nicotinamide  adenine  dinucleotide  phosphate  
NAPE      N-­‐arachidonoyl  phosphatidylethanolamine  
NAPE-­‐PLD   NAPE-­‐phospholipase  D  
NE      Neonatal  Encephalopathy  
NFKb      Nuclear  actor  kappa-­‐light-­‐chain-­‐enhancer  of  activated  B  cells  
NHIE      Neonatal  Hypoxia-­‐Ischemia  Encephalopathy  
NMDA     N-­‐methyl-­‐D-­‐aspartate  
NO      Nitric  oxide  
NOR      Novel  Object  Recognition  
OGD      Oxygen  and  glucose  deprivation  (in  vitro  model)  
OPC      Oligodendrocyte  progenitor  cell  
PAIS      Perinatal  Arterial  Ischemic  Stroke  
PBS      Phosphate  Buffer  Saline  
PKA      Protein  kinase  A  
PND      Postnatal  day  
PPAR      Peroxisome  proliferator-­‐activated  receptors  
preOL      Preoligodendrocye    
ROS      Reactive  oxygen  species  
SR2      SR144528  
SVZ      Subventricular  zone  
TdT      Terminal  deoxynucleotidyl  transferase  
TH      Therapeutic  hypothermia  
THC      D9-­‐  tetrahydrocannabinol  
TNFa        Tumor  necrosis  factor  alpha  
TRAIL      TNF-­‐related  apoptosis  induced  ligand  
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TRPA1     Transient-­‐receptor-­‐potential-­‐related  A1  
TRPV1      Transient  receptor  potential  type  V  1  
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Neonatal   hypoxic-­‐ischemic   (HI)   brain   injury   is   a   severe   condition   which   main   deleterious  
consequence  is  cerebral  palsy.  Two  main  neonatal  hypoxic-­‐ischemic  pathologies  are  described:  
Neonatal   Hypoxia-­‐Ischemia   Encephalopathy   (NHIE),   a   global,   diffuse   brain   damage,   and  
Perinatal  Arterial  Ischemic  Stroke  (PAIS),  a  focal  HI  insult  which  usually  affects  the  left  middle  
cerebral  artery  territory.    
The  primary  cause  of  damage  in  NHIE  and  PAIS  is  the  decrease  of  glucose  and  oxygen  due  to  the  
depletion  of  brain  blood   flow,  which   induced   the   so-­‐called   “deadly   triad”,   a   combination  of  
excitotoxicity,   oxidative   stress   and   inflammation   that   eventually   leads   to   cell   death   and  HI-­‐
induced  brain  damage.  Oligodendrocytes  are  particularly  sensitive  to  HI  damage,  mainly  in  its  
preoligodendrocyte  stage,  and  eventually  HI-­‐induced  hypomyelination.  Astrocytes  and  microglia  
contribute  actively  promoting  the  “deadly   triad”  but   are  also  key   in   the  reparative  response  
triggered  after  HI.    
Nowadays  only  hypothermia  is  approved  for  moderate  to  severe  NHIE  treatment,  while  PAIS  
treatment  is  focused  in  treating  the  main  symptoms.  Therefore,  there  is  an  urgent  need  of  new  
molecules  that  can  improve  NHIE  and  PAIS  outcome  and  cannabidiol  (CBD)  has  risen  as  a  really  
promising   drug.      CBD   is   a   phytocannabinoid  with   no   psychostimulant   effect   that  modulates  
excitotoxicity,   inflammation  and  oxidative  stress.   Its   administration  reduces  brain  damage   in  
neonatal  models  of  HI  in  both  rodents  and  piglets  and  is  able  to  prevent  myelin  loss  in  adult  mice  
models   of   demyelinating   diseases.   Although   its   mechanism   is   not   clear,   some   works   have  
pointed   out   that   the   CB2   receptor,   a   cannabinoid   receptor,   might   be   involved   in   CBD  
neuroprotective  actions.  
Therefore,   it   is  hereby  hypothetized  that  CBD  administration  post-­‐injury  will  exert  short-­‐  and  
long-­‐term  protective  effects  in  models  of  either  neonatal  global  or  focal  HI,   i.e.  NHIE  or  PAIS  
respectively.  To  study  this  hypothesis  four  goals  were  set:  
1.   To  characterize  medium-­‐  and  long-­‐term  CBD  neuroprotective  effects  in  a  focal  model  of  
hypoxic-­‐ischemic  brain  injury  in  newborn  rats.  
2.   To  analyze  HI-­‐induced  long-­‐lasting  hypomyelination  in  White  and  Grey  Matter  and  its  
prevention  by  CBD.    
3.   To   assess   whether   CBD   hypomyelination   prevention   is   related   with   brain   cell  
proliferation  activation  and  glial  response  modulation.  
4.   To   study   the   involvement   of   CB2   receptor   activation   in   CBD   protective   effects   in   a  
newborn  rat  model  of  hypoxic-­‐ischemic  brain  damage.  
Summary  
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In   the   focal  model  of  HI,   the   iadministration  of  CBD  5mg/Kg  was  able   to  prevent   the  motor  
impairment  induced  by  MCAO  one  week  and  one  month  after  the  insult.  Along  with  this  result,  
CBD  animals  showed  lower  levels  of  excitotoxicity,  oxidative  stress  and  cell  death  one  week  after  
damage,  that  agreed  with  the  preserved  neuronal  population  observed  at  both  ages  in  MCAO-­‐
CBD  animals  versus  MCAO-­‐VEH.  Although  no  differences  in  brain  volume  loss  were  observed  by  
magnetic  resonance  imaging  (MRI),  CBD  significantly  reduced  the  perilesional  hyperintense  area  
which   one  month   after   the   insult   correlated   with   CBD-­‐induced   decreased   astrogliosis.   CBD  
administration  was   not   only   able   to   reduce  MCAO-­‐induced   astro-­‐   and  microgliosis,   but   also  
promoted  an  anti-­‐inflammatory  glial  state,  preserving  astroglial  function.  
A  decrease  of  myelin  content  was  observed  in  both  global  and  focal  models  one  month  after  the  
insult.  Global  HI  led  to  myelination  impairment  and  axonopathy  in  both  White  and  Grey  Matter,  
although   only   in   cerebral   cortex   a   decrease   of   mature   oligodendrocytes   was   observed.  
Hypomyelination   correlated   with   HI-­‐induced   long-­‐lasting   sequelae.   Specifically,   a   positive  
correlation  was  observed  between  White  Matter  MBP  and  hemiparesis,   and   cerebral   cortex  
hypomyelination  and  memory  impairment.    When  oligodendrocyte  was  studied,  early  death  of  
oligodendrocytes  was  observed  in  both  areas,  followed  by  the  restoration  of  cellularity  seven  
days   after   the   insult.   CBD   administration   increased   Olig2+   cell   density   and      prevented   the  
decrease  of  SOX10+  over  the  fourth  and  the  sixth  day  after  the  insult.  Besides,  a  more  active  
differentiation  of  Olig2+  population  into  astroglial  lineage  was  observed  in  vehicle  animals  but  
not   in  CBD  group.   In  agreement,     CBD   led  to   the  reduction  of  astro-­‐  and  microgliosis  and  of  
cytokines  release,  excitotoxicity  and  oxidative  stress.  
To  study  if  CB2  receptors  were  involved  in  CBD  neuroprotection,  we  compared  the  effects  of  
CBD  and  those  of  HU-­‐308,  a  specific  CB2  agonist,  when  administered    after  HI.  CBD  exerted  a  
remarkable  neuroprotective  effect  reducing  motor  impairment,  brain  volume  damage  and  brain  
TNFα   concentration   increase.  By   contrast,  HU-­‐308  only  partially   reduced  motor   impairment,  
showing  an  additive  effect  when  was  co-­‐administrated  with  CBD,  but  with  no  effect  on  the  other  
tests.   The   co-­‐administration  of  CBD  and  SR144528,   a  CB2   antagonist,   reversed   some  of  CBD  
protective  effects.  
In  conclusion,  HI  insult  led  to  brain  injury  resulting  in  long-­‐lasting  motor  and  cognitive  sequelae  
that  correlated  with  acute  cell  death  in  a  manner  related  with  excitotoxicity,  increased  oxidative  
stress   and   inflammation.   HI   triggered   a   strong  micro-­‐   and   astrogliosis   characterized   by   the  
increase  in  the  number  of  cells  and  its  transformation  into  an  activated  state  as  well  as  the  loss  
of  astrocytic  function,  and  eventually  leading  to  the  development  of  a  glial  scar,  corresponding  
Summary  
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to  an  increased  hyperintense  area  observed  one  month  later.  Therefore,  HI  led  to  a  remarkable  
decrease  on  neuronal  population  and  myelin  content.  Particularly,  global  HI  was  associated  to  
White   and  Grey  Matter   axonopathy  and  hypomyelination,  which   correlated  with  motor   and  
cognitive   disabilities   in   a   region-­‐specific   manner,   probably   because   of   the   different  
oligodendrocyte  maturative  stage.    
CBD  administration  post-­‐HI  was  neuroprotective   in   the   short-­‐   and   long-­‐term,   reducing  brain  
volume   loss   and   motor   and   cognitive   sequelae.   CBD   neuroprotection   was   linked   to   the  
preservation  of  neuronal  population  by  reducing  HI-­‐induced  cell  death  in  a  manner  related  with  
the  reduction  of  excitotoxicity,  oxidative  stress  and  inflammation.  CBD  administration  reduced  
HI-­‐induced  astro-­‐  and  microgliosis,  promoting  its  non-­‐activated  state  and  preserving  astrocyte  
function   as   well   as   oligodendrocyte   lineage   promotion   over   astroglial’s.   Furthermore,   CBD  
blunted  HI-­‐induced  hypomyelination  and  axonopathy   in  a   region-­‐specific  manner,  preserving  
proper   oligodendrocyte   maturation   and   myelination.   Finally,   CB2   receptor   activation   was  
somehow  involved  in  CBD  neuroprotection,  likely  by  its  indirect  activation,  although  other  ways  
might  also  participate  in  CBD  effects.
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El  daño  hipóxico-­‐isquémico   (HI)  neonatal  es  una  patología  grave  cuya  principal  secuela  es   la  
parálisis  cerebral.  Dos  de  las  principales  patologías  HI  neonatales  son  la  Encefalopatía  Hipóxico-­‐
Isquémica  Neonatal   (NHIE)1,   caracterizado  por  un  daño   cerebral   global   y  difuso,   y   el   Infarto  
Isquémico  Arterial  Perinatal  (PAIS),  un  daño  HI  focal  que  afecta  principalmente  al  territorio  de  
la  arteria  cerebral  media  izquierda.    
El  origen  del  daño  HI  es  el  descenso  de  glucosa  y  oxígeno  causado  por  la  disminución  del  flujo  
cerebral,  que  induce  la  llamada  “triada  mortal”  (excitotoxicidad,  estrés  oxidativo  e  inflamación),  
que  conduce  a  la  muerte  celular  y  al  daño  cerebral.  Al  ser  los  oligodendrocitos,  especialmente  
en   su   etapa   de   pre-­‐oligodendrocitos,   especialmente   sensibles   al   daño   la   HI   produce   una  
hipomielinización.  Los  astrocitos  y  la  microglia  promueven  activamente  la  “triada  mortal  “  pero  
también  son  fundamentales  en  la  respuesta  reparativa  generada  por  la  HI.  
La  hipotermia  es  el  único  tratamiento  actual  para  la  NHIE    moderada  o  severa,  mientras  que  en  
el  PAIS  el  tratamiento  es  sintomático.  Por  ello,  es  perentoria  la  búsqueda  de  nuevas  moléculas,  
entre   las   que   destaca   el   cannabidiol   (CBD).   Este   fitocannabinoide   no   psicoactivo  modula   la  
excitotoxicidad,  la  inflamación  y  el  estrés  oxidativo.  Su  administración  tras  la  HI  neonatal  reduce  
el   daño   cerebral   en   roedores   y   lechones,   y   previene   la   pérdida   de  mielina   en  modelos   de  
desmielinización  en  roedores  adultos.  Aunque  su  mecanismo  no  está  claro,  algunos  trabajos  han  
demostrado  que  el  receptor  cannabinoide  CB2  puede  mediar  alguno  de  sus  efectos  protectores.  
  
En  consecuencia,   la  hipótesis  es  que   la  administración  de  CBD  tras  el   daño  HI  neonatal  será  
neuroprotectora   a   corto   y   largo   plazo   tanto   en   un   modelo   global   como   focal,   NHIE   o   PAIS  
respectivamente.  Para  ello,  se  han  establecido  cuatro  objetivos:  
1.     Caracterización  a  medio  y  largo  plazo  del  papel  neuroprotector  del  CBD  en  un  modelo  focal  
del  daño  HI  en  rata  neonatal.  
2.   Análisis  de  la  hipomielinización  inducida  por  la  HI  en  Sustancia  Gris  y  Blanca,  y  su  prevención  
por  el  CBD.  
3.   Estudiar   si   el   efecto   protector   del   CBD   en   la   hipomielinización   está   relacionado   con   la  
activación  de  la  proliferación  de  células  cerebrales  o  la  modulación  de  la  respuesta  glial.  
4.   Analizar  el  papel  de  la  activación  del  receptor  CB2  en  los  efectos  protectores  del  CBD  en  un  
modelo  de  daño  HI  global  en  rata  neonata.  
                                                                                                                
1  Las  abreviaturas  hacen  referencia  a  la  denominación  inglesa  de  la  patología,  como  se  pueden  encontrar  
en  el  apartado  de  abreviaturas.  
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En  el  modelo  de  HI  focal  se  observó  que  el  CBD  a  5  mg/Kg  prevenía  el  daño  motor  asociado  al  
MCAO  una  semana  y  un  mes  después  de  la  lesión.  Los  animales  tratados  con  CBD  mostraron  
menores  niveles  de  excitotoxicidad,  estrés  oxidativo  y  muerte  celular  una  semana  después  del  
daño,  preservando  la  población  neuronal  a  ambas  edades.    Aunque  el  análisis  del  volumen  de  
lesión  por  resonancia  magnética  nuclear  no  mostró  diferencias,  el  CBD  redujo  el  volumen  del  
área  hiperintesa  perilesional,  correlacionándose  con  una  menor  astrogliosis  un  mes  después  de  
la  lesión.  El  CBD  no  solo  redujo  la  micro-­‐  y  la  astrogliosis  sino  también  promovió  un  fenotipo  
antinflamatorio,  preservando  la  función  astroglial.  
En  ambos  modelos  se  observó  un  descenso  de  mielina  un  mes  después  de  la  lesión.    La  HI  global  
produjo  una  axonopatía  y  una  mielinización  deficiente  en  Sustancia  Blanca  y  Gris,  aunque  el  
número   de   oligodendrocitos   maduros   sólo   disminuyó   en   la   corteza   cerebral.   La  
hipomielinización  se  asoció  con  las  secuelas  a  largo  plazo  de  la  HI,  observándose  una  correlación  
entre  la  MBP  de  Sustancia  Blanca  y  la  hemiparesis,  y  la  hipomielinización  de  corteza  cerebral  y  
la  alteración  de  memoria.  Se  observó  una  muerte  temprana  de  oligodendrocitos,  seguida  de  un  
restablecimiento   de   su   celularidad   siete   días   después   de   la   HI.   La   administración   de   CBD  
incrementó  la  densidad  celular  Olig2+  y  previno  el  descenso  de  la  SOX10+  durante  el  cuarto  al  
sexto  día  después  de  la  HI.  Ésta  indujo  una  diferenciación  más  activa  hacía  el  linaje  astroglial  de  
las  células  Olig2+,  efecto  prevenido  por  CBD.  Asimismo,  el  CBD  redujo  la  astro-­‐  y  la  microgliosis,  
la  liberación  de  citoquinas,  el  estrés  oxidativo  y  la  excitotoxicidad  inducidos  por  la  HI.  
Para  estudiar  si  el  receptor  CB2  estaba  implicado  en  la  neuroprotección  del  CBD,  comparamos  
los   efectos  del  CBD  y  del  HU-­‐308,   agonista  específico  del   receptor  CB2.  El  CBD  demostró  un  
notable   efecto   neuroprotector   y   antinflamatorio.   Sin   embargo,   el   HU-­‐308   sólo   redujo  
parcialmente  el  daño  motor,  mostrando  un  efecto  aditivo  con  el  CBD,  pero  sin  efecto  en  el  resto  
de   pruebas.   La   coadministración   de   SR144528,   antagonista   de   CB2,   previno   algunos   de   los  
efectos  protectores  del  CBD.  
Como  conclusión,  la  HI  indujo  daño  cerebral  con  secuelas  motoras  y  cognitivas  a  largo  plazo  que  
se   correlacionó   con   la  muerte   celular   aguda   asociada   a   excitotoxicidad,   aumento   del   estrés  
oxidativo   e   inflamación.   La   HI   indujo  micro-­‐   y   astrogliosis   caracterizada   por   el   aumento   del  
número  de  células  y  su  transformación  a  estado  activado  y  la  pérdida  de  función  astrocitaria,  
que  finalmente  indujo  la  cicatriz  glial  asociada  con  el  aumento  del  área  hiperintensa  observado  
un  mes  después.  En  consecuencia,  la  HI  produjo  un  marcado  descenso  de  la  población  neuronal  
así  como  hipomielinización  y  axonopatía  de  la  Sustancia  Gris  y  Blanca,  cada  área  específicamente  
Resumen  
   12  
asociada  con  determinadas  secuelas  motora  y  cognitiva,  probablemente  por  el  diferente  estado  
madurativo  del  oligodendrocito.  
La  administración  del  CBD  fue  neuroprotectora  a  corto  y  largo  plazo,  reduciendo  la  pérdida  de  
volumen   cerebral   y   las   secuelas  motoras   y   cognitivas,   preservando   la  población  neuronal   al  
reducir    la  muerte  inducida  por  la  HI  en  relación  al  descenso  de  excitotoxicidad,  estrés  oxidativo  
e  inflamación.  La  administración  del  CBD  redujo  la  micro-­‐  y  astrogliosis,  promoviendo  su  estado  
no-­‐activado,  preservando   la   función  astrocitaria   y   el   predominio  del   linaje  oligodendrocítico  
sobre  el  astrocitario.  Además,  el  CBD  previno  la  hipomielinización  y  axonopatía,  preservando  la  
maduración  del  oligodendrocito  y  la  mielinización.  Finalmente,   la  activación  del   receptor  CB2  
participó   en   la   neuroprotección   del   CBD,   probablemente   mediante   su   activación   indirecta,  
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1.NEONATAL  PERIOD    
The  neonatal  period  has  been  defined  by  the  World  Health  Organization  (WHO)  as  the  period  
ranging  from  birth  to  the  end  of  fourth  week  of  life  (28  completed  days)  (Ryninks  et  al.,  2006)  
and  is  the  most  vulnerable  in  infants’   life.  Approximately  0.662  million  neonates  die  because  
intrapartum  complications  every  year  in  the  world  (Liu  et  al.,  2015),  being  the  WHO  estimation  
that  8%  of  children  deaths  under  5  years-­‐old  are  caused  by  asphyxia  at  birth  (Bryce  et  al.,  2005).  
Remarkably,  although  global  childhood  mortality  showed  a  reducing  trend  from  1990  to  2013,  
neonatal   and   specially   early  neonatal   (less   than   seven  days   after  birth)  mortality   rates  have  
barely   decreased   (Lehtonen   et   al.,   2017).   This   is   specially  worrying   in   developing   countries,  
where  death  is  the  main  consequence  of  intrapartum  asphyxia  (Lee  et  al.,  2013;  Liu  et  al.,  2015).  
Whereas  the  improvement  of  health  care  system  in  developed  countries  resulted  in  increased  
survival  rate  (Lee  et  al.,  2013;  Lehtonen  et  al.,  2017),  it  has  also  increased  the  incidence  of  long-­‐
lasting  sequelae,  being  the  major  one  cerebral  palsy  (CP).  CP  is  considered  the  most  prevalent  
childhood  motor  disability  (Johnston  and  Hoon,  2006),  with  an  average  lifetime  cost  of  921.000  
$  per  person  (Centers  for  Disease  Control  and  Prevention,  2004;  Johnston  and  Hoon,  2006).  
The  clinical  term  that  englobes  these  complex  neonatal  pathologies  is  Neonatal  Encephalopathy  
(NE).  NE  is  defined  by  the  American  Academy  of  Pediatrics  as  “a  clinically  defined  syndrome  of  
disturbed  neurologic  function  in  the  earliest  days  of  life  in  an  infant  born  at  or  beyond  35  weeks  
of   gestation,   manifested   by   a   subnormal   level   of   consciousness   or   seizures,   and   often  
accompanied  by  difficulty  with  initiating  and  maintaining  respiration  and  depression  of  tone  and  
reflexes”  (D’Alton  et  al.,  2014).  A  major  cause  of  NE  is  an  hypoxia-­‐ischemia  (HI)  event,  by  itself  
or  in  combination  with  other  factors  as  infection  (Volpe,  2012).  During  HI  brain  blood  flow  and  
then  oxygen  and  glucose  decreased  globally  or  regionally  in  the  brain.  That  depletion  triggers  a  
continuum  of  events  of  cell  death,  excitotoxicity,  inflammation  and  oxidative  stress  that  will  end  
in  tissue  damage  and  different  neurological  sequelae.     The  two  main  pathologies  in  which  HI  
plays   a   key   role   are  neonatal   hypoxia-­‐ischemia  encephalopathy   (NHIE)   and  perinatal   arterial  
ischemic  stroke  (PAIS).  
2.NEUROLOGIC  PERINATAL  PATHOLOGIES  
2.1  Neonatal  Hypoxia-­‐Ischemia  Encephalopathy  
NHIE  has  an  incidence  of  2  to  6  per  1000  live  births  in  developed  countries  (Arnaez  et  al.,  2017;  
Gale  et  al.,  2017;  García-­‐Alix  et  al.,  2009;  Hayakawa  et  al.,  2014;  Kurinczuk  et  al.,  2010).  The  
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aetiology   of   NHIE   is   not   always   apparent,   although   intrapartum   events   often   precede   the  
pathology   (Martinez-­‐Biarge   et   al.,   2013).   Some   of   them   are   umbilical   cord   knots,   shoulder  
dystocia,   placental   abruption   or  maternal   shock   (Abdelaziz   et   al.,   2017;   Hayes   et   al.,   2013;  
Martinez-­‐Biarge  et  al.,  2013).  Other  relevant  antepartum  risk  factors  are  gestational  age  longer  
than  41  weeks,  pre-­‐eclampsia,  as  well  as  placental  abnormalities  and  chorioamnionitis  (Hayes  
et  al.,  2013;  Martinez-­‐Biarge  et  al.,  2013).  
To  diagnose  NHIE  it  is  mandatory  that  perinatal  asphyxia  was  previously  detected.  International  
agreement  determines  that  perinatal  asphyxia  is  defined  by  the  presence  at  birth  of  one  or  more  
of  the  following:  10-­‐minute  Apgar  score  <  5,  prolonged  resuscitation  (>  10  minutes)  after  birth,  
umbilical  cord  or  first  neonatal  blood  gas  pH  <  7.0,  or  cord  or  base  deficit  >  12  (D’Alton  et  al.,  
2014;   Parikh   and   Juul,   2018).      In   addition,   clinical   evidences   of   brain   disturbance  
(encephalopathy)  must  be  apparent:  decreased  level  of  consciousness,  decreased  tone  and/or  
spontaneous   activity,   decreased   primitive   reflexes   and   abnormal   autonomic   function,  
abnormalities  on  amplitude-­‐integrated  EEG  are   taken   into  account  when  available   to  detect  
encephalopathy   (Parikh   and   Juul,   2018).   The   diagnosis   must   be   complemented   with  
neuroimaging  evidence,  being  magnetic  resonance  imaging  (MRI)  the  standard  one  (D’Alton  et  
al.,  2014;  Ho  et  al.,  2016;  Weeke  et  al.,  2018).  Severity  of  encephalopathy   is  graded  as  mild  
(grade  I),  moderate  (grade  II)  and  severe  (grade  III)  (Sarnat  and  Sarnat,  1977).  While  mild  cases  
have  almost  no  sequelae,  moderate  to  severe  NHIE  develops  seizures  and  other  neurological  
abnormalities  soon  after  the  insult  (Adhikari  and  Rao,  2016)  and  75%    will  develop  CP  in  the  first  
years  of  life  with  delayed  motor,  social  and  language  milestone  accomplishment  (Adhikari  and  
Rao,   2016;  Martinez-­‐Biarge  et   al.,   2011).   Long-­‐term   studies  have  demonstrated   this   lifelong  
impairment   with  memory,   language,   sensorimotor   and   even   behavioural   deficits   present   in  
children  from  seven  to  eighteen  years  old  (de  Vries  and  Jongmans,  2010)  (Fig.1).  
That   neurodevelopmental  
outcome  correlated  with  the  
intensity   and   localization  of  
damage  as  observed  in  MRI  
(de   Vries   and   Jongmans,  
2010;  Martinez-­‐Biarge  et  al.,  
2011;  Twomey  et  al.,  2010).  
The   classic   topography   of  
damage  includes  parasagittal  cerebral  cortex,  basal  ganglia,  thalamus  and  brainstem.  Usually,  
Figure  1.  Scheme  of  NHIE  outcome.  Adapted  from  Lee  et  al.,  2013    
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watershed  regions  are  affected  as  a  consequence  of  the  poor  vascularization  and  regulation  of  
vascular   branches.   Consistently,   after   an   acute   and   very   severe   damage   for   example   as   a  
consequence   of   placental   abruption,   peri-­‐rolandic   cerebral   cortex,   paracentral   cortex,   basal  
ganglia  or   thalamus  are  affected,  besides  a  significant  damage  of   the   internal  capsule  or   the  
cranial  nerve  motor  nuclei  in  the  brainstem  (Johnston  and  Hoon,  2006;  Michoulas  et  al.,  2011;  
Uria-­‐Avellanal  and  Robertson,  2014;  Volpe,  2012).  This  produces  an  extrapyramidal  pattern  of  
impairment  with  rigidity  and  movement  disorder  (Johnston  and  Hoon,  2006).  Although  white  
matter   is   less   vulnerable   than   in   previous   stages   of   development,   it   can   still   be   affected,  
particularly  the  subcortical  cerebral  white  matter  and  the  overlying  grey  matter  (Johnston  and  
Hoon,   2006;   Volpe,   2012).   In   this   case   brain   damage   is   associated   with   a   more   important  
cognitive   than   motor   impairment,   which   is   defined   by   spasticity   and   upper   motor   neuron  
abnormalities  (Johnston  and  Hoon,  2006;  Volpe,  2012)  and  it  is  usually  caused  by  less  intense  
but  longer  insult  (Johnston  and  Hoon,  2006;  Uria-­‐Avellanal  and  Robertson,  2014)  .  
2.2  Perinatal  Arterial  Ischemic  Stroke  
PAIS  is  defined  as  “a  group  of  heterogeneous  conditions  in  which  there  is  focal  disruption  of  
cerebral   blood   flow   secondary   to   arterial   or   cerebral   venous   thrombosis   or   embolization,  
between  20  weeks  of  fetal  life  through  the  28th  postnatal  day,  confirmed  by  neuroimaging  or  
neuropathological  studies”  (Raju  et  al.,  2007).  PAIS  is  diagnosed  from  birth  to  28th  postnatal  day  
and  affects  1/2300  to  1/5000  live  newborns  (Machado  et  al.,  2015;  Raju  et  al.,  2007;  Swartz  et  
al.,  2017).  Although  the  aetiology  remains  sometimes  unclear,  most  of  the  risk  factors  are  shared  
with  NHIE  (Machado  et  al.,  2015;  Martinez-­‐Biarge  et  al.,  2016;  Michoulas  et  al.,  2011;  Sreenan  
et  al.,  2000).  Intrapartum  period  is  considered  the  one  with  the  highest  risk  (Martinez-­‐Biarge  et  
al.,   2016).   Other   risk   factors   are   pre-­‐eclampsia,   chorioamnionitis,   placental   abruption,  
meconium  aspiration  syndrome  or  hypoglycaemia   (Hayes  et  al.,  2013;  Machado  et  al.,  2015;  
Martinez-­‐Biarge  et  al.,  2016;  Raju  et  al.,  2007;  Sreenan  et  al.,  2000).  However,  PAIS  specific  risk  
factors  are  thrombophilia  (Kenet  et  al.,  2010),  placental  abnormalities  (Hayes  et  al.,  2013)  and  
congenital  heart  diseases  (Fernández-­‐López  et  al.,  2014).  Probably  because  of  the  direct  vascular  
route  from  the  cava  vein  to  the  left  carotid  artery  through  the  Ductus  Arteriosus  (Fernández-­‐
López   et   al.,   2014),   perinatal   arterial   ischemic   stroke   (PAIS)   predominantly   affects   the   left  
hemisphere  (Lee  et  al.,  2010;  Machado  et  al.,  2015;  Michoulas  et  al.,  2011),  affecting  the  left  
middle  cerebral  artery  territory  (Hayward  and  Adappa,  2014;  Sreenan  et  al.,  2000).  
Seizures  are  an  important  symptom  after  PAIS,  usually  in  the  first  48  hours  of  life  (Billinghurst  et  
al.,  2017;  Klemme  et  al.,  2017;  Lee  et  al.,  2010;  Machado  et  al.,  2015;  Nelson  and  Lynch,  2004).  
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25%   of   seizing   PAIS   babies   will   suffer   epilepsy   or   remote   symptomatic   seizures   afterwards  
(Billinghurst  et  al.,  2017).  Half  of  the  affected  newborns  develop  motor  or  cognitive  impairment  
as  hemiplegia,  spasticity  or  language  delay  (Lee  et  al.,  2010;  Nelson  and  Lynch,  2004;  Sreenan  et  
al.,  2000).  
2.3  Pathophysiology  
As  mentioned  before,  the  primary  cause  of  damage  in  PAIS  and  NHIE  is  the  depletion  of  brain  
blood  flow  and  consequently  the  levels  of  glucose  and  oxygen.  In  fact,  in  focal  HI  damage  (stroke)  
the   injury   can  be  divided   in   two  main   regions:   the   core  of   the   insult,  where   the  blood   flow  
decreases   until   less   than   7mL/100g/min   when   normal   flow   is   50-­‐60mL/100g/min,   and  
penumbra,  with  a  blood  flow  between  7  and  17mL/100g/min  (Mehta  et  al.,  2007)  (Fig.  2A).    Such  
differentiation   is   less   clear   in   diffuse   HI   damage,   where   selective   neuronal   necrosis   is  




Pathophysiology  of  NHIE  and  PAIS  is  an  evolving  process.  It  starts  with  the  decrease  of  glucose  
and  oxygen  leading  to  a  primary  energy  failure,  triggering  the  anaerobic  metabolism  (James  and  
Patel,   2014)   (Fig.   2B).   Due   to   the   anaerobic   metabolism   fails   preventing   the   reduction   of  
nucleotide  triphosphate  concentration  like  adenosine  triphosphate  (ATP)  cannot  be  prevented  
(Blumberg  et  al.,  1996;  Lorek  et  al.,  1994;  Penrice  et  al.,  1997a);  also,  a  severe  acidosis,  caused  
by  the  lactic  acid  and  by  proton  pumping  ATPases  impairment  occurs  (Penrice  et  al.,  1997a;  Uria-­‐
Avellanal   and   Robertson,   2014).   Finally,   blood   flow   returns   to   basal   condition   initiating   the  
Figure   2.   Spatial   and   temporal   scheme   of  
perinatal   hypoxia-­‐ischemia.   A)   ATP   level  
variations   during   the   first   48   hours   after   HI,  
adapted   from   Uria-­‐Avellanal   et   al.,   2014.   B)  
The   different   regions   due   to   the   severity   of  
blood  deprivation.  Adapted  from  Mehta  et  al.,  
2007.  
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reperfusion  phase  when  pH,  metabolites  levels  and  ATP  recover  their  basal  levels  (Blumberg  et  
al.,  1996;   James  and  Patel,  2014;  Lorek  et  al.,  1994)   (Fig.  2B).  However,  eventually  a  second  
energy  failure  happens,  characterized  by  a  decrease  of  ATP  with  no  pH  changes  and  increased  
lactate   levels   (Fig.2B).   This   energy   impairment   is   mainly   a   consequence   of   a  mitochondrial  
dysfunction  and  a  continuum  of  oxidative  stress,  inflammation  and  excitotoxicity  (Blumberg  et  
al.,  1996;   James  and  Patel,  2014;  Lorek  et  al.,  1994;  Northington  et  al.,  2007;  Penrice  et  al.,  
1997a).   Taken   together   those   events   lead   to   a   complex   situation,   in  which   oxidative   stress,  
inflammation  and  excitotoxicity  feedback  potentiates  each  other  in  the  so-­‐called  “deadly-­‐triad”,  
that  can  last  for  hours  or  even  days.  
Besides  the  energy  depletion  per  se,  this  first  phase  triggers  two  main  pathophysiological  events.  
One   is   the   oedema   as   a   consequence   of   the   ATP-­‐dependent   pump   impairment   like   Na+/K+  
ATPase,  responsible  for  the  Na+/K+  gradient  (Alix,  2006).    This  induced  an  important  influx  of  Na+,  
Cl-­‐  and  water  inside  the  cell  producing  a  cytotoxic  oedema  (Brekke  et  al.,  2017),  observed  soon  
after  HI  and  that  last  for  several  days  (Mujsce  et  al.,  1990),  although  last  days  is  mainly  vasogenic  
(Justicia  et  al.,  2008;  Siemonsen  et  al.,  2012).      The  second  one   is  excitotoxicity,  caused  by  a  
combination   of   the   excitatory   aminoacid   release,   like   glutamate,   due   to  membrane   polarity  
failure   (Brekke  et  al.,  2017)  and  the  reversal  of   the  glutamate  transporter   in  astrocytes,  as  a  
consequence  of   sodium  gradient   loss   (Johnston,   2005)   and  nuclear   factor   kappa-­‐light-­‐chain-­‐
enhancer   of   activated   B   cells   (NFKb)   activation   (Fatemi   et   al.,   2009)   (Fig.   3).   High   levels   of  
glutamate   are   observed   shortly   after   HI   (Dang   et   al.,   2017;   Pazos   et   al.,   2013),   and   remain  
elevated   for   days   (Dang   et   al.,   2017;   Pazos   et   al.,   2012).   In   fact,   levels   of   glutamate   in  
cerebrospinal  fluid  (CSF)  correlates  with  the  severity  of  NHIE  (Johnston  and  Hoon,  2006).  
These  events  lead  to  a  remarkable  intracellular  calcium  increase  induced  by  increased    Na+  influx  
that  revers  the  Na+/Ca2+  exchange  protein  (Alix,  2006;  Uria-­‐Avellanal  and  Robertson,  2014)  and  
glutamate  activation  of    glutamate  receptor  N-­‐methyl-­‐D-­‐aspartate  (NMDA),  a-­‐amino-­‐3-­‐hydroxy-­‐
5-­‐methyl-­‐4-­‐isoxazolepropionic   acid   (AMPA)   and   kainate   receptor.      Calcium   is   an   important  
second  messenger   that   play   a   key   role   in   the   pathogenesis   of   HI   promoting   cell   death   and  
oxidative  stress  (James  and  Patel,  2014).  On  the  one  hand,  high  cytosolic  calcium  concentration  
actives  lipases,  proteases  or  endonucleases  that  promote  cell  death  (James  and  Patel,  2014).  It  
also   activates   calmodulin,  which   increases   the   nitric   oxide   (NO)   levels   through  NO   synthase  
(Thornton   et   al.,   2017b   a)   and   promotes   superoxide   production   via   nicotinamide   adenine  
dinucleotide  phosphate   (NADPH)  oxidase   (Thornton   et   al.,   2017a  b).   This   superoxide   can  be  
transformed  into  hydrogen  peroxide  and  then  to  water,  by  superoxide  dismutase  and  catalase.  
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Also,   it   can   interact  with  NO   to   produce   peroxynititre,   an   effect   aggravated   by   the  massive  
production  of  NO  due  to  the  induction  of  inducible  NO  synthase  (iNOS)  (Martínez-­‐Orgado  et  al.,  
2006).   Peroxynitrite   is   highly   toxic,   promoting   lipid  peroxidation,  protein  oxidation  and  DNA  
damage  (Thornton  et  al.,  2017a  b).    On  the  other  hand,  immature  mitochondria  are  less  efficient  
at  buffering  calcium,  thus  its  concentration  increases  rapidly  inside  the  organelle.  Calcium  and  
NO  will   disrupt   the   electron   transport   chain,   producing   reactive   oxygen   species   (ROS),   and  




As   explained   before,   the   disruption   of   mitochondrial   electron   transport   systems,   NADPH  
oxidases  and  NO  synthases  are  one  the  main  sources  of  oxidative  stress  in  HI.  During  primary  
energy   failure,  ROS  and  reactive  nitrogen  species  increment   inside  cells,  but   it   is   reperfusion  
which  will  boost  its  production  into  a  high  toxicity  level  (James  and  Patel,  2014).  Microglia  is  the  
other  main  source  of  ROS  and  NO  (Li  et  al.,  2005;  Zhao  et  al.,  2016)  (Fig.  3).    
HI  also  produces  a  prompt   inflammation  response,  being  microglia   the   first  agent.  Microglia  
rapidly   proliferates   and   acquires   a   macrophage-­‐like   phenotype,   phagocyting   cell   debris,  
producing   inflammatory   and   anti-­‐inflammatory   cytokines,   ROS,   NO   and   metalloproteases  
(Hellström  Erkenstam  et  al.,  2016;  Liu  and  McCullough,  2013).  Besides,  microglia  not  only  release  
glutamate  thus   increasing  excitotoxicity   (Hagberg  et   al.,  2015),  but  also  expresses   functional  
NMDA  receptors  (Kaindl  et  al.,  2012).  Its  activation  triggers  a  long-­‐lasting  morphological  change  
BOX1:  Calcium  during  a  HI  event  
Calcium  precipitates  can  be  observed  in  the  mitochondria  of  neurons  in  the  core  of  the  insult  
since  the  very  first  30  minutes  after  HI  (Puka-­‐Sundvall  et  al.,  2000)  (Puka-­‐Sundvall  et  al.,  
2000  a)  as  well  as   in  swollen  synaptic  structures   (Puka-­‐Sundvall  et  al.,  2000  a).  The   first  
precipitates  are  observed   in  penumbra  neurons  3  hours  after  HI.  For   the  next  24  hours,  
calcium  accumulates  in  other  neuronal  structures  like  cytoplasm  or  endoplasmic  reticulum  
meanwhile  cells  shows  morphologic  abnormalities  or  undergo  cell  death  (Puka-­‐Sundvall  et  
al.,  2000  a).    Calcium  accumulation  happens  also  in  astrocytes  (Puka-­‐Sundvall  et  al.,  2000),  
oligodendrocytes  and  myelin  sheats  (Micu  et  al.,  2006).  It  is  important  to  remark  that  due  
to   its   small   volume,   even   small   increments   of   calcium   via   NMDA   receptors   could   be  
excitotoxic   in   oligodendrocyte   processes   and   neuron   dendrites   (Jantzie   et   al.,   2015).  
Activation  of  NMDA  receptors  during  HI  has  demonstrated  to  be  pro-­‐apoptotic  (Fan  et  al.,  
2015)  and  damaging    premyelinated  axons  (Alix  and  Fern,  2009).      
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into  an  active  shape,  promoting  the  secretion  of  numerous  cytokines,  ROS  or  NO  (Kaindl  et  al.,  
2012).    Microglia  releases  a  wide  array  of  interleukins  (IL)  as  IL-­‐1a  ,  IL-­‐1b,  IL-­‐6,  IL-­‐10,  IL-­‐12,  IL-­‐13;  
monocyte  chemoattractant  protein-­‐1  (MCP1)  or  agonists  of  death  receptors  like  tumor  necrosis  
factor-­‐related  apoptosis  induced  ligand  (TRAIL),  tumor  necrosis  factor  alpha  (TNFa)  or    FasL  (Fas  
ligand)  (Hagberg  et  al.,  2015;  Hellström  Erkenstam  et  al.,  2016;  Kaindl  et  al.,  2012;  Kichev  et  al.,  
2014).    Other  cells  like  astrocytes  or  mast  cells  contribute  to  inflammation  response  releasing  
TNFa,   IL-­‐1b,  TGF-­‐b1  (transforming  growth   factor  beta-­‐1)  or  MCP1;  both  of   them  being  early  
responders  too  (Faustino  et  al.,  2011;  Hagberg  et  al.,  2015;  Jin  et  al.,  2009).    Astrocytes  are  also  
an  important  source  of  TRAIL,  which  induce  oligodendrocyte  and  neurons  death  through  DR5  
receptor   (Kichev   et   al.,   2014).   Furthermore,   this   activated   and   neurotoxic   astroglia   can   be  
induced   by   activated   microglia   through   IL-­‐1b,   TNFa   and   the   complement   molecule   C1q  
(Liddelow  et  al.,  2017)  (Fig.  3).  
After  this  innate  immune  response  that  can  last  several  days  after  HI,  there  is  also  an  adaptive  
immune  response  of  T  Lymphocytes  (Liu  and  McCullough,  2013;  Winerdal  et  al.,  2012).  Both  T-­‐
helper  and  T-­‐cytotoxic  cell  have  been  characterized  from  second  week  to  the  third  month  after  
HI  (Winerdal  et  al.,  2012),  or  even  up  to  the  seven  month  (Hagberg  et  al.,  2015).      
  
BOX2:  Astrocytes  and  microglia,  the  other  side  of  the  coin.  
Although  astroglia  and  microglia  contributes  actively  to  inflammation  and  hypomyelination,  
it  also  plays  neuroprotective  key  roles  after  HI  and  during  development.  State-­‐of-­‐the  art  
microglial   research   has   characterized   different   anti-­‐inflammatory,   wound-­‐healing   and  
tissue  homeostasis-­‐protectant  phenotypes  (Liu  and  McCullough,  2013;  Mecha  et  al.,  2016)  
which  would  help  to  reduce  the  damage.  
Furthermore,   astrocytes   are  an   important   source  of   glutathione,   thioredoxins   and  other  
antioxidants  defences,  provide  metabolic  support  and    reuptake  glutamate  (Brekke  et  al.,  
2017;   Liu   and   McCullough,   2013;   Romero   et   al.,   2014).   They   release   PDGFRa   (platelet  
derived   growth   factor   receptor   a)   and   other   molecules   needed   for   oligodendrocyte  
progenitor  cell  (OPC)  maturation  and  short  and  long  term  survival  (Clemente  et  al.,  2013;  
Gard   et   al.,   1995;  Moore   et   al.,   2011).   Because   of   this   protective   role,   the      damage   to  
astrocytes  by  HI,  with  their  processes  disintegrating  and  its  metabolism  affected  (Alix  et  al.,  
2012;  Back  et  al.,  2007;  Brekke  et  al.,  2017),  might  be  particularly  harmful.  
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BOX3:  Cell  death.  
Cell   death  during  perinatal   brain   injury  has  been   characterized  as   an  apoptotic-­‐necrotic  
continuum,  where  morphological  and  biochemical  characteristics  of  both  kind  of  cell  death  
and  a  hybrid  between  both  can  be  observed  (Northington  et  al.,  2007).  It  is  well  know  that  
immature  brain  is  prone  to  apoptosis    (Hagberg  et  al.,  2016),  and  caspase-­‐3  is  involved  in  
cell-­‐death  after  HI  (Manabat  et  al.,  2003;  Northington  et  al.,  2007).  Necrosis  is  the  main  kind  
of  cell  death  in  the  core  (Carloni  et  al.,  2007).    However,  several  studies  have  pointed  out  
that   the  presence  of   this  hybrid   apoptosis-­‐necrosis   cell   death  may  be   consequence  of   a  
failed  fulfilment  of  apoptosis  due  to  the  energy  deprivation  (Carloni  et  al.,  2007;  Portera-­‐
Cailliau  et  al.,  1997).  This  would  explain  why  the  area  of  necrotic  cells  increases  over  time  
affecting  the  penumbral  area  (Carloni  et  al.,  2007;  Portera-­‐Cailliau  et  al.,  1997).  In  NHIE,  this  
“non-­‐controlled   death”   is,   for   example,   the   one   caused   by   cytosolic   oedema  when   the  
membrane   rupture   releases  molecules   known   as   DAMPs   (damage   associated  molecular  





































Figure  3.  Pathophysiology  of  a  HI/PAIS  event.  Scheme  of  the  events  which  followed  a  HI/PAIS  event.    
The   high   increase   of   intracellular   calcium   induces   the   release   of   glutamate,  which   cannot   be   re-­‐
uptaked  by   the   astrocytes   due   to   the   energy   deprivation.   Therefore,   the   activation   of   glutamate  
receptors   potentiates   calcium   influx,   the   oxidative   stress   and   eventually   the   cell   death   by  
excitotoxicity.  This  produces  a  strong  inflammatory  response  which  exacerbates  both  oxidative  stress  
and   excitotoxicity.   ROS=reactive   oxygen   species;   NO=nitric   oxide;   NMDA   receptor=N-­‐methyl-­‐D-­‐
aspartate   receptor,   AMPA   receptor=a-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic   acid.  
Adapted  from  Johnston  et  al.,  2007.  
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2.4  Hypomyelination  
As   explained   before,   damage   induced   in   white   and   grey   matter   after   a   neonatal   HI   insult  
correlated  with  motor  and  cognitive  impairment  that  is  not  repaired  by  adolescence  (de  Vries  
and  Jongmans,  2010;  Martinez-­‐Biarge  et  al.,  2011)  (Fig.  4A).  
After   neurons,   oligodendrocytes  
are   the  most  sensitive  cell   to   the  
“deadly   triad”-­‐induced   by   the   HI  
insult(Back  et  al.,  2002a;  Buser  et  
al.,   2010;   Miller   et   al.,   2007;  
Rosenberg   et   al.,   2003),  
particularly   the   late  
oligodendrocyte   progenitor   or  
preoligodendrocyte   (preOL)  
stage   (Fig.   4B).   First,  
excitotoxicity   through   NMDA  
and   AMPA   activation   causes  
both  morphology  alteration  and  
death   in   preOL   (Follett,   2004;  
Jantzie  et  al.,  2015;  Káradóttir  et  
al.,   2005;   Salter   and   Fern,   2005).   Second,   oxidative   stress   induces   accumulation   of   lipid  
peroxidation  (Back  et  al.,  2005)  and  glutathione  depletion  NMDA-­‐mediated  (Rosenberg  et  al.,  
2003),  which  are  particularly  harmful  to  those  cells,  mainly  because  of  its  immature  antioxidant  
system  (Fragoso  et  al.,  2004).  Moreover,  microglia  and  astrocytes  can  directly  damage  preOL  by  
activating   oxidative   stress   releasing   substances   like   ROS   and   peroxynitrite,   and      releasing  
cytokines  (Deng  et  al.,  2008;  J.  Li  et  al.,  2008;  Li  et  al.,  2005;  Miller  et  al.,  2007).     Astrogliosis  
overlapping  the  lesion  days  after  damage  has  been  widely  described    (Buser  et  al.,  2012;  Segovia  
et  al.,  2008).    Although  oligodendrocyte  progenitor  cells  (OPC)  proliferation  and  maturation  is  
enhanced  after  HI,  they  fail  to  mature,  remaining  in  a  preOL  stage  (Segovia  et  al.,  2008)  (Fig.  4C  
and  D).  This  arrested  maturation  will  eventually  lead  to  hypomyelination  that  has  been  studied  
in  humans   (Buser   et   al.,   2012),   rats   (Janowska  and  Sypecka,   2018;  Villapol   et   al.,   2011)   and  
rabbits   (Buser   et   al.,   2010).   This   hypomyelination   has   been   also   observed   in   rat   pups   after  
neonatal  stroke  (Villapol  et  al.,  2011).    
Figure   4.   HI   induced   damage   on   oligodendrocytes   and  
myelination.  A)  A  MRI  T2-­‐weighted   image  which  shows  diffuse  
gray   and   white   matter   volume   loss   and   dilatation   of   lateral  
ventricules;  B)  Pyknotic  preOLs    24h  after  HI  versus  control  cell  
(inset);  C)   and  D)   Gliotic   lesion   in  white  matter,   where   strong  
astrocytes   staining   (GFAP)   correlated   with   few   immature  
oligodendrocytes   (O1)  and  a   strong  preOL  signal   (O4),   showing  
an   arrested  maturation   stage,   one  week   after   ischemia.  Taken  
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Noteworthy,  along  with  hypomyelination  axonopathy  can  also  be  observed  (Alix  et  al.,  2012).  
Axons  are  also  sensitive  to  HI  damage  by  glutamate  receptor  activation  and  calcium  influx  (Alix  
et  al.,  2012;  Back  et  al.,  2007;  Micu  et  al.,  2006;  Puka-­‐Sundvall  et  al.,  2000;  Shen  et  al.,  2012).    
2.5  Particularities  of  immature  brain  
Immature  brain  has  several  characteristics  which  makes  it  more  sensitive  to  HI  or  stroke  than  
the  adult  brain  (Martínez-­‐Orgado  et  al.,  2007).    However,  neonatal  brain  has  a  reduced  cerebral  
blood   flow   autoregulation   which   impairs   buffering   the   CBF   increase   occurring   after   HI   and  
inducing  oxidative  stress  (Vutskits,  2013).    Besides,  immature  brain  is  more  sensitive  to  glucose  
deprivation  since  it  has  less  glucose  transporter  and  with  lower  capacity  (Brekke  et  al.,  2017).  
Neonatal  brain  is  also  more  susceptible  to  excitotoxicity  (Fatemi  et  al.,  2009).  Around  last  weeks  
of   pregnancy   and   first   postnatal   weeks,   immature   brain   is   highly   excitable   due   to   an   over  
expression  of  NMDA  and  AMPA  receptor  and  to  the  fact  that  gamma-­‐aminobutyric  acid  (GABA)  
receptor  is  excitatory  at  that  age  (Jensen,  2002).  Furthermore,  both  NMDA  and  AMPA  receptor  
are  particularly  permeable  to  calcium  (Kirson  et  al.,  1999;  Talos  et  al.,  2006  a;  Talos  et  al.,  2006  
b;  Ewald  and  Cline,  2009)  because  upregulation  of  NR2B  and  NR2D  NMDA  subunits  (Ewald  and  
Cline,  2009;  Kirson  et  al.,  1999)  and  nonGluR2/GluR2  AMPA  conformation  in  rodents  (Talos  et  
al.,  2006  a)  and  humans  (Talos  et  al.,  2006  b).  Its  regulation,  and  therefore  sensitivity,  its  time-­‐  
and  cell-­‐  dependent  (Jensen,  2002;  Talos  et  al.,  2006  a;  Talos  et  al.,  2006  b;  Kaindl  et  al.,  2012).  
Furthermore,   glutamate  and  aspartate   levels   in   cerebrospinal   fluid   correlates  with   the  NHIE  
severity  (Johnston  and  Hoon,  2006).  
Another   important  characteristic   is   that   immature  brain   is  more  sensitive   to  oxidative  stress  
(Johnston  et  al.,  2011).  Since  arterial  oxygenation  saturation  in  fetal  blood  is  around  40-­‐45%  and  
it   is   increased  to  80-­‐90%  after  delivery,  neonatal  brain   is  already   in  a  pro-­‐oxidative  situation  
(Fatemi  et  al.,  2009).  This  is  aggravated  by  the  lower  concentration  of  antioxidant  molecules  like  
vitamin  E,  b-­‐carotene  or  melatonin  (Gitto  et  al.,  2009);  the  presence  of  unsaturated  fatty  acid    
(Gitto  et  al.,  2009;  Perrone  et  al.,  2015)  which  potentiates  lipid  peroxidation  and  ROS  generation;  
and  the  developmental  regulation  of  enzymes  involved  in  ROS  clearance  (Perrone  et  al.,  2015;  
Shim  and  Kim,  2013),  with   less  catalase  activity  and  glutathione  peroxidase  concentration   in  
developing  than  in  mature  oligodendrocyte,  for  example  (Baud  et  al.,  2004).  Moreover,  plasma  
from  healthy  term  newborns  shows  higher  quantities  of  free  iron  due  to  less  iron-­‐binding  protein  
concentrations,  which  produces  hydroxyl  radicals  by  hydrogen  peroxide  reaction  (Buonocore  et  
al.,  2001).    
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Immune  response  and   inflammation  are  also  more  harmful   for   immature  than  mature  brain  
(Johnston  et  al.,  2011).  Besides  the  fact  of  a  different  intracellular  signalling  of  inflammatory  
pathways  as  NF-­‐Kb  (Vexler  and  Yenari,  2009),  the  profile  of  immune  cell  infiltration  after  brain  
damage  is  different  in  adults  and  neonates  (Vexler  and  Yenari,  2009;  Winerdal  et  al.,  2012).  In  
this  context,  the  integrity  of  brain  blood  barrier  (BBB)  is  decisive.  Last  studies  pointed  out  that  
BBB   is   more   developed   at   birth   than   usually   supposed   (Moretti   et   al.,   2015)   and   that   its  
permeability  is  better  preserved  after  neonatal  than  after  adult  stroke  (Fernández-­‐López  et  al.,  
2012).  By  contrast,  as  HI  is  a  more  global  and  diffuse  damage,  a  time-­‐lapse  leakage  of  BBB  have  
been   observed   after   a   HI   insult   (Ek   et   al.,   2015).   Although   BBB   shows   higher   stability   after  
neonatal  stroke,  physiological  BBB  maturation   is   impaired  which  could  affect  developmental  
angiogenesis  (Fernández-­‐López  et  al.,  2013a).  
Another  possible  developmental  alteration  could  arise  from  the  activated  state  of  microglia  after  
the  damage.    Since  microglia  have  an  important  role  during  postnatal  development  promoting  
myelination,   synaptic   pruning   and   neuronal   activity   (Low   and  Ginhoux,   2018),   its   prolonged  
activation  may  alter  the  appropriate  circuitry  development.      
Overall,   these   characteristics   are   aggravated   by   the   fact   that   during   postnatal   development  
different  neurons  undergo  apoptosis   (Denaxa  et  al.,  2018;  Kim  and  Sun,  2011;  Nikolić  et  al.,  
2013).   That   physiological   process   is   important   to   prune   neuronal   networks,   eliminating   the  
excess   of   progenitor   cells   and   neurons,   in   order   to   reach   an   excitatory-­‐inhibitory   balance  
(Denaxa  et  al.,  2018;  Kim  and  Sun,  2011).  Not  only  neuronal  activity  but  also  neurotrophins  are  
important   to   promote   or   inhibit   apoptosis,   for   which   neonatal   neurons   are   predisposed   to  
(Denaxa  et  al.,  2018;  Nikolić  et  al.,  2013).    
Finally,  postnatal  brain   is  known  for   its  plasticity  and  the  synapse   formation   (Kolb  and  Gibb,  
2011).  Moreover,  proliferative  long-­‐term  responses  in  the  subventricular  zone  and  subgranular  
zone  has  been  described  after  HI  in  both  ipsilateral  and  contralateral  hemisphere  (Brégère  et  al.,  
2017;  Ong  et  al.,  2005).  Although  some  new  immature  neurons  are  observed,  particularly  in  the  
subgranular   zone   (Brégère   et   al.,   2017),   these   HI-­‐induced   cells   are   mainly   astrocytes   and  
oligodendrocytes  (Ong  et  al.,  2005).    
2.6  Neuroprotective  Strategies  
Despite  the  high  incidence  and  deleterious  consequences  of  both  PAIS  and  NHIE,  there  is  no  
other  approved  treatment  than  hypothermia  for  NHIE  in  term  infants    (Sagredo  et  al.,  2018).  
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Newborns  with  a  diagnosis  of  PAIS  are  only  treated  for  complications  as  infection  or  seizures,  
with  no  proper  treatment  for  the  stroke  itself  (Armstrong-­‐Wells  and  Ferriero,  2014;  Cnossen  et  
al.,  2009).    
Therapeutic  hypothermia  
Therapeutic  hypothermia  (TH)  is  the  only  treatment  currently  approved  for  HI,  in  which  whole  
body  are  cooled  to  33.5ºC  for  72h  after  HI  (Davidson  et  al.,  2015).    Use  of  TH  after  HI  improves  
survival  and  reduce  disabilities  in  different  clinical  and  preclinical  studies  (Fatemi  et  al.,  2009).    
However,   when   TH   is   applied   later   than   6   hours   after   HI   or   the   pathology   is   more   severe,  
hypothermia  is  not  neuroprotective  (Davidson  et  al.,  2015;  Edwards  et  al.,  2010;  Sabir  et  al.,  
2012).  In  fact,  TH  itself  could  be  harmful  for  neonates  if  is  prolonged  or  if  lower  temperatures  
are  used  (Shankaran  et  al.,  2017).  
Hereby,  there  is  a  need  of  new  synergic  molecules  which  can  act  with  TH,  increasing  therapeutics  
windows  or   improving  neuroprotective  effects  after  moderate  or  severe  HI.  Other  promising  
molecules   are  melatonin   and   erythropoietin.   Both  melatonin   and   erythropoietin   have   been  
proved  to  reduce  cell  death    and  brain  damage  in  animal  models  (Lee  et  al.,  2016;  Sinha  et  al.,  
2018),  by  mechanisms  that  include  neurogenesis  and  anti-­‐inflammatory  modulation  (Blanco  et  
al.,  2017;  Fan  et  al.,  2011;  Lee  et  al.,  2016;  Sinha  et  al.,  2018;  Wu  et  al.,  2016).    
In  conclusion,  due  to  the  high  incidence  and  deleterious  consequences  of  both  NHIE  and  PAIS  
and  the  partial  results  of  TH  in  NHIE,  the  research  of  new  molecules  which  administrated  with  
hypothermia  could  help  to  improve  the  pathology  outcome  is  one  of  the  first  need  of  current  
paediatric  research.  The  multifactorial  complexity  of  pathologic  events    prompt  the  necessity  of  
a  pleiotropic  molecule,  which  can  act  at  many  different  levels.  In  this  context,  cannabinoids  have  
risen  as  interesting  therapeutic  compounds  (Fernández-­‐Ruiz  et  al.,  2015;  Martínez-­‐Orgado  et  al.,  
2007;  Sagredo  et  al.,  2018).  
3.  CANNABINOIDS  
Cannabis  sativa  is  a  domesticated  hemp  whose  medical  use  has  been  explored  worldwide  for  
centuries,  from  ancient  China  to  Assyria  or  Persia  (Ligresti  et  al.,  2016).  “Cannabinoid”  is   the  
traditional  name  given  to  a  group  of  terpenophenolic  compounds  mainly  found  in  the  C.  sativa  
plant  (Andre  et  al.,  2016).  However,  since  the  description  of  the  Endocannabinoid  System  (ECS),  
the  term  cannabinoid  term  includes:  1)  phytocannabinoids,  the  ones  produced  by  the  plant;  2)  
endocannabinoids,      the   cannabinoids   synthesized   by   vertebrate   animals   and   3)   synthetic  
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cannabinoids,  which  have  been  chemically  synthesized   in   the   laboratory   (Andre  et  al.,  2016;  
Ligresti  et  al.,  2016).    
3.1  The  Endocannabinoid  System  
Research  on  phytocannabinoids   in   the  XX  century   led  to   the  discovery  of  ECS   (Ligresti  et  al.,  
2016).  The  ECS  is  an  endogenous  system  with  complex  interaction  with  other  systems,  like  the  
endocrine   or   the   immune   system,   playing   important   physiological   roles   such   as  
neurotransmission  modulation.  ECS  consists  of  ligands,  the  endocannabinoids,  the  synthesis  and  
degradation  enzymes  and  the  receptors  (Table  1).  
3.1.1  Endocannabinoids  
Defined  as  small  lipids-­‐derived  signalling  molecules,  endocannabinoids  can  be  found  throughout  
the  human  body,  including  peripheral  and  central  nervous  system  (Augustin  and  Lovinger,  2018).  
The  two  main  endocannabinoids  are  2-­‐arachidonoylglycerol   (2-­‐AG)   (Mechoulam  et  al.,  1995;  
Sugiura   et   al.,   1995)   and  N-­‐arachidonoylethanolamine   or   anandamide   (AEA)   (Devane   et   al.,  
1992)  (Fig.  5).    
2-­‐AG   was   discovered   in   1995  
(Mechoulam  et  al.,  1995;  Sugiura  et  
al.,   1995)   and   it   is   a   full   agonist   of  
cannabinoid  receptor  1   (CB1)  and      2  
(CB2)   (Stella   et   al.,   1997;   Zou   and  
Kumar,  2018).  At  least  in  one  order  of  
magnitude  more  abundant  than  AEA  
(Stella   et   al.,   1997;   Sugiura   et   al.,  
1995),   2-­‐AG   is   produced  
The  Endocannabinoid  System  
Endocannabinoids   2-­‐arachidonoylglycerol  (2-­‐AG);  N-­‐arachidonoylethanolamine  (AEA)  
Synthesis  enzymes  




Monoacylglycerol  lipase  (MAGL);  Fatty  acid  amide  hydrolase  (FAAH)  
Receptors   Cannabinoid  Receptor  1  (CB1);  Cannabinoid  Receptor  2  (CB2)  
Figure   5.   Chemical   structures   of   N-­‐








Anandamide (AEA) 2,Arachidonoyl3glicer l3(2,AG)
﻿N,Palmitoylethanolamine (PEA)
﻿N,Oleoylethanolamine (OEA)
Table  1.  Main  components  of  the  Endocannabinoid  System  
Introduction  
   27  
constitutively  at  basal  conditions  (Hashimotodani  et  al.,  2007;  Lee  et  al.,  2015).  On  the  other  
hand,  AEA    is  a  partial  agonist  of  CB1  with  non-­‐effect  on  CB2  receptor  (Silva  et  al.,  2013;  Zou  and  
Kumar,   2018).   AEA   acts   also   as   an   agonist   of   transient   receptor   potential   type   V   1   (TRPV1)  
(Fenwick  et  al.,  2017).    
3.1.2  Synthesis  machinery  
Endocannabinoids  are  synthesized  “on  demand”  after  an  increase  of  intracellular  calcium  and/or  
in  presence  of  substrate  (Gregg  et  al.,  2012;  Hashimotodani  et  al.,  2013;  Shonesy  et  al.,  2015)  
and  released  with  a  mechanism  that  remains  unknown  (Nicolussi  and  Gertsch,  2015).    
2-­‐AG  is  mainly  synthesized  by  diacylglycerol-­‐lipase  (DAGL)  from  diacylglycerol  (Shonesy  et  al.,  
2015;  Tanimura  et  al.,  2010).  Although  there  are  two  isoforms,  DAGLa  and  DAGLb  (Blankman  
and  Cravatt,  2013),  only  DAGLa  is  expressed  in  brain,  localized  in  postsynaptic  neurons  (Gregg  
et  al.,  2012),  astrocytes  and  microglia  (Suárez  et  al.,  2011).  
AEA   synthesis   is   far   more   complex   than   2-­‐AG’s   with   at   least   four   pathways   involved   in   its  
production   (Blankman   and   Cravatt,   2013).   The   principal   substrate   is   N-­‐arachidonoyl  
phosphatidylethanolamine  (NAPE)  which  is  directly  cleaved  by  NAPE-­‐phospholipase  D  (NAPE-­‐
PLD)   to  AEA      (Di  Marzo  et   al.,   1994;   Leishman  et   al.,   2016).  NAPE-­‐PLD   is   expressed   in  post-­‐
synaptic  terminals  (Hegyi  et  al.,  2012;  Reguero  et  al.,  2014)  and  in  micro  and  astroglia  processes  
(Hegyi  et  al.,  2012)  .    
3.1.3  Degradation  machinery  
After  an  endocannabinoid  has  exerted  its  function,  it   is  rapidly  re-­‐uptaken  into  the  cell  to  be  
degraded.  The  re-­‐uptake  mechanism  is  not  full  elucidated  but  it  may  include  binding  to  highly  
caveolae-­‐rich  membrane  domains    (Nicolussi  and  Gertsch,  2015)  or  passive  diffusion  through  
membrane    (Kaczocha  et  al.,  2009;  Nicolussi  and  Gertsch,  2015).  Some  studies  have  pointed  out  
the  existence  of  intracellular  carrier  like  fatty  acid  binding  proteins  (FABPs)  which  will  transport  
either   AEA   and   other   cannabinoids   like   cannabidiol      (CBD)   (Kaczocha   et   al.,   2012)   to   other  
intracellular  targets  such  as  peroxisome  proliferator-­‐activated  receptors  (PPAR)  (Kaczocha  et  al.,  
2012;   Yu   et   al.,   2014)   or   endocannabinoids   degradation   enzymes   (Kaczocha   et   al.,   2009;  
Nicolussi  and  Gertsch,  2015)  (Fig.  6).  
Fatty  acid  amide  hydrolase  (FAAH)  is  an  integral-­‐membrane  protein,  which  metabolize  AEA  to  
arachidonic  acid  and  ethanolamide  (Zou  and  Kumar,  2018).  In  brain  FAAH  expression  is  mainly  
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localized  on  dendrites  and  dendritic  spines  of  postsynaptic  neurons,  correlating  with  presynaptic  
CB1  receptor  (Baggelaar  et  al.,  2017;  Gulyas  et  al.,  2004).  
2-­‐AG  hydrolysis  to  arachidonic  
acid   and   glycerol   is   mainly  
carried   out   by  
monoacylglycerol   lipase  
(MAGL)   (Dinh   et   al.,   2002).  
MAGL  is  found  presynaptically  
in   axon   terminals   of   cerebral  
along   the   brain,   matching  
presynaptic   CB1   expression  
(Baggelaar  et  al.,  2017;  Dinh  et  
al.,   2002;  Gulyas  et   al.,   2004).  
Other   two   enzymes,   a/b-­‐
hydrolase   domain   contain   6  
(ABHD6)  and  12  (ABHD12)  are  
also   able   of   metabolize   2-­‐AG  
(Navia-­‐Paldanius  et  al.,  2012).  
Several   enzymes   like  
lipoxygenases,   NAE-­‐
hydrolyzing   acidamidase  
(NAAA),   cytochrome      P450,  
and   the   cyclooxygenase   2   (COX2)  may   degrade   AEA   or   2-­‐AG,   producing   some   endogenous  
metabolites  like  prostaglandins  (Blankman  and  Cravatt,  2013;  Gómez-­‐Ruiz  et  al.,  2007;  Nicolussi  
and  Gertsch,  2015)  
3.1.4.  Cannabinoid  Receptors    
3.1.4.a  Cannabinoid  Receptor  1  
CB1  receptor  is  a  G  protein-­‐coupled  receptor  (GPCR)(Hua  et  al.,  2016;  Matsuda  et  al.,  1990),  first  
discovered  and  cloned  in  rat  and  human  brain  (Devane  et  al.,  1988;  Gerard  et  al.,  1990;  Gérard  
et  al.,  1991;  Matsuda  et  al.,  1990).   Its  structure  has  been  recently  characterized   (Hua  et  al.,  
2016).  CB1  is  considered  the  most  abundant  receptor  protein  of  the  GPCR  family  in  the  brain,  
Figure   6.   Transport   and   degradation   machinery   of   the  
endocannabinoids  AEA  and  2-­‐AG.  Whether  by  diffusion  or  by  the  
membrane   transporter   activity,   the   endocannabinoids   are  
introduced  into  the  cell,  possibly   transported  by  FABP  and   then  
degraded  by  different  enzymes.  From  left  to  right:  AA=arachidonic  
acid;   MAGL=   monoacylglycerol   lipase;   2-­‐AG=2-­‐arachidonoyl  
glycerol;   ABHD6/12=a/b-­‐hydrolase   domain   contain   6/12;  
CB1=cannabinoid  receptor  1;  AEA=  N-­‐arachidonoylethanolamine  
or   anandamide;   EMT=putative   endocannabinoid   membrane  
transporter;   FABP=   fatty   acid   binding   protein;   FAAH=fatty   acid  
amide   hydrolase;   COX-­‐2=cyclooxygenase   2;   LOX=lipoxigenase;  
NAAA=  NAE-­‐hydrolyzing   acidamidase;   P450=  cytochrome     P450.  
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widely  expressed  in  both  central  and  peripheral  nervous  system  (Freundt-­‐Revilla  et  al.,  2017;  
Howlett   et   al.,   2002;   Zou   and   Kumar,   2018).   Its   localization   is   mainly   presynaptic,   in   axon  
terminals  of  both  GABAergic   and  glutamatergic  neurons   (Gulyas  et   al.,   2004;  Howlett   et   al.,  
2002).  It  has  been  involved  in  long-­‐term  depolarization  and  depolarization-­‐induced  suppression  
of  inhibition  or  excitation  and  consequently  memory  and  plasticity  phenomenon  (Augustin  and  
Lovinger,  2018;  Ohno-­‐Shosaku  and  Kano,  2014;  Oliveira  da  Cruz  et  al.,  2016;  Tanimura  et  al.,  
2010;  Wang  et  al.,  2018).  Outside  the  nervous  system,  CB1  is  expressed  in  liver  (Dai  et  al.,  2017),  
intestines  (Wright  et  al.,  2005),  muscles  (Mendizabal-­‐Zubiaga  et  al.,  2016),  adipocytes  (Lee  et  
al.,  2009)  or  testis  (Gérard  et  al.,  1991)  among  others.  
3.1.4.b  Cannabinoid  Receptor  2    
CB2   has   been   considered   the   “peripheral”   cannabinoid   receptor   since   its   discovery   in   1993  
(Munro  et  al.,  1993).  CB2  is  a  GPCR  receptor  mainly  expressed  in  immune  tissues,  like  tonsils  or  
spleen  (Galiègue  et  al.,  1995;  Munro  et  al.,  1993),  and  immune  cells  like  natural  killers  cells  and  
macrophages  (Galiègue  et  al.,  1995;  Turcotte  et  al.,  2016).  However,  in  the  nervous  system,  CB2  
has  been  well  characterized  in  microglial  cells  (Núñez  et  al.,  2004)  and  astrocytes  (Fernández-­‐
Trapero  et  al.,  2017a),  where   it   is  up-­‐regulated  in  activated  states   (Fernández-­‐Trapero  et  al.,  
2017a;  López  et  al.,  2018;  Maresz  et  al.,  2005;  Turcotte  et  al.,  2016).    CB2  presence  in  neurons  is  
controversial;   several   studies  have  not   found  expression   in   the  brain   (Galiègue  et   al.,   1995;  
Munro  et  al.,  1993)  while  others  have  found  it  in  brain  (Callén  et  al.,  2012;  Onaivi  et  al.,  2006),  
in  neuronal  or   endothelial   cells   in  physiological   conditions   (Brusco  et   al.,   2008;   Sickle   et   al.,  
2005).  Furthermore,  several  studies  have  proved  that  brain  CB2  receptor  is  up-­‐regulated  after  
stress   triggers   (Robertson   et   al.,   2017)   or   other   pathological   states   (Benito   et   al.,   2008;  
Fernández-­‐Trapero  et  al.,  2017a;  López  et  al.,  2018).  On  the  other  hand,  CB2  receptor  could  be  
responsible  for  a  specific  plasticity  in  hippocampus  (Stempel  et  al.,  2016)  as  well  as  neurogenesis  
in  subventricular  zone  (Goncalves  et  al.,  2008;  Palazuelos  et  al.,  2012).  Its  presence  and  role  has  
been  also  characterized  in  the  gastrointestinal  tract  (Wright  et  al.,  2005),  liver  (Dai  et  al.,  2017),  
reproductive  (El-­‐Talatini  et  al.,  2009)  or  cardiovascular  (Galiègue  et  al.,  1995)  system,  among  
others  (Zou  and  Kumar,  2018).    As  other  GPCRs,  CB2  forms  heteromers  with  CB1  (Callén  et  al.,  
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2012),  GPR55  (Balenga  et  al.,  2014)  and  chemokine  receptor  CXCR4  (Coke  et  al.,  2016)  have  been  
found.  
3.1.4.c.  Non-­‐CB1  Non-­‐CB2  Receptors  
Cannabinoid  ligands  are  known  to  interact  with  many  other  systems  and  receptors.  GPR55  is  a  
seven  membrane  coupled  to  a  protein  G  receptor  that  was  discovered  in  1999  (Sawzdargo  et  al.,  
1999).  GPR55  is  found  in  rat  and  human  brain  (Sawzdargo  et  al.,  1999;  Sharir  and  Abood,  2010)  
as  well  as  in  non-­‐nervous  tissues  like  lung,  liver  or  bladder  (Sharir  and  Abood,  2010).  Although  
the  exact  pathways  involved  in  GPR55  action  is  still  under  debate,  it  seems  that  both  Gq  and  Ga  
11/12  may  be  involved  (Lauckner  et  al.,  2008;  Sharir  and  Abood,  2010).  Both  CB1  and  CB2  are  able  
to  form  an  heteromer  with  GPR55,  attenuating  GPR55  signalling  pathways  (Balenga  et  al.,  2014;  
Kargl  et  al.,  2012).    
BOX4:  CB2  agonism  as  treatment  for  neurodegerative  diseases.  
  
The  direct  agonism  of  CB2  has  been  largely  used  as  a  target  for  the  treatment  of  both  acute  
and  chronic  neurodegenerative  pathologies  (Fernández-­‐Ruiz  et  al.,  2007)    
A   CB2   up-­‐regulation   has   been   observed   in   diverse   animal   models   of   chronic  
neurodegenerative   diseases   such   as   Huntington   (Sagredo   et   al.,   2009),   sclerosis   lateral  
amyotrophic   (Espejo-­‐Porras   et   al.,   2018),   Alzheimer   (López   et   al.,   2018)   or   Parkinson  
(Concannon   et   al.,   2016).   The   use   of   CB2   agonism   has   been   able   to   increment   neuron  
survival  (Espejo-­‐Porras  et  al.,  2018;  Oddi  et  al.,  2012;  M.  T.  Viscomi  et  al.,  2009)  and  improve  
neurological  outcome  (Espejo-­‐Porras  et  al.,  2018;  M.  T.  Viscomi  et  al.,  2009).  CB2  has  been  
found  in  glial  cells,  where  its  activation  seem  to  decrease  of  glia  activation,  associated  with  
neuronal  survival  (Espejo-­‐Porras  et  al.,  2018;  Fernández-­‐Ruiz  et  al.,  2007;  López  et  al.,  2018;  
Sagredo  et  al.,  2009;  Tolón  et  al.,  2009).  CB2  agonism  also  blocks  the  augmentation  of  iNOS  
expression  and  activity  and  reduces  ROS  and  peroxynitrites  levels  (Oddi  et  al.,  2012).  
Moreover,   the   administration   of   a   CB2   agonist   prevented   the   motor   and   cognitive  
impairment  associated  to  a  subarachnoid  haemorrhage  in  adult  rats,  reducing  the  oedema  
and  BBB  disruption  induced  by  this  pathology  (Fujii  et  al.,  2014b).    More  remarkably  for  this  
thesis  topic  similar  results  were  obtained  in  a  model  of  germinal  matrix  haemorrhage,  a  
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Other  important  target  receptor  for  cannabinoids  is  TRPV1.  TRPV1  is  a  channel  receptor  with  six  
transmembrane  domains   (De  Petrocellis   and  Di  Marzo,   2005)  which  plays   a   key   role   in  pain  
modulation  in  sensorial  neurons  (Bisogno  et  al.,  2001;  Gómez-­‐Ruiz  et  al.,  2007;  Lee  et  al.,  2015).  
Different   endocannabinoids   as   AEA   or   phytocannabinoids   as   CBD   are   able   to   activate   this  
receptor  (Bisogno  et  al.,  2001;  Kano  et  al.,  2009;  Marinelli  et  al.,  2007).    
Finally,   many   receptors   have   been   seen   to   interact   with   cannabinoids   like   PPAR   receptors  
(Kaczocha  et  al.,  2012;  Yu  et  al.,  2014)  or  several  orphan  GPCRs  as  GPR18  (Morales  and  Reggio,  
2017)  as  well  as  other  receptors  like  serotonin  (Russo  et  al.,  2005)  or  adenosine  (Morales  and  
Reggio,  2017)  receptors.  This  shows  the  complex  pharmacology  of  this  endogenous  system  as  
well  as  of    either  synthetic  and  pharmacological  compounds.  
3.1.5  Signalling  of  Cannabinoid  Receptors  
Broadly,  the  signalling  pathways  activated  by  CB1/CB2  receptor  depend  on  the  type  of  cell  and  G  
protein  coupled  to  the  receptor.  Usually  both  CB1  and  CB2  receptors  are  coupled  to  Gi/0  protein,  
which  supresses  the  adenylate  cyclase  and  consequently  reduces  the  cAMP  (cyclic  adenosine  
monophosphate)(Bouaboula  et   al.,   1996),   the  protein   kinase  A   (PKA)   activation  and   calcium  
influx   to   the   cell   (Kim   et   al.,   2005).      The   cannabinoid   receptor   activation   also   induces   the  
activation  of  ERK1/2  and  MAPK  pathway  (Bouaboula  et  al.,  1996;  Hytti  et  al.,  2017),  as  well  as  
the  activation  of    PI3K/Akt/mTORC1  pathway  (Blázquez  et  al.,  2015;  Kim  et  al.,  2005;  Palazuelos  
et  al.,  2012)  which   is  highly   involved   in   the  protective  and  neuroproliferative  effect  of   these  
receptors  (Blázquez  et  al.,  2015;  Palazuelos  et  al.,  2012).  On  the  other  hand,  CB1  also  binds  to  
Gs,  increasing  cAMP,  and  Gq11  (Gómez-­‐Ruiz  et  al.,  2007;  Zou  and  Kumar,  2018).  The  activation  of  
this  receptor  may  increase  
the  cytosolic  calcium  from  
endoplasmic  reticulum,  via  
phospholipase  C  and  1,4,5-­‐  
triphosphate   (IP3)  
(Redmond   et   al.,   2016;  
Zoratti   et   al.,   2003).   That  
mechanism   plays   an  
important   role   in   the  
release  of  glutamate   from  
astrocytes  (Oliveira  da  Cruz  

















Figure  7.Signalling  of  cannabinoid  receptors.  Depending  on  the  alpha  
subunit  associated   to   the  cannabinoid   receptor,   its  activation  would  
induce   an   specific   signalling   pathways,   explaining   the   complex   and  
diverse  response  associated  to  these  receptors.  CB1/CB2=cannabinoid  
receptor   1/2;   PLC=phospholipase   C;   IP3=1,4,5-­‐   triphosphate;   cAMP=  
cyclic   adenosine   monophosphate;   PKA=protein   kinase   A;  
ERK=extracellular  signal–regulated  kinases;  PI3K=phosphoinositide-­‐3-­‐
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Moreover,   CB1   modulates   the   inhibition   of   N-­‐type   and   P/Q-­‐type   calcium   channel   and   the  
activation  of  rectifying  potassium  channel  via  Gi/0  (Guo  and  Ikeda,  2004)  (Fig.  7).    
3.1.6.  Physiologic  roles  of  the  Endocannabinoid  System  
One  of  the  main  functions  of  the  ECS  in  the  Central  Nervous  System  is  the  modulation  of  synaptic  
transmission,  mainly  by  retrograde  modulation  in  which  the  endocannabinoids  released  by  the  
postsynaptic   neuron   after   synapse   activates   the   presynaptic   CB1   receptor.   This   activation  
triggers   the   hyperpolarization   of   the   neuron   and   consequently   ceases   the   neurotransmitter  
secretion   in  both  glutamatergic  and  GABAergic  pathways   (Augustin  and  Lovinger,  2018;  Haj-­‐
Dahmane  et  al.,  2018;  Hashimotodani  et  al.,  2013;  Ohno-­‐Shosaku  and  Kano,  2014;  Yu  et  al.,  
2014).  This  mechanism  participates  in  several  mechanism  of  plasticity  (Fenwick  et  al.,  2017;  Lee  
et  al.,  2015)  and  neural  function  (Augustin  and  Lovinger,  2018).  On  the  other  hand,  astrogial  CB1  
modulates  homo-­‐  and  hetero-­‐synapses  (Oliveira  da  Cruz  et  al.,  2016).  
On  the  other  hand,  ECS  plays  a  key  role  in  energy  and  metabolism  regulation   (Bénard  et  al.,  
2012;  Hillard,  2018;  Mendizabal-­‐Zubiaga  et  al.,  2016)  and  in  cardiovascular  (García  et  al.,  2009;  
Ho  et  al.,  2008)  or  endocrine  system  modulation  (Doboviŝek  et  al.,  2016),  among  others.  For  the  
topic  of  this  dissertation,  is  also  particularly  important  the  modulation  role  of  ECS  in  the  immune  
system  (Castaneda  et  al.,  2017;  Lou  et  al.,  2018).  
  
BOX5:  Endocannabinoid  modulation  of  oligodendrocyte  maturation.  
  
The  endocannabinoid  system  has  been  reported  to  modulate  oligodendrocyte  proliferation  
and  maturation  by  the  endocannabinoid  2-­‐AG  and  receptors  CB1  and  CB2   (Gomez  et  al.,  
2015).    Pharmacological  approximations  have  demonstrated  that  the  inhibition  of  DAGL,  or  
CB1  or  CB2   antagonism  decreased  myelin  production,  both   in   vitro   and   in   vivo   (Arevalo-­‐
Martin  et  al.,  2007;  Gomez  et  al.,  2010).  What  is  more,  cannabinoid  receptors  as  well  as  
endocannabinoid  synthesis/degradation  machinery  are  modulated  during  oligodendrocyte  
maturation,  with  a  peak  of  DAGL  expression  in  oligodendrocyte  progenitors  (Gomez  et  al.,  
2010).  In  fact,  a  recent  study  has  demonstrated  that  the  inhibition  of  MAGL,  main  hydrolytic  
enzyme   of   2-­‐AG,   is   able   to   reduce   oligodendrocyte   death   by   mild   activation   of   AMPA  
receptors  in  vitro  (Bernal-­‐Chico  et  al.,  2015).    
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3.2  Synthetic  cannabinoids  
The  name  of  synthetic  cannabinoids  references  to  all  the  compounds  chemically  synthesized  in  
a  laboratory  and  that  pharmacologically  interacts  with  the  ECS.  
3.2.1  Agonist  Ligands  
Agonist  ligands  can  be  classified  attending  its  chemical  structure:    
1)   Classical  cannabinoids  englobe  all  the  dibenzopyran  derivatives  produced  by  C.  sativa  
and  its  synthetic  analogues.  Some  of  the  most  important  are  D9-­‐  tetrahydrocannabinol  
(THC),   the  main  component  of   the  plant   (Gaoni  and  Mechoulam,  1964)  and  a  partial  
agonist  of  both  CB1  and  CB2  receptor,  HU-­‐210  or  JWH-­‐133  (Howlett  et  al.,  2002;  Pertwee  
et  al.,  2010;  Soethoudt  et  al.,  2017).    
2)   Non-­‐classical   cannabinoids   eliminate   the   pyran   ring   of   THC   structure.   Two   useful  
synthetic  non-­‐classical  cannabinoids  are:  CP-­‐55940,  a  potent  CB1/CB2  agonist,  and  HU-­‐
308,   a   highly   selective   CB2   receptor   agonist   (Howlett   et   al.,   2002;   Pertwee,   2009;  
Soethoudt  et  al.,  2017)  (Fig.  8).  HU-­‐308  is  highly  used  in  scientific  research  due  to  its  high  
specific   preference   for   CB2   receptor   and   a   well-­‐balanced   ligands   activation   of   the  
different  CB2-­‐associated  pathways  (Soethoudt  et  al.,  2017).  However,  HU-­‐308  also  binds  
some  off-­‐target  receptor  as  TRPV1  or  the  dopamine  transporter  (Soethoudt  et  al.,  2017).    
  
3)   Aminoalkylindoles   are  markedly  different   from  previous   cannabinoids   since   they  are  
derivatives  of  pravadoline.  The  main  cannabinoid   is  WIN55212,  a  potent   full  CB1/CB2  
agonist  (Howlett  et  al.,  2002).  
The   fourth   chemical   structure   of   cannabinoids   are   the   eicosanoids,   which   are   exclusively  
represented  by  endocannabinoids  as  AEA  or  2-­‐AG  (Howlett  et  al.,  2002;  Pertwee  et  al.,  2010).    
3.2.2  Antagonist  Ligands  
There   are   two  main   types   of   cannabinoid   antagonists:   diarylpyrazoles,   like   SR141716A   –   an  
specific  CB1  antagonist  (Soethoudt  et  al.,  2017)-­‐  ,  or  other  chemical  series,  like  6-­‐ioprovadalina  
or   AM630.   AM630   and   SR144528   are   both   selective   CB2   antagonist   (Pertwee   et   al.,   2010;  
Soethoudt  et  al.,  2017)  (Fig.  8),  even  though  AM630  is  also  a  full  agonist  of  transient-­‐receptor-­‐
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potential-­‐related  A1  (TRPA1)  (Soethoudt  et  al.,  2017).  However,    these  antagonists    can  also  act  




These  cannabinoids  are   terpenophenolic  molecules  extracted   from  the  plant  Cannabis  sativa    
(Iuvone  et   al.,   2009;  Pertwee,   2008)   (Fig.   9).     As   it   has  been  previously   explained,   this   field  
research  started  with  the  discovery  of  CBD  and  THC.  THC  is  the  main  component  of  the  plant,  
and  main  responsible  for  its  psychotropic  effects  (Gaoni  and  Mechoulam,  1964)  and  the  well-­‐
known  tetrad  effect  of  cannabis:  hypolocomotion,  hypothermia,  anhedonia  and  antinoception  
(Metna-­‐Laurent  et  al.,  2017;  Pertwee,  2008).  It  is  a  classical  cannabinoid  which  binds  of  both  CB1  
and  CB2  receptors  (Howlett  et  al.,  2002;  Pertwee,  2008),  with  slightly  preference  for  CB1  (Howlett  
et  al.,  2002;  Pertwee  et  al.,  2010);  the  principal  responsible  for  its  activities  (Blázquez  et  al.,  2015;  







Figure   8.   Chemical  
structures   of   CB2  
agonist   HU-­‐308  
and  CB2  antagonist  
SR144628   (SR2),  
taken  from  Rinaldi-­‐
Carmona,  1998.  
Figure   9.   The   structures  
of   the    
phytocannabinoids     THC,  
CBD,   cannabidiolic   acid,  
cannabigerol   and  
cannabinol   from  
Cannabis   sativa.   Taken  
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3.3.1  Cannabidiol  
This  phytocannabinoid  was  characterized   in  1963  by  Mechoulam  and  Shuo   (Mechoulam  and  
Shvo,  1963)  and    is  the  second  major  cannabinoid  in  the  plant,  modulating  collateral  effects  of  
THC  (Pisanti  et  al.,  2017).  Due  to   its   lipophilic  nature,  CBD  has  poor  bioavailability  but  easily  
crosses  the  brain  blood  barrier,  and  it  is  lately  inactivated  by  cytochrome  P450  (Pisanti  et  al.,  
2017).    
CBD   has   a   complex   pharmacology.   It   has   micromolar   affinity   for   CB1   and   CB2   receptor  
(McPartland  et  al.,  2014).  Recent  studies  have  proved  that  can  act  as  allosteric  modulator  of  
both  receptors  (Laprairie  et  al.,  2015;  Martínez-­‐Pinilla  et  al.,  2017).  In  fact,  several  studies  have  
proved  that  both  CB1  and  CB2  mediated  CBD  action  (McPartland  et  al.,  2014;  Stanley  et  al.,  2015)  
whereas  CBD  prevents  both  AEA  re-­‐uptake  and  hydrolysis  (Bisogno  et  al.,  2001).  CBD  is  a  TRPV1  
agonist  (Bisogno  et  al.,  2001;  Costa  et  al.,  2004;  Hassan  et  al.,  2014;  Sagredo  et  al.,  2007)  and  
binds  to  serotonin  receptor  5-­‐HT1A  and  several  PPAR  receptors  (Hegde  et  al.,  2015;  Hind  et  al.,  
2016;  Pazos  et  al.,  2013;  Russo  et  al.,  2005).  Moreover,  CBD  interacts  with  adenosine  receptors  
(Castillo  et  al.,  2010;  Sagredo  et  al.,  2007)  .  
On  the  other  hand,  by   its  own  structure  with  
the   phenol   ring   and   alcohol   group,   CBD   is   a  
potent   antioxidant,   more   potent   even   than  
ascorbate   (Hampson   et   al.,   1998).   Indeed,  
decreased   levels   of   reactive   oxygen/nitrogen  
species   has   been   observed   after   CBD  
administration  (El-­‐Remessy  et  al.,  2003;  Iuvone  
et   al.,   2004;   Mukhopadhyay   et   al.,   2011).    
Furthermore,   CBD   is   also   able   of   modulate  
intracellular   calcium   (Hassan   et   al.,   2014;  
Iuvone   et   al.,   2004;   Mato   et   al.,   2010;  
McPartland  et  al.,  2014)  and  reduce  glutamate  
release   (Castillo   et   al.,   2010;   Gobira   et   al.,  
2015;   Lafuente   et   al.,   2016).   CBD   is   also   a  















Figure  10.  Neuroprotective  effects  of  CBD.    
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al.,  2013)  and  cytokines  and  chemokines  release  (Esposito  et  al.,  2007;  Mecha  et  al.,  2013;  Vilela  
et  al.,  2017)  (Fig.  10).    
CBD  administration  is    protective  in  models  of  different    diseases  in  which  inflammation  plays  a  
key  role,  as  multiple  sclerosis  (Mecha  et  al.,  2013),  hepatic  ischemia(Mukhopadhyay  et  al.,  2011)  
or  Alzheimer  (Esposito  et  al.,  2007).  Moreover,  CBD  treatment  has  showed  myelin  protective  
effects,  preventing  OPC  death  by  both  inflammatory  and  oxidative  stress  in  vitro  (Mecha  et  al.,  
2012).  In  different  animal  models  of  demyelinating  diseases  CBD  by  itself  or  co-­‐administrated  
with   other   cannabinoids   improves   the   neurobehavioral   outcome   diminishing   demyelination  
severity  and  axonal  damage  by  modulating   inflammation   (Feliú  et  al.,  2015;  Giacoppo  et  al.,  
2015;  Rahimi  et  al.,  2015).  CBD  has  also  demonstrated  being  a  potent  anticonvulsivant  drug  
(Gobira  et  al.,  2015;  Vilela  et  al.,  2017),  culminating  with  the  approval  of  cannabidiol  (Epidiolex  
©),   for   refractory  epilepsies   and  with   remarkable   results   in  Dravet   syndrome   (Kaplan  et   al.,  
2017;  Porter  and  Jacobson,  2013)  
4.  THE  ENDOCANNABINOID  SYSTEM  IN  HYPOXIC-­‐ISCHEMIC  BRAIN  
DAMAGE  
The   ECS   is   affected   by   the   hypoxia-­‐ischemia   insults.   Firstly,   the   levels   of   AEA,   2-­‐AG   and  
endocannabinoids-­‐like   molecules,   oleoylethanolamide   and   palmitoylethanolamide,   increase  
shortly  after  the  damage  in  adult  (Hillard,  2008)  and  newborn  animals  (Pazos  et  al.,  2013).  Due  
to  AEA  and  oleoylethanolamide  activity  in  BBB  permeabilization  (Hind  et  al.,  2015)  they  might  
play  an  important  role  after  HI/PAIS  insult.  On  the  other  hand,  an  increase  of  CB2  but  not  CB1  
receptor  has  been  observed  in  newborn  rats  in  the  subventricular  zone  48  hours  after  the  insult,  
which      is  normalized  one  week  after  damage  (Fernández-­‐López  et  al.,  2010).   Interestingly,  a  
rapid  increase  of  CB1  but  not  CB2  has  been  observed  in  an  oxygen  and  glucose  deprivation   in  
vitro  model  (OGD)  (Fernández-­‐López  et  al.,  2006).  
ECS  alteration  has  also  been  studied  in  an  adult  mice  model  of  stroke,  where  a  rapid  increase  of  
CB1  and  slower  augmentation  of  CB2  levels,  after  an  initial  decrease,  is  observed  (Zhang  et  al.,  
2008).  Controversially,  another  study  has  proved  that  CB1  receptor  is  decreased  in  both  cortex  
and  striatum  24  hours  after  middle  cerebral  artery  occlusion   in  adult  mice   (Hayakawa  et  al.,  
2007b).  
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5.   CANNABINOIDS   AS   TREATMENT   IN   NEONATAL   HYPOXIA-­‐
ISCHEMIA  ENCEPHALOPATHY  AND  PERINATAL  ARTERIAL  ISCHEMIC  
STROKE    
Several   pharmacological   ECS   modulation   has   been   studied   in   several   animal   models   of  
NHIE/PAIS  treatment.  On  one  hand,  the  administration  of  endocannabinoids  such  as  AEA  or  2-­‐
AG   after   neonatal   HI   in   rats,   reduces   damage   and   cell   death   one   week   after   damage   by  
modulating   intracellular   calcium   and   decreasing   ROS   production   (Lara-­‐Celador   et   al.,   2012).  
Endocannabinoid-­‐like  oleylethanolamide  administration  diminishes  BBB  permeabilization  after  
OGD  (Hind  et  al.,  2015).    
The   agonism   of   CB1   and   CB2   receptors   is   neuroprotective   both   in   vitro   and   in   vivo.   The  
administration  of  WIN55212-­‐2after  HI  insult  in  newborn  rat  pups  reduces  brain  volume  damage  
as  well  as  cell  death  (Fernández-­‐López  et  al.,  2007),  which  correlates  with  in  vitro  results  where  
WIN55212-­‐2  also  prevents  the  increase  on  glutamate,  iNOS  and  TNFa  (Fernández-­‐López  et  al.,  
2006).   Moreover,   WIN55212-­‐2   also   induces   myelin   restoration   and   the   increase   of   OPC  
proliferation  and  maturation   (Fernández-­‐López  et  al.,  2010).  However,  different  studies  have  
proved   that   over-­‐activation   of   CB1   receptor   in   the   perinatal   period   could   be   harmful,   since  
neonatal  brain  is  more  susceptible  to  neuronal  death  induced  by  CB1  (Downer  et  al.,  2007).  CB1  
over-­‐activation   in   immature   brain   also   induces   long-­‐lasting   T   cell   development   impairment  
(Lombard   et   al.,   2011)   and   alters   cell   adhesion   molecules   in   neurons   involved   in   brain  
development  (Gómez  et  al.,  2007).    
In  the  last  years  CBD  has  been  pointed  out  as  a  good  treatment  for  infant  pathologies  because  
it  does  not  bind  CB1  receptors  (McPartland  et  al.,  2014).  In  HI  animal  models,  CBD  administration  
post-­‐insult  is  associated  with  a  neurophysiological  and  neurobehavioral  improvement  (Alvarez  
et  al.,  2008;  Lafuente  et  al.,  2011;  Pazos  et  al.,  2013,  2012),  in  both  short  (Alvarez  et  al.,  2008;  
Lafuente   et   al.,   2011)   and   long-­‐term   studies   (Pazos   et   al.,   2012).      This   CBD   protection   is  
associated  with  decreased  cell  death   in  vitro  (Castillo  et  al.,  2010)  and   in  vivo,   in  both  piglets  
(Alvarez  et  al.,  2008;  Lafuente  et  al.,  2011;  Pazos  et  al.,  2013)  and  rat  pups  (Pazos  et  al.,  2012).    
Such  effects  are  related  with  the  reduction  of  excitotoxicity,  neuroinflammation  and  oxidative  
stress  (Alvarez  et  al.,  2008;  Castillo  et  al.,  2010;  Pazos  et  al.,  2013,  2012).  Finally,  CBD  is  able  to  
prevent   the   increase  of  BBB  permeability  associated  to  OGD   in  an   in  vitro   study   (Hind  et  al.,  
2016).  
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CBD  has  also  been  used  for  stroke  treatment  in  adult  mice,  where  it  reduces  the  infarct  volume  
via  serotonin  receptor  5-­‐HT1A  activation  (Mishima  et  al.,  2005)  but  not  via  TRPV1  (Mishima  et  
al.,   2005)   or   CB1   (Hayakawa   et   al.,   2007a,   2004).   This   neuroprotection   is   correlated   with  
inflammation  decrease  (Hayakawa  et  al.,  2007a;  Khaksar  and  Bigdeli,  2017).  
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As  described  in  the  Introduction,  nowadays  there  is  an  urgent  need  for  additional  treatments  to  
hypothermia   for   neonatal   encephalopathies.   Its   complex   and  multifactorial   pathophysiology  
requires   pleiotropic  molecules,   such   as   cannabinoids,   which   can   act   on   different   processes  
involved   in   the   damage.   In   this   context,   CBD   has   been   pointed   out   as   a   promising   drug   for  
neonatal   hypoxic-­‐ischemic   brain   damage.   This   phytocannabinoid   decreases   excitotoxicity,  
oxidative  stress  and  inflammation,   i.e.  the  “deadly  triad”  in  a  hypoxic-­‐ischemic  event.  In  fact,  
very  exciting  results  have  been  reported  in  previous  works.  Furthermore,  this  compound  has  no  
psychotropic  activity  which  allows  its  safe  use  in  newborns.      
HYPOTHESIS  
CBD  administration  post-­‐injury  will  exert  short-­‐  and  long-­‐term  protective  effects  in  models  of  
either  neonatal  global  or  focal  HI,   i.e.  NHIE  or  PAIS  respectively.  CBD  will  exert  its  protective  
effects  by  inhibiting  the  “deadly  triad”  independently  from  the  global  or  focal  nature  of  the  insult  
and  consequently,  protect  oligodendrocytes  and  neurons  and  modulate  microglia  and  astroglia  
activation,  in  a  manner  in  which  CB2  receptor  activation  would  be  involved.    
GOALS  
1.   To  characterize  short-­‐  and  long-­‐term  CBD  neuroprotective  effects  in  a  focal  model  of  
hypoxic-­‐ischemic  brain  injury  in  newborn  rats.  
  
2.   To  analyze  HI-­‐induced  long-­‐lasting  hypomyelination  in  White  and  Grey  Matter  and  its  
prevention  by  CBD.    
  
3.   To   assess   whether   CBD   hypomyelination   prevention   is   related   with   brain   cell  
proliferation  activation  and  glial  response  modulation.  
  
4.   To   study   the   involvement   of   CB2   receptor   activation   in   CBD   protective   effects   in   a  
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1.  ANIMAL  MODELS  
All  the  animal  experimental  procedures  were  previously  approved  by  the  Ethical  Committee  for  
Animal  Welfare  of  the  Hospital  Universitario  Puerta  de  Hierro  Majadahonda  and  Hospital  Clínico  
San  Carlos  (Madrid,  Spain),  and  met  the  European  and  Spanish  regulation  (86/609/EEC  and  RD  
1201/2005,  and  2010/63/EU  and  RD  53/2013).    
Two  models  were   used   to   study   the   neuroprotective   effect   of   CBD   on  NHIE.   Global   HI  was  
reproduced  using  the  Rice-­‐Vannucci  procedure,  from  now  on  named  just  as  HI,  while  temporary  
middle   cerebral   artery   occlusion   (MCAO)   protocol   was   used   for   PAIS.   Both   models   were  
performed   in  7   to  10  days  old  Wistar   rat  pups,   the   equivalent   to  35-­‐to-­‐38  week-­‐old  human  
newborn  (Semple  et  al.,  2013).  The  experiments  were  designed  to  use  the  minimal  number  of  
animals  to  achieve  statistical  significance.      
In  order  to  avoid  rejection,  dam  was  conditioned  previously  to  the  surgical  procedure  for  the  HI  
experiment.      The   dam   and   its   litter  were   kept   in   different   cages   for   ten  minutes   and   then  
reunited   for   another   ten.   That   was   repeated   twice,   and   in   every   separate   time   pups   were  
sprayed  with  chlorhexidine,  the  antiseptic  used  after  the  procedure,  so  the  dam  may  get  used  
to  the  odour.  Importantly,  during  the  second  separation  the  dam  was  kept  in  another  room.  
Pups  from  each  litter  were  randomly  assigned  to  the  surgical  protocol  or  control.  
1.1  Hypoxic-­‐Ischemic  brain  damage  induction  
As  explained  before,   the  aim  of   this  animal  model   is   to  reproduce  the  diffuse  brain  damage  
caused  by  NHIE.    HI  brain  damage  animal  model  was  based  on  Rice-­‐Vannucci  protocol  (Vannucci  
&  Vannucci,  2005)  with  slight  modifications  (Pazos  et  al.,  2012).  On  postnatal  day  (PND)  7  to  10  
Wistar  rats  were  anesthetized  by  sevofluorane  (5%  induction,  1%  maintenance)  and  their  left  
carotid  artery  was  isolated  and  electrocoagulated.  Then  they  were  returned  to  their  dam  for  3  
hours  to  recover.  After  that,  pups  were  placed  into  500mL  jars  in  groups  of  three  and  exposed  
to  hypoxia  (10%  fraction  of  inspired  oxygen)  for  112  minutes  (HI-­‐operated  animals).  Jars  were  
kept  in  a  warm  water  bath  at  37ºC  in  order  to  avoid  hypothermia.  For  control  group  (SHAM-­‐
operated   animals),   similar   surgical   procedure   was   performed   but   without   carotid  
electrocoagulation  or  hypoxia  (Fig.11).  
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Ten  minutes  after  the  end  of  hypoxia  or  equivalent  period,  SHAM  and  HI  rat  pups  were  randomly  
treated  with  a  subcutaneous  (s.c)   injection  of  vehicle  (HV)  or  CBD  1mg/kg  (HC),  as  previously  
described  by  Pazos  et  al.,  2012  (Fig.1).  Following  drug  administration,  pups  returned  to  their  
cage  with  their  dam  for  24  hours  (24h)  or  7  days  (7  d).  In  the  case  of  pups  followed  for  up  to  30  
days  (30  d),  weaning  was  at  PND21  and  then  males  and  females  were  grouped  separately.  
For   CB2   experiment,   the   specific   CB2   agonist   HU-­‐308   and   the   antagonist/inverse   agonist  
SR144528  (SR2)  were  chosen.  The  HU-­‐308  dose  was  previously  optimized  by  a  dose  curve  from  
1  to  10  mg/kg  due  to  the  high  variability  of  doses  found  in  bibliography,  while  SR2  was  used  at  
3   mg/kg   (Fujii   et   al.,   2014a;   Tao   et   al.,   2015;   Maria   Teresa  
Viscomi   et   al.,   2009).      Six   different   experimental   group  were  
designed:  VEH/VEH  (HI+VEH),  VEH/CBD  (HI+CBD),  VEH/HU-­‐308  
(HI+HU),   SR2/VEH   (HI+SR2),   SR2/CBD   (HI+SR2+CBD),   SR2/HU-­‐
308  (HI+SR2+HU)  and  HU-­‐308/CBD  (HI+HU+SR2).  Following  the  
HI  protocol  previously  described,  ten  minutes  after  the  end  of  
hypoxia,   HU-­‐308,   SR2   or   vehicle   were   administrated   and   ten  
minutes  later,  well  CBD  1mg/kg  or  VEH  were  co-­‐administrated.  
Finally,   pups   were   returned   to   their   dam   for   7   days   before  
sacrifice  (Table  2).  
1.2  Temporary  Middle  Cerebral  Artery  Occlusion    
This  model  is  an  adaptation  of  the  well-­‐known  stroke  model  in  adult  rodents  adapted  for  7-­‐to-­‐
9-­‐day  old  rats  by  Derugin  et  al.  (Derugin  et  al.,  1998).  Each  pup  was  anesthetized  by  sevofluorane  
(5%  induction,  1%  maintenance),  and  the  left  carotid  was  dissected  up  the  internal  and  external  
branches.  A  small  cut  was  done  at  the  beginning  of  the  internal  carotid  artery,  then  an  occluder  
(0.21mm  of  diameter)  was   introduced  until   it   stucks  at   the  origin  of   the   left  middle  cerebral  
artery   (8.5-­‐9mm).   Then,   the   wound   was   sealed,   the   pup   awakened   for   a   three-­‐hour-­‐long  
Figure  11.  Rice-­‐Vanucci  animal  model  protocol  
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occlusion  period.    Then,  pups  were  anesthetized  again  and  the  occluder  removed.  The  carotid  
was  quickly  sealed  with  collagen  to  avoid  bleeding.  During  all  the  procedure  pups  were  kept  at  
37-­‐38ºC  using  a  heat  blanket.   Control   group   (SHM)   undergo   the   same  protocol  without   left  
carotid   dissection   or   middle   cerebral   artery   occlusion.   Ten   minutes   after   occluder   removal  
animals   were   randomly   assigned   to   receive      CBD   (MCAO-­‐CBD)   or   vehicle   (MCAO-­‐VEH)  
intraperitoneally  (i.p.)  (Fig.  2).  Different  doses  of  CBD,  such  as  1,  5,  10,  50  or  100  mg/Kg.  Finally,  




1.3  Drug  preparation  
CBD  and  VEH  were  a  gift  from  GW  Research  Ltd  (Cambridge,  UK)  while  HU-­‐308  was  a  generous  
donation  from  Prof.  Raphael  Mechoulam  of  Institute  for  Cannabinoid  Research  at  the  Medical  
Faculty  in  the  Hebrew  University  (Jerusalem,  Israel).  Because  of  cannabinoid  hydrophobicity  all  
plastic  tubes  were  pre-­‐treated  with  Sigmacote  (Sigma-­‐Aldrich;  San  Luis,  USA).  
For  the  HI  and  MCAO  models,  CBD  was  prepared  as  follows:  CBD  was  dissolved  in  ethanol  and  
then  Solutol  (BASF  SE,  Ludwigshafen,  Germany)  and  saline  were  slowly  added  at  60ºC  to  a  final  
proportion  of  ethanol:solutol:saline  1:1:17.  Finally,  the  stock  solution  at  5mg/mL  was  aliquoted  
and  immediately  stored  at  -­‐20ºC.    
For  PAIS  experiments  both  CBD  stock  at  3  mg/mL  concentration  and  VEH  were  supplied  by  GW  
Research  Ltd  (Cambridge,  UK).  The  injectable  solution  was  prepared  the  day  of  the  experiment  
by  diluting  the  stock  at  3mg/mL  with  saline  to  the  desired  dose.  
HU-­‐308  and  SR2  were  directly  dissolved  in  ethanol,  gassed  with  nitrogen  to  avoid  oxidation  and  
rapidly  stored  at  -­‐20ºC  as  a  stock  solution  containing  HU-­‐308  40mg/mL  or  SR2  47.62mg/mL.  The  
day   of   the   experiment   HU-­‐308   or   SR2   were   further   diluted   in   Solutol   or   Tween-­‐80   (Sigma-­‐
Aldrich;  San  Luis,  USA)  and  saline  to  a  final  proportion  of  1:1:17.    
Figure  12.  Middle  Cerebral  Artery  Occlusion  protocol  
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In  all  cases  the  injectable  solution  was  prepared  in  order  to  administrate  0.1mL  per  animal  at  
the  desired  concentration.  
2.  NEUROBEHAVIORAL  TESTS  
To  evaluate  functional  impairment  after  HI  and  MCAO  models,  different  tests  were  performed  
seven   and   thirty   days   after   the   insult.   Due   to   both   motor   and   cognitive   skills   are   not   fully  
developed  at  PND14-­‐PND17,  only  motor  reflexes  and  basic  motor  coordination  were  assessed  
at  this  age.  One  the  other  hand,  at  least  two  motor  and  one  cognitive  test  were  performed  in  
each  model  thirty  days  after  the  insult,  in  order  to  evaluate  neurobehavioral  impairment.  The  
functional  tests  were  analyzed  by  two  different  examiners  blinded  to  the  experimental  group.    
2.1  Neonatal  rat  motor  tests.  
Seven  days  after  the  brain  damage  several  motor  test  were  performed  to  analyze  motor  reflexes  
and  motor  coordination  (Bouet  et  al.,  2010;  Heyser,  2004)  (Fig.  13):    
-­‐   Negative   geotaxis:   the   negative   geotaxis   test   was   developed   to   asses   motor  
coordination  in  young  rat.  Each  pup  was  placed  facing  down  a  45º  slope  and  the  time  
required  to  turn  up  the  slope  was  measured.  Animals  with  greater  motor  affectation  will  
used  more  time  to  complete  the  task  (Ten  et  al.,  2003).  
-­‐   Front-­‐limb  suspension  test:  this  test  was  applied  to  measure  the  forelimb  strength  of  
pups.  Briefly,  pups  were  suspended  hanging  from  a  wire  with  both  forelimbs.  The  time  
to  fall  is  recorded,  with  smaller  time  in  animals  with  poorer  outcome  (Fan  et  al.,  2005).  
-­‐   Grip   reflex:   the   goal   of   this   test   is   analyzing   the   reflex   lost   in   contralateral   limb   as  
consequence  of  unilateral  brain  damage.  The  rat  was  held  by  the  experimenter  and  a  
thin  rod  is  used  to  measure  the  grasp  reflex  in  both  fore-­‐  and  hind-­‐limbs.  Being  2  =  digit  
flexion;  1  =  partial  or  delayed  (more  than  2  seconds)  digit  flexion;  0  =  digit  extension  
(Bouet  et  al.,  2010).  
-­‐   Grasp  reflex:  this  test  measures  the  reflex  of  getting  a  support  surface  when  the  pup  is  
held  in  the  air  by  the  examiner.  With  the  rat  held  by  the  experimenter  by  the  neck,  a  rod  
is   approximated   to   both   hind-­‐limbs   and   the   reflex   of   carrying   its   own   weight   is  
measured.  Being  2  =  full  weight;  1  =  partial;  0  =  no  movement.  
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2.2  Adult  rat  motor  and  cognitive  tests.  
One  month  after  the  brain  damage  different  cognitive  and  sensorimotor  tests  were  used  (Bouet  
et  al.,  2010;  Pazos  et  al.,  2012;  Russel  et  al.,  2011;  Schaar  et  al.,  2010)  (Fig.14):  
-­‐   Beam  test:  to  measure  motor  and  coordination  deficits  (Patel  et  al.,  2015;  Russel  et  al.,  
2011;  Schaar  et  al.,  2010;  Woodworth  et  al.,  2011).  In  this  test  the  rat  was  encouraged  
to  cross  a  beam  1  m-­‐long  with  a  flat  surface  1  cm  wide  held  at  50  cm  height.  At  the  start  
point  of  the  beam,  a  strong  white  lamp  was  used  to  incite  the  rat  movement  while  a  
dark  chamber  was  located  at  the  end.    A  training  day  was  necessary  to  avoid  rat  turns  
or  stops,  in  which  rat  first  crossed  by  a  close  platform  followed  by  crossing  the  beam  
(Schaar  et  al.,  2010).  The  rat  was  let  in  dark  chamber  with  palatable  food  for  10  seconds  
each  time.  The  time  required  to  cross  the  beam  was  measured.    
-­‐   Cylinder   Rearing   test   (CRT):   to   asses   lateral   bias   of  motor   deficits   (Kim   et   al.,   2017;  
Woodworth   et   al.,   2011).   The   animal   is   placed   in   a   transparent   cylinder   (20   cm   in  
diameter  and  30  cm  in  height)  for  five  minutes  and  the  number  of  each  forepaw  placing  
in  the  surface  of  the  cylinder  is  counted.  The  possible  bias  to  the  left  -­‐ipsilateral-­‐  forepaw  
use  was  calculated  as  [(left  -­‐  right)/(left  +  right  +  both)]*100.  At  least  four  wall  contacts  
per  rat  were  necessary  for  trial  analysis.  
-­‐   Adhesive  Removal  Test:  to  analyse  motor  coordination  and  fine  sensorimotor  deficits  
(Schaar  et  al.,  2010;  Woodworth  et  al.,  2011).  Rats  were  previously  habituated  to  the  
cylinder  (20  cm  in  diameter  and  30  cm  in  height).  Equal  adhesive  tapes  were  placed  in  
each   forepaw   with   the   same   force   and   the   time   required   to   detect   -­‐showed   by   a  
forepaw’s  contact-­‐  is  measured  (Bouet  et  al.,  2010).      
Figure   13.   Motor   Reflexes   and   Motor   Coordination   tests   seven   days   after   damage.   A)   Negative  
geotaxis;  B)  Fore-­‐limb  suspension  test;  C)  Grip  reflex;  D)  Grasp  reflex.  
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-­‐   Novel  Object  Recognition  test  (NOR):    to  asses  non-­‐spatial  working  memory  (Patel  et  al.,  
2015;  Pazos  et  al.,  2012).  Habituation  to  the  cage  (40  x  40  x  30  cm)  was  done  the  day  
before  the  experiment.  On  the  texting  day,  the  animal  was  previously  placed  in  the  cage  
with  two  identical  objects  for  five  minutes.  Rats  rested  for  an  hour  and  then  returned  to  
the  cage  where  one  object  had  been  replaced  by  a  new  one  for  the  trial.  The  trial  lasted  
five  minutes  and  was  recorded  for  forthcoming  quantification  of  the  exploring  time  of  
each  object.  The  discrimination  index  was  calculated  as:  (Timenew  object  –  Timefamiliar  object)/    
(Timenew  object  +  Timefamiliar  object).  
3.  SAMPLING  
After  the  functional  tests,  rats  were  sacrificed  under  deep  anesthesia  (diazepam:ketamin  [i.p.])  
and  transcardially  perfused  with  0.1M  phosphate-­‐buffered  saline,  pH  7.4  (PBS)  followed  by  4%  
paraformaldehyde  to  perform  MRI  followed  by  immunohistochemical  studies.  For  the  electron  
microscopy  studies,  rats  were  perfused  with  PBS,  followed  by  the  fixative  solution  made  up  of  
4%   formaldehyde,   0.2%  picric   acid,   and  0.1%  glutaraldehyde   in  PBS.  Brains   remained   in   the  
fixative  solution  for  1  week  at  4°C  and  then  stored  at  4°C  in  a  1:10  diluted  fixative  solution  until  
use.    
For  Western-­‐Blot  experiments  and  Magnetic  Resonance  Spectroscopy  (H+-­‐MRS),  7  days  post-­‐HI  
rats  were  sacrificed  by  carbon  dioxide  followed  by  a  rapid  decapitation.  Brains  were  dissected,  
snap-­‐frozen  in  isopentane  and  stored  at  -­‐80ºC.  
4.  MAGNETIC  RESONANCE  IMAGING  
MRI   is   a   well-­‐known   system   to   quantify   brain   damage   and   oedema   (Larpthaveesarp   and  
Gonzalez,  2017;  Pazos  et  al.,  2012).  Brain  MRI  scans  were  performed  at  MRI  Unit  of  the  Instituto  
Figure   14.  Neurobehavioral   tests  performed   thirty   days  after   damage.   A)  Beam   test;  B)  Cylinder  
Rearing  test;  C)  Adhesive  Removal  test;  D)  Novel  Object  Recognition  test.  
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de  Investigaciones  Biomédicas  “Alberto  Sols”  (CSIC-­‐UAM,  Madrid,  Spain)  on  a  BIOSPEC  70/16  
(Bruker-­‐Medical,  Ettlingen,  Germany)  or  at  the  CAI  de  Resonancia  Magnética  Nuclear  y  Espín  
Electrónico  (Instituto  Multidisciplinar,  Universidad  Complutense  de  Madrid)  on  a  BIOSPEC  47/40  
(Bruker-­‐Medical,  Ettlingen,  Germany).    MTI  devices  operates  at  4.7  T,  equipped  with  an  actively  
shielded  gradient  insert  with  an  11.2  cm  bore,  a  maximal  gradient  strength  of  200  mT/m,  an  80  
μs  rise   time,  and  a  home-­‐made  4  cm  surface  coil.  T2WI  was  acquired  with  a  multislice  rapid  
acquisition  (TR  =  3.4  s,  RARE  factor  =  8,  interecho  interval  =  30  ms,  TEeff  =  120  ms;  matrix  size  =  
256   x  256   (pixel   dimensions  117   x  117  μm),   field  of  view   (FOV)  =  3   cm2).   The   slice  package  
consisted  of  26  consecutive  0.5-­‐mm-­‐thick  slices  in  the  axial  plan  with  an  interslice  gap  of  0.1  mm  
to  image  the  entire  brain.  To  perform  the  MRI  scan,  brains  were  placed  in  Fluorinert  FC-­‐40  (3M,  
Minnesota,  USA)  and  then  re-­‐placed  in  paraformaldehyde  .    
Both  the  entire  brain  volume  loss  and  the  percentage  of  high  intensity  signal  area  were  analysed  
using  the  ImageJ  1.43u  software  (National  Institute  of  Health  [NIH],  Bethesda,  USA)  (Pazos  et  al.,  
2012).  
5.  MAGNETIC  RESONANCE  SPECTROSCOPY    
Frozen  samples  from  ipsilateral  cortex  were  used  for  H+-­‐MRS  analysis.  H+-­‐MRS  was  performed  
on  a  Bruker  AMX500  spectrometer  11.7  T  at  the  MRI  Unit  of  the  Instituto  de  Investigaciones  
Biomédicas   “Alberto   Sols”   (CSIC-­‐UAM,  Madrid,   Spain).   The  device  operates   at   4ºC  on   frozen  
samples  (3  mg)  placed  within  a  50-­‐µl  zirconium  oxide  rotor  with  a  cylindrical  insert  and  spun  at  
4000  Hz.  Standard  solvent-­‐suppressed  spectra  were  acquired  as  16  k  data  points  and  averaged  
over  256  acquisitions.  The  total  acquisition  time  was~14  min  using  a  sequence  based  on  the  first  
increment  of  the  NOESY  pulse  sequence  to  affect  suppression  of  the  water  resonance  and  limit  
the  effect  of  Bo  and  B1   inhomogeneities   in   the   spectra   (relaxation  delay-­‐90º-­‐t1-­‐90º-­‐tm-­‐90º-­‐
acquire  free  induction  decay),  in  which  a  secondary  radio  frequency  irradiation  field  was  applied  
at  the  water  resonance  frequency  during  the  relaxation  delay  of  2s  and  during  the  mixing  period  
(tm  =  150  ms),  with  t1  fixed  at  3  µs.  A  spectral  width  of  8333.33  Hz  was  used.  All  spectra  were  
processed  using  TOPSPIN  software,  version  1.3  (Bruker  Rheinstetten,  Germany).  Prior  to  Fourier  
transformation,  the  free  induction  decays  were  multiplied  by  an  exponential  weight  function  
corresponding   to   a   line   broadening   of   0.3   Hz.   Spectra  were   phased,   baseline-­‐corrected   and  
referenced  to  the  sodium  (3-­‐trimethylsilyl)-­‐2,2,3,3-­‐tetradeuteriopropionate  singlet  at  δ  0ppm.  
  
SpinWorks  3.1.7.0  software  were  used  to  analyze  the  data  by  curve  fitting.  Several  ratios  were  
calculated:   lactate/N-­‐acetylaspartate   (Lac/NAA),   glutamate/N-­‐acetylaspartate   (Glu/NAA),  
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gluthatione/creatine   (GSH/Cr)   and  myoinositol/creatine   (mI/Cr)   ratios   to   analyze   changes   in  
phosphorylation  potential  (Li  et  al.,  2010;  Penrice  et  al.,  1997b),  excitotoxicity    (Groehandal  et  
al.,   2010),   oxidative   stress   (Satoh   and   Yoshioka,   2006)   and   astrocyte   function   (Harris   et   al.,  
2015),  respectively.  
6.  HISTOCHEMICAL  ANALYSES  
After  MRI  analysis,  brains  were  processed  and  embedded  in  paraffin.  Coronal  sections  of  4μm  
of  width  were  obtained  using  a  microtome  and  the  chosen  area  of  study  was  from  plate  14  to  
18  of  Paxinos   (Paxinos   and  Watson,   1996).   For  HI   experiment   immunohistochemical   studies  
were   performed   in   the   ipsilateral   parietal   cortex,   corpus   callosum   (external   capsule),   as  
examples  of  Grey  and  White  Matter  areas  damaged  by  HI,  and  the  subventricular  zone  (SVZ)  
since   is   one   of   the  main   proliferative   niches   of   the   brain   and   it   is   responsible   for   the   OPC  
generation  that  lately  migrate  and  differentiate  into  white  matter  areas    (Mao  et  al.,  2013).  For  
MCAO   experiments,   the   ipsilateral   parieto-­‐occipital   cortex   adjacent   to   the   infarct   area   was  
analysed  (Fernández-­‐López  et  al.,  2013a).  
6.1  Nissl  staining  
For  Nissl  staining,  a  toluidine  blue  solution  was  utilized  as  a  basic  dye  which  binds  to  Nissl  bodies  
in  neurons  and  nucleic  acids.  Widely  used  to  stain  neuronal  bodies,  it  allows  to  asses  neuronal  
damage  after  HI  by  identifying  pyknotic/necrotic  neurons.    Firstly,  tissues  were  deparaffinized  
and  rehydrated.  Then,  tissues  were  dept  in  toluidine  blue  (0,5%  in  distilled  water)  for  30  seconds.  
After   that,   tissues  were  destained  with  water  and   increasing  alcoholic  solutions   to   finish   the  
dehydration  in  xylene.  Finally,  it  slides  were  mounted  with  non-­‐aqueous  mounting  medium  DPX  
new  (Merck  Millipore;  Billerica,  USA)  and  let  dry.  
Parietal   cortex   was   examined   using   a   light   microscope   (200X)   and   neuronal   damage   were  
assessed  by  a  damage  score  from  0  to  5.  Being  0,  less  than  2%  of  cell  death;  1,  few  cells  damaged  
(<25%);  2,  several  neurons  damaged  (25-­‐40%);  3,  moderate  damage  (40-­‐65%);  4,  severe  damage  
(>  65%),  and  5,   total  cell  death  or  absent   tissue.  Damaged  neurons  were   identified  when  no  
distinction  could  be  made  between  cytoplasm  and  nucleus  or  as  shrunken  neurons,  with  a  high  
stained   center   surrounded   by   tissue   loss.   By   contrast,   apparently   healthy   neurons   are  
characterized  by  a  differentiated  cytoplasm,  soft  stained,  and  nucleus,  darker  and  with  distinct  
nucleolus.  The  analysis  was  performed  by  two  researchers  blinded  to  the  experimental  group  
(Alvarez  et  al.,  2008;  Pazos  et  al.,  2012).  
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6.2  Immunohistochemical  analyses  
Tissue  sections  were  deparaffinized  and  rehydrated,  and  then  heat-­‐induced  antigen  retrieval  
was  made  by  using  citrate  solution  (pH6,  10mM)  or  Tris-­‐EDTA  (pH9,  TRIS  10mM-­‐EDTA  1mM)  
with  0.05%  of  Tween-­‐20  buffer  at  high  temperature  and  pressure.  Tissues  were  washed  with  
phospahate  buffer  saline  (PBS)  followed  by  an  ammonium  chloride  (10mM)  incubation  for  ten  
minutes   at   room   temperature.   After   several   PBS   washes,   brain   sections   were   incubated  
overnight   at   room   temperature   with   the   primary   antibody   in   a   humidified   chamber.   The  
different  primary  antibodies  used  are  shown  in  Table  3.  After  extensively  washes,  tissues  were  
incubated   with   the   corresponding   secondary   antibody   (1:200,   α-­‐rabbit,   α-­‐mouse   or   α-­‐goat  
Alexa-­‐Fluor  488  or  546   (Molecular  Probes,  Oregon;  USA)   for  2  hours  at  37ºC   in  a  humidified  
chamber.  TO-­‐PRO  (1:500;  Life  Technologies  Spain)  was  used  for  nucleus  staining.  Slides  were  
finally  mounted  with  Glicerol:PBS  aqueous  mounting  medium.  
Target   Antibody   Company   Dilution  
Astrocytes   GFAP   Sigma-­‐Aldrich;  San  Luis,  USA   1:1000  
Microglia   Iba-­‐1  
Wako;  Osaka,  Japan   1:400  
Neurons   NeuN   Merck  Millipore;  Billerica,  USA   1:300  
Neuron  Progenitor   NeuroD1   Abcam;  Cambridge,  UK   1:200  
Mature  
oligodendrocyte  
GST-­‐π   Abcam;  Cambridge,  UK   1:100  
OPC   Olig2   R&D  Systems;  Minneapolis,  USA   1:100  
PreOL   SOX10   Santa  Cruz  Biotechnology;  Dallas,  USA   1:100  
Myelin  Basic  
Protein  





BrdU   Novus  Biologicals;  Littleton,  USA   1:200  
Proliferating  cells   Ki67   Master  Diagnostica;  Granada,  Spain   1:400  
Table  3.  Primary  antibodies  for  immunohistochemical  studies.  
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To  analyze  proliferation  after  HI,  the  synthetic  nucleoside  5-­‐bromo-­‐2'-­‐deoxyuridine  (BrdU)  was  
used   (Sigma-­‐Aldrich;   San   Luis,   USA).   This   nucleoside   is   an   analog   of   thymidine   and,   as   a  
consequence,  it  will  be  incorporated  into  the  new  synthesized  DNA  strains,  thus  marking  the  
new  cells  produced  during  the  treatment  period.  Rat  pups  were  injected  with  BrdU  (50mg/kg,  
dissolved   in   saline)   in   days   4,   5   and   6   after   HI   damage,   as   has   been   previously   described  
(Fernández-­‐López  et  al.,  2013b,  2010),  and  the  animal  euthanized  at  day  7  after  damage.    
Tissues   were   photographed   using   a   TCS   SP5   confocal   microscope   (Leica   Microsystems,  
Germany).  Analyses  were  performed  by  an  examiner  blinded  to  the  experimental  group  using  
the  ImageJ  1.43u  software  (NIH,  Bethesda,  USA)  to  calculate  the  cell  density  and  signal  intensity.  
In   addition,   MBP   intensity   of   signal   was   determined   with   the   LEICA   LASF   Software   (Leica  
Microsystems,  Germany),  and  expressed  as  ratio  of  Ipsilateral  MBP  vs  total  (ipsi+contralateral)  
MBP  immunostaining  due  to  interassay    and  animal  autofluorescence  variabilities    (Liu  et  al.,  
2002).  
6.3  TUNEL  immunohistochemical  staining  
DeadEndTM   Fluorometric   TUNEL   System   (Promega;   Madison,WI,   USA)   was   used   for   TUNEL  
staining.  This  technique  specifically  labels  the  free  3-­‐OH  termini  of  DNA  strains  in  situ  after  DNA  
fragmentation   caused   by   endonucleases   during   apoptosis.   Nevertheless,   although   DNA  
fragmentation  precedes  cell  death,  if  it  is  by  apoptosis  or  another  kind  of  cell  death,  cannot  be  
differentiated  by  TUNEL  technique  alone.  Briefly,  modified  nucleotides,  fluorescein-­‐12-­‐dUTP(a)  
are  incorporated  to  DNA  3-­‐OH  end  by  terminal  deoxynucleotidyl  transferase  (TdT)  until  it  forms  
a  fluorescent  oligomer  which  can  be  directly  observed  by  fluorescence  microscopy.  Firstly,  tissue  
sections  were  deparaffinized,  washed  for  10  minutes  in  sodium  chloride  and  finally  washed  with  
PBS.  Then  proteinase  K  (20µg/mL  in  PBS,  100µL/tissue)  was  applied  for  8-­‐10  minutes  at  room  
temperature   to  permeabilize   tissue,   followed  by   three  PBS  washes.  After   that,   Equilibration  
Buffer  was  applied  for  5  to  10  minutes  followed  by  the  incubation  with  TdT  enzyme  and  the  
modified  nucleotides,  fluorescein-­‐12-­‐dUTPs,  for  1  hour  at  37ºC  in  a  humified  chamber.  Then  the  
reaction  was  stopped  by  the  stop  buffer,  and  the  tissues  washed  several  times  with  PBS  and  
deionized  water.  After  washes  to  remove  unincorporated  modified  nucleotides,  samples  were  
incubated  with  TO-­‐PRO  (1:500;  Life  Technologies  Spain)  for  10  minutes  and  then,  wash  again.  
Finally,  slides  were  mounted  with  Glicerol:PBS  aqueous  mounting  medium.  
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6.4  Electron  Microscopy  studies  
Electron  microscopy   studies   were   performed   at   Prof.   Pedro   Grandes’   laboratory   (School   of  
Medicine  and  Nursery,  Universidad  del  País  Vasco;  Bilbao,  Spain).  Animals  were  sacrificed  and  
perfused,  and  the  brain  obtained  as  previously  explained   in  sampling.  Brain  coronal  sections  
were  cut  at  50  μm  in  a  vibratome  and  collected  in  PBS  at  room  temperature.     Sections  were  
osmicated  (1%  osmium  tetroxide  in  PBS  pH  7.4)  for  60  minutes  at  0°C,  dehydrated  in  graded  
alcohols  to  propylene  oxide,  and  plastic-­‐embedded  in  Epon  resin  812.  Ultrathin  sections  of  60nm  
were  collected  on  mesh  nickel  grids,  stained  with  2.5%  lead  citrate  for  20  minutes,  and  examined  
in  a  Philips  EM208S  electron  microscope.  Tissue  preparations  were  photographed  by  using  a  
digital  camera  coupled  to  the  electron  microscope.  Three  animals  were  analyzed  per  treatment  
and  the  ultramicrographs  were  analyzed  by  the  ImageJ  1.43u  software  (NIH,  Bethesda,  USA).  
  
To  calculate  the  number  of  axons  electron  micrographs  were  taken  at  x5,600  magnification  and  
10  photos  were  made  per  animal  of  the  two  analyzed  areas,  external  capsule  and  cortex.  The  
analyzed   area   per   photo   was   308   μm2.   For   myelin   sheath   thickness   analysis   and   g-­‐ratio  
calculation,  micrographs  were  taken  at  x11,000  magnification.  Firstly,  the  fiber  perimeter  of  the  
axon  was  marked.  Later,  the  ratio  distance  from  the  center  of  the  axon  to  the  fiber  and  myelin  
sheath  perimeter  was  measured  in  four  different  point  of  the  axon,  and  its  average  calculated.  
Ten  axons  per  animal  were  analyzed.  The  number  of  axons  analyzed  and  the  magnification  of  
the  micrographs  were  the  same  for  external  capsule  and  cortex.    
The  g-­‐ratio   is   a  parameter  used  as   a   structural   index  of   axonal  myelination.   The  g-­‐ratio  was  
calculated  by  dividing   the  measured   inner   (axon)  perimeter  by   the  measured  outer   (myelin)  
perimeter   of   all   axons   in   each  micrograph.   Since   the   form   of   the   axons   is   sometimes   very  
variable,  the  use  of  the  perimeter  instead  of  the  diameter  is  more  reliable  (Ford  et  al.,  2015)  
(Ford  et  al.,  2015).  For  the  g-­‐ratio  the  axon  perimeter  and  the  fiber  perimeter  of  all  the  axons  
were   analyzed   in   each  micrograph.   An   average   of   150   axons   per   treatment   in   the   external  
capsule  and  an  average  of  100  axons  in  the  cortex  were  analyzed.  The  axons  used  to  analyze  the  
g-­‐ratio  were  also  used  to  analyze  the  axon  perimeter  and  area.    
7.  WESTERN-­‐BLOT  
  
For  protein  extraction,  frozen  tissues  were  homogenized  in  tissue  protein  extraction  reagent  (T-­‐
PER,  1  g  of  tissue/10  mL;  Pierce  Biotechnology,  Rockford,  USA)  and  centrifuged  at  10,000g  for  5  
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min  at  4ºC.     Pierce  BCA  Protein  Assay  Kit   (Pierce  Biotechnology;  Rockford,  USA)  was  used  to  
quantify  the  protein  concentration.    
20µg  of  denatured  protein  of  each  sample  were  separated  on  12%  acrylamide/bis-­‐acrylamide  
gels   (TGX  Stain-­‐Free  Acrylamide  Kit   12%,  Bio-­‐Rad;  Hercules,  USA).   Stain-­‐Free  gels   allows   the  
direct  quantification  of  protein  loaded  per  lane,  increasing  internal  control  accuracy  and  saving  
the  use  of  another  protein  control  quantification  such  as  b-­‐actin.  After  electrophoresis  Proteins  
were  transferred  to  polyvinylidene  fluoride  membranes  (GE  Healthcare;  Little  Chalfont,  UK),  and  
total  protein  loading  was  visualized  by  ultraviolet  exposition.  Then  membranes  were  blocked  for  
one  hour  in  TBS  (TRIS  25mM  pH7.4,  NaCl  1.37M)  -­‐Tween  0.1%  containing  5%  nonfat  dried  milk  
at  room  temperature.  Subsequently,  blots  were  incubated  with  the  primary  antibody  overnight  
at  4ºC.  The  different  primary  antibodies  used   for  western-­‐blot  studies  are   listed  on  Table  4.  
Membranes  were   finally   incubated  with   the   corresponding  HRP-­‐labeled   secondary   antibody  
(1:5000;   GE   Healthcare;   Little   Chalfont,   UK)   for   1h   at   room   temperature.      An   enhanced  
chemiluminescence  Kit  (GE  Healthcare;  Little  Chalfont,  UK)  was  used  for  the  peroxidase  reaction  
and  a  Gel-­‐Doc  station  with  Quantity  One  4.5.1  (basic)  analysis  software  (Bio-­‐Rad;  Hercules,  USA)  
was   used   for   detection.   Resultant   images   of   both   target   protein   and   loaded   protein   were  
analyzed   with   ImageLab   software   (version   6.0.0,   Bio-­‐Rad;   Hercules,   USA)   to   determine   the  
intensity   per   mm2   of   each   band   and   lane,   respectively.   Results   of   BDNF   and   GDNF   were  
expressed  as  the  ratio  of  target  protein/total  protein.  For  TNFa,  GAPDH  was  used  for  loading  
control,  so  results  are  expressed  as  a  ratio  of  TNFα/GAPDH.  
  
Target   Antibody   Company   Dilution  



















Table  4.  List  of  primary  antibodies  for  western-­‐blot  studies.  
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7.1  Oxyblot  
To   study  oxidative   stress  OxyBlot  protein  oxidation   detection   kit   (Millipore,   Iberica;  Madrid,  
Spain)   was   used   according   to   manufacturer’s   protocol.   This   commercial   kit   allows   the  
quantification  of  protein  carbonyl  groups,  protein  modifications  produced  by  reactive  species  
like  ROS,  and  consequently  analyzed  the  oxidative  stress  levels  of  the  sample.  Briefly,  a  total  
protein  amount  of  10µg  was  denaturalized  using  sodium  dodecyl  sulfate  6%  and  then,  carbonyl  
groups   were   derivatized   to   2,4-­‐dinitrophenylhydrazone   by   samples   incubating   with   2,4-­‐
dinitrophenylhydrazine   for   15  minutes.   After   finishing   the   reaction,  b-­‐mercaptoethanol  was  
added  to  protein  reduction.  Then,  samples  were  loaded  in  a  10%  TGX-­‐Stain  Free  gels  (Bio-­‐Rad;  
Hercules,  USA).    
Western-­‐blot   protocol   followed   was   similar   to   the   one   described   before,   but   with   specific  
primary  antibody  for  2,4-­‐dinitrophenylhydrazone  groups  (1:150)  and  its  secondary  (1:300).  An  
enhanced   chemiluminescence   Kit   (GE   Healthcare;   Little   Chalfont,   UK),   was   used   for   the  
peroxidase  reaction  and  chemiluminescence  was  detected  in  Gel-­‐Doc  station  with  Quantity  One  
4.5.1  (basic)  analysis  software  (Bio-­‐Rad;  Hercules,  USA).  Images  were  analyzed  with  ImageLab  
software  (version  6.0.0,  Bio-­‐Rad;  Hercules,  USA).  Relative  intensity  quantification  of  each  lane  
was  normalized  by  total  protein  loading,  so  results  were  expressed  as  OxyBlot/Total  protein.    
8.  ELISA  
Insulin-­‐like  growth  factor  1  (IGF-­‐1)  concentration  was  determined  from  20µg  of  protein  samples  
by  a  commercial  ELISA  kit  (Cloud-­‐Clone  Corp.,  USA),  according  to  the  manufacture's  protocol.  
Briefly,  100µL  of  samples  and  standard  were  added  to  each  well  of  the  kit  plate  and  incubated  
for  two  hours  at  37ºC.  After  that,  the  liquid  was  aspirated,  and  the  wells  were  incubated  again  
with  100µL  of  Detection  Reagent  A  for  one  hour  at  37ºC.  Later,  Detection  Reagent  was  aspirated,  
and  wells  were  washed  three  time  with  the  Washing  Solution.  Then  100µL  Detection  Reagent  B  
were   added   per  well   and   the   plate   for   one   hour   at   37ºC.   After   five  washes,   the   plate  was  
incubated  with  the  Substrate  Solution  for  20  minutes  at  37ºC  and  the  stopped  with  the  Stop  
Solution.   Rapidly,   the   plate   was   read   at   450nm,   using   a   Thermo   Scientific   Multiskan   EX  
(ThermoFisher  Scientific;  Waltham,USA).  
9.  STATISTICAL  ANALYSES  
GraphPad  5.0  software  was  used  for  the  statistical  analyses  (GraphPad  Software;  La  Jolla,  USA).  
Kolmogorov-­‐Smirnov  normality  test  was  applied  before  running  statistical  test.    The  results  are  
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presented  as  the  mean ± standard  error,  except  for  CB2  experiment  which  is  presented  as  the  
median  ±  interquartilic  range.  Statistical  comparisons  were  made  by  ANOVA  tests  followed  by  
Bonferroni  or  Newman-­‐Keuls  post-­‐hoc   test   for  multiple   comparisons.  When  data  were  non-­‐
parametric  Kruskal-­‐Wallis  test  was  used.  For  goal  4,  due  to  the  small  n  of  the  group  ANOVA  test  
was   completed   by   t-­‐tests   between   groups   with   Bonferroni’s   correction   for   significance.   To  
analyze   the   correlation   between   neurobehavioral   studies   and   myelin   staining   intensity,  
Spearman  test  was  used.  A  p  value  less  than  0.05  was  considered  as  statistically  significant.
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1.   CBD   NEUROPROTECTIVE   EFFECTS   IN   A   FOCAL   MODEL   OF  
PERINATAL  ARTERIAL  ISCHEMIC  STROKE  IN  NEWBORN  RATS.  
Since  CBD  neuroprotective  effect  has  been  previously   reported   in  models  of  diffuse  HI  brain  
damage  in  newborn  rodents  (Castillo  et  al.,  2010;  Pazos  et  al.,  2012)  and  piglets  (Alvarez  et  al.,  
2008;  Lafuente  et  al.,  2016,  2011;  Pazos  et  al.,  2013),  our  first  goal  was  to  determine  if  CBD  was  
similarly  neuroprotective  in  a  focal  model  of  HI.  
1.1  Dose  optimization  
Since  to  our  knowledge  no  previous  studies  have  used  CBD  as  treatment  for  PAIS,  the  first  step  
of   this  objective  was   to  determine   the  optimal  CBD  protective  dose.  We  performed  a  dose-­‐
response  curve  testing  1,  5,  50  and  100  mg/Kg.  Only  the  dose  of  100  mg/Kg  produced  a  decrease  
of  the  survival  rate,  with  a  20%  of  animal  death  in  the  first  24  hours  after  the  stroke.  
MCAO  was  associated  to  weight  loss  observable  one  week  after  the  insult  (Fig.  15A).  Whereas  
doses  from  5  to  100  mg/Kg  did  not  enhance  weight  loss,  1  mg/Kg  slightly  reduced  it  (Fig.  15A).  
Accordingly   to   these  results,  MRI  studies  showed  that  none  of  CBD  dosages  prevented  brain  
volume  loss  induced  by  MCAO  seven  days  after  the  insult  (Fig.  15B),  although  brain  volume  loss  
after  CBD  1  and  5  mg/Kg  treatment  tended  to  be  lower  than  that  of  VEH-­‐treated  animals.  
At  this  early  age,  only  motor  reflexes  could  be  tested.  In  both  negative  geotaxis  and  grip  tests  
MCAO  led  to  motor  impairment  and,  although  all  doses  improved  negative  geotaxis  results,  only  
CBD  1  or  5  mg/Kg    reduced  motor  impairment  as  assessed  in  both  tests  (Fig.  15C  and  D).  From  a  
clinical  point  of  view  the  recovery  of  motor  impairment  is  very  important.  Hence,  since  5  mg/kg  













1.2  CBD  neuroprotection  one  week  after  the  insult  
To  fully  characterize  motor  reflexes,  rope  test  was  added  to  the  assessment.  MCAO  induced  a  
reduction  of  paw  strength  which  was  not  averted  by  CBD  administration  (Fig.  16).  
  
In  MRI  studies  no  significant  differences  were  observed  in  brain  volume  loss  between  MCAO-­‐
VEH  and  MCAO-­‐CBD  (Fig.  17);  however,  CBD-­‐treated  animals  showed  a  smaller  hyperintense  





Figure  15.  CBD  dose  determination  studies.  Different  weight  and  motor  reflexes  as  well  as  imaging  
studies  were   performed   7   days   after  a   perinatal   arterial   ischemic   stroke   (PAIS)   insult   induced   in  
PND7-­‐10  Wistar  rats  which  received  vehicle  (VEH)  or  CBD  at  different  doses  (CBD-­‐1,5,50,100  mg/kg)  
and   its   control   littermates   (SHM).   A)  Weight   gain   average;   B)   Percentage   of   brain   volume   loss  
measured  by  MRI.  C)  Grip  reflex  teat;  D)  Negative  geotaxis  test.  Bars  represent  mean±SEM.    *p<0.05  
vs  SHM;  **  p<0.01  vs  SHM;  ***  p<0.001  vs  SHM;  ##  p<0.01  vs  HV  by  ANOVA.  
  
Figure  16.  Rope  test  performance.  Duration  of  the  rat  holding  to  
the  rope,  performed  seven  days  after  PAIS  insult  and  its  treatment  
with  vehicle  (MCAO-­‐VEH)  or  5mg/kg  (MCAO-­‐CBD).  Bars  represent  
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prevent   MCAO-­‐induced   increase   of   brain   lactate   and   glutamate   concentration   detected   in  
MCAO-­‐VEH  group,  keeping  those  levels  similar  to  SHM  (Fig.  18B  and  C)    
  
Different  histological  analyses  of  brain  tissue  were  conducted  to  asses  cell  death.  Using  Nissl  
staining,   it   was   observed   that   MCAO   rats   displayed   a   higher   neuropathological   score,  
independently  of  the  treatment  (Fig.  19A).  However,  when  cell  death  was  studied  by  TUNEL+  
cells   quantification   the   increased   count   observed   in  MCAO-­‐VEH  was   remarkably   reduced   in  
MCAO-­‐CBD  group  (Fig.  19B).  In  agreement,  MCAO  led  to  a  significant  decrease  of  NeuN+  cells  as  
observed  in  the  perilesional  cortex  of  MCAO-­‐VEH  animals,  an  effect  that  was  prevented  by  CBD  






BRAIN  VOLUME  LESION             
A 
B   
Figure  17.  Damage  characterization  by  MRI  one  week  after  MCAO.  MRI  studies  performed  one  week  
after  PAIS  insult  .  A)  Representative  MRI    images  of  rat  pups  submitted  to  a  MCAO  and  treated  with  vehicle  
(MCAO-­‐VEH)  or  CBD  5mg/Kg  (MCAO-­‐CBD);  B)  Graphical  representation  of  brain  volume  lesion  (left)  and  
hyperintense  area  (right)  quantification.  Bars  represent  mean±SEM.  #  p<0.05  vs  HV  by  ANOVA  
Results  
  




The  study  of  glial  response  showed  a  remarkable  increase  of  GFAP+  cells  in  both  MCAO-­‐VEH  and  
MCAO-­‐CBD  as  compared  to  SHM  (Fig.  20A).  MCAO  also  induced  the  loss  of  astrocytic  function,  
as  observed  by  myoinositol  reduction,  an  effect  not  observed  in  MCAO-­‐CBD  group  (Fig.  18D).  
Besides,  microgliosis  was  also  augmented  after  stroke  as  shown  by  the  increase  of  the  number  
of  Iba-­‐1+  cells  (Fig.  20B).    MCAO-­‐induced  glial  density  population  increase  was  associated  with  a  
more  activated  morphology  phenotype  so  that  in  MCAO-­‐VEH  those  cells  showed  bigger  soma  
and  shorter  processes  (Fig.  20C  and  D).  By  contrast,   the  administration  of  CBD  reduced  both  








C D mI/Cre 
Figure  18.  H+-­‐RMS  studies  performed  in  cerebral  cortex.  H+-­‐RMS  analysis  carried  out  on  cerebral  cortex  
one  week  after  rat  pups  were  submitted  to  MCAO.  A)  Representative  H+-­‐RMS  spectre  with  the  analyzed  
metabolites;  B)   Lactate   (Lac/NAA);  C)  Glutamate   (Glu/NAA);  D)  myoinositol   (mI/Cre).  Bars   represent  
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Figure   19.   Study   of   cell   death   in   perilesional   cerebral   cortex.      Representative   images   (right)   and  
graphical   representation   (left)   of   Nissl   and   immunohistochemical   staining   of   cell   death   (TUNEL)   and  
mature   neurons   (NeuN)   performed   in   the   perilesional   cortex   7   days   after   PAIS   insult.   A)   Semi-­‐
quantitative  scoring  of  cell  death  using  a  Nissl  staining  and  B)TUNEL  positive  cell  quantification.  C)  NeuN-­‐
positive  cell  quantification.  Bars  represent  mean±SEM.    Scale  bar:  50μm.  *  p<0.05  vs  SHM;  ***  p<0.001    
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1.3  CBD  neuroprotection  one  month  after  damage  
In   line   with   motor   reflexes   impairment   observed   one   week   after   the   damage,   MCAO-­‐VEH  
animals  had  poorer  performance  in  beam  test,  with  more  time  needed  to  cross  the  beam  (Fig.  
21A).  CBD  administration  prevented  this  motor  coordination  impairment  (Fig.  21A).  Moreover,  






SHM MCAO-­‐VEH MCAO-­‐CBD 
Iba-­‐1/TO-­‐PRO
 
MCAO-­‐VEH SHM MCAO-­‐CBD 
Figure   20.   Immunohistochemical   gliosis   characterization   in   perilesional   cerebral   cortex.    
Immunohistochemical   studies  performed  in   the  perilesional  cortex  7  days  after  PAIS   insult.  A)  GFAP-­‐  
positive  cells  quantification  (left)  and  representative  microphotographs  (right);  B,  C,  D)  Iba-­‐1  staining  
for  microglia  cells  where  Iba1-­‐positive  cells  were  quantified  (B)  and  the  morphology  of  the  cells  analyzed  
by  Iba1-­‐positive  cells  soma  quantification  (C)  and  its  processes  length  (D).  Bars  represent  mean±SEM.    
Scale  bar:  50μm.  *  p<0.05  vs  SHM;  **  p<0.01  vs  SHM;  ***  p<0.001  vs  SHM;  #  p<0.05  vs  HV  by  ANOVA  
Results  
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the  adhesive  removal  test,  respectively.  MCAO-­‐CBD  animals  scored  similarly  to  SHM  in  those  
tests  (Fig.  21B  and  C).  No  differences  were  observed  in  memory  tests  (NOR)  (Fig.  21D).  
  
In  agreement  with  the  aforementioned  MRI  results  one  week  after  brain  injury,  CBD  treatment  
did  not  modify   the   volume  of  brain   loss   one  month   later   (Fig.   22A),  whereas   it   significantly  
reduced  the  hyperintense  area  (Fig.  22B).  What  is  more,  at  this  age  hyperintense  area  correlated  
with  a  strong  astrogliosis  which  was  decreased  in  MCAO-­‐CBD  as  compared  to  MCAO-­‐VEH  (Fig.  
22C).  Noteworthy,  one  month  after  the  insult  a  strong  microglial  response  was  still  observed  in  
MCAO-­‐VEH  (Fig.  23);  CBD  treatment  partially  prevented  the   increase   in  microglia  population  





Figure  21.  Neurobehavioral  tests.  Neurobehavioral  tests  conducted  in  Wistar  rats  thirty  days  after  PAIS  
and  being   treated  with  vehicle   (MCAO-­‐VEH)  or  CBD   (MCAO-­‐CBD).   Its   littermates  were  used  as  control  
animals  (SHM).  A)  Beam  test;  B)  CRT  test;  C)  Adhesive  test;  D)  NOR  test.  Bars  represent  mean±SEM.    
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      A 
B               
C 
Figure   22.  Damage   characterization  one  month   after  MCAO.  MRI   and   gliosis   immunohistochemical  
analysis  performed  one  month  after  PAIS   insult.  Representative   images  of  astroglia   scar   taken   in   the  
hyperintense  area  observed  by  MRI.  A)  MRI  studies  quantifying  the  brain  volume  lesion;  B)  Hyperintense  
area  quantification  by  MRI;  C)  GFAP-­‐positive  cell  quantification.  Bars  represent  mean±SEM.  ***  p<0.001  
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Finally,  MCAO  led  to  both  neuron  (Fig.  24A)  and  myelin  loss  (Fig.  22B)  one  month  after  the  insult.  
The  effect  of  MCAO  on  neurons  was  reduced    by  CBD  administration  (Fig.  24A  and  B).    
1.4  Summary  
In  conclusion,  MCAO  induced  short-­‐  and  long-­‐  term  motor  impairment  which  correlates  with  
brain   damage   as   observed   by   MRI   studies   and   histological   neuron   density   quantification.  
Besides,  increased  cell  death  labelling  and  glutamate  levels  were  still  observed  in  perilesional  
cortex  seven  days  after  the  insult.  Remarkable  micro-­‐  and  astrogliosis  was  apparent  seven  and  
thirty  days  after  PAIS.  By  contrast,  CBD  administration  prevented  the  motor  impairment  induced  
by  MCAO.  Although  no  differences  were  observed  in  the  volume  of  brain  damage,  CBD  reduced  
the   hyperintense   area   as   observed   in  MRI   studies,  which   correlated  with   the   astroglial   scar  







Figure   23.   Microgliosis   response   one   month   after   MCAO.   Microgliosis   immunohistochemical  
characterization  performed  thirty  days  after  PAIS  insult.  Illustrative  microglia  population  images  of  Iba-­‐
1  positive-­‐cell  density  and  representative  microglia  cell  morphology  could  be  observed  .  A)  Iba1-­‐positive  
cell  quantification;  B)  Soma  measurement;  C)  Processes  length.  Bars  represent  mean±SEM.  **  p<0.01  vs  
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showed  lower  cell  death,  excitotoxicity  and  microgliosis  than  MCAO-­‐VEH  seven  days  after  PAIS,  
and  reduced  neuron  loss  one  month  after  the  damage.  
2.  ANALYSIS  OF  HI-­‐INDUCED  LONG-­‐LASTING  HYPOMYELINATION  IN  
WHITE  AND  GREY  MATTER  AND  ITS  PREVENTION  BY  CBD    
The  long-­‐term  hypomyelination  detected  in  the  neonatal  stroke  model  in  goal  1  has  also  been  
observed   in   models   of   global   HI.   Indeed,   as   it   has   been   described   in   the   introduction,  
hypomyelination  is  one  of  the  main  deleterious  consequences  of  NHIE  in  humans.    In  previous  
experiments  of  our   group   in  newborn   rats  CBD   remarkably  prevented   long-­‐term  motor   and  
cognitive  impairment  as  observed  in  neurobehavioral  tests  even  though  only  a  small  reduction  
of  brain  volume  loss  was  detected  by  MRI  after  HI  (Pazos  et  al.,  2012).  We  hypothesized  that  this  
apparently  contradictory  result  might  be  explained  by  a  possible  beneficial  effect  of  CBD  on  HI-­‐
induced  hypomyelination.  Therefore,  hypomyelination  studies  were  performed  in  the  HI  model  
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Figure  24.  Neuron  and  myelin  study  in  parieto-­‐occipital  cortex.    Representative  microphotographs  and  
graphical   representation   of   immunohistochemical   studies   performed   one  month   after   PAIS   insult   in  
perilesional   cortex.  A)   NeuN-­‐positive  cells   quantification;  B)  MBP   intensity   signal   quantification.   Bars  
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To   characterize   the   hypomyelination   process   after   an   HI   insult   and   the   possible   long-­‐term  
protection  offered  by  CBD  administration,  two  different  brain  areas  were  studied  one  month  
after  HI  damage:  corpus  callosum  and  parietal  cortex.    
2.1  Corpus  callosum  
No  differences  were  found  neither  in  GST-­‐п+  cells  density  (Fig.  25A)  nor  in  MBP  intensity  signal  
(Fig.   25B)   among   the   three   groups.   However,   electronic   microscopy   analysis   revealed   that,  
despite  the  normal  MBP  immunohistochemistry,  HV  animals  had  fewer  axons  (Fig.  26A)  as  well  
as  a  thinner  myelin  sheath  (Fig.  26B).  Moreover,  the  surviving  axons  showed  a  smaller  perimeter  
in  HV  than  in  controls  (Fig.  26C).  G-­‐ratio  was  used  to  avoid  myelin  thickness  analysis  bias  due  to  
axon  perimeter  variability,  confirming  that  the  g-­‐ratio  in  HV  group  was  bigger  than  in  SHM  group  
(Fig.  26D).  
Administration  of  CBD  after  HI  blunted  that  myelin  damage,  not  only  preventing  the  axonopathy  
(Fig.  26A  and  C)  but  also  the  decrease  in  myelin  thickness  (Fig.  26B  and  D).  
  








SHM HV HC 
A 
Figure  25.    Quantification  of  mature  oligodendrocyte  population  and  myelin  intensity  signal  in  white  
matter.   Graphical   representation   of   immunohistochemical   studies   and   representative  
microphotographs  performed  in  the  external  capsula  of  the  corpus  callosum  30  days  after  a  hypoxic-­‐
ischemic  (HI)   insult   induced   in  P7-­‐10  Wistar  rats   then   receiving  vehicle   (HV)  or  cannabidiol   (HC),  or  a  
similar  period  in  control  rats  (SHM).  A)  GST-­‐π  and  B)  myelin  basic  protein  (MBP)  staining.  Bars  represent  
mean±SEM.    Scale  bar:  50μm.    
Results  
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2.2  Parietal  cortex  
In   contrast   of   what   was   observed   in   white   matter,   HI   led   to   a   remarkable   loss   of   mature  
oligodendrocyte   one   month   after   the   insult   (Fig.   27A).   Oligodendrocyte   reduction   was  
associated  with  a  significant  hypomyelination  in  HV  animals  as  compared  to  SHM  (Fig.  27B).  By  
contrast,  CBD  administration  prevented  the  loss  of  GST-­‐п+  cells  (Fig.  27A)  and,  consequently,  








Figure   26.      Myelin   study   in   white   matter   by   electron   microscopy.   Electron   microscopy   studies  
performed  in  the  external  capsula  of  the  corpus  callosum  30  days  after  a  hypoxic-­‐ischemic  (HI)  insult  
induced  in  PND7-­‐10  Wistar  rats  then  receiving  vehicle  (HV)  or  cannabidiol  (HC),  or  a  similar  period  in  
control  rats  (SHM).  A)  Number  of  axons;  B)  myelin  sheath  thickness;  C)  Axon  perimeter;  D)  g-­‐ratio;  E)  
Representative  micrographs.  Bars  represent  mean±SEM.  Scale  bar:  10µm  *  p<0.05  vs  SHM;  #  p<0.05  vs  
HV  by  ANOVA.  
Results  
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The  characterization  of  this  hypomyelination  by  electron  microscopy,  showed  that  HV  animals  
not  only  had  thinner  myelin  sheaths  (Fig.  28B),  corroborated  by  the  g-­‐ratio  increase  (Fig.  28D),  
but   also  a   remarkable   reduction  of   axons   (Fig.   28A).  No  differences   in   axon  perimeter  were  
observed   in   cortex   (Fig.   28C).   CBD   prevented   both   axon   loss   (Fig.   28A)   and   myelin   sheath  
thickness  reduction  (Fig.  28B),  with  g-­‐ratio  values  similar  to  those  of  SHM  (Fig.  28D).  
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Figure   27.   Analysis   of   mature   oligodendrocyte   population   and   myelin   staining   in   cerebral   cortex.    
Graphs  and  its  representative  images  of  immunohistochemical  studies  performed  in  the  parieto-­‐occipital  
cortex  of  PND  37  rats  submitted  to  neonatal  HI  and  that  were  treated  with  vehicle  (HV)  or  cannabidiol  
(HC),   while   its   littermates   remained   as   control   (SHM).  A)   GST-­‐π   and  B)  myelin   basic   protein   (MBP)  
staining.  Bars  represent  mean±SEM.    Scale  bar:  50μm.  *  p<0.05  vs  SHM;  #  p<0.05  vs  HV  by  ANOVA.  
Results  
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2.3  Functional  studies  
HI   damage   led   to   hemiparesis   as   illustrated   by   the   preference   for   the   use   of   the   ipsilateral  
forepaw  in  the  CRT  (Fig.  29A).    HV  group  also  had  a  significant  cognitive  disability  as  studied  in  
the  memory  test  (NOR),  with  HV  animals  displaying  similar  time  exploring  both  the  new  and  the  
old  object  (Fig.  29B).  When  this  motor  and  cognitive  impairment  was  compared  with  the  MBP  
signal  intensity  in  both  White  and  Grey  Matter,  a  positive  correlation  was  observed  between  




Figure   28.      Myelin   characterization   in   cerebral   cortex   by   electron   microscopy.   Myelin   analysis  
performed  in  the  parieto-­‐occipital  cortex  of  rats  one  month  after  they  were  submitted  to  a  neonatal  HI  
insult  and  received  vehicle  (HV)  or  cannabidiol  (HC),  or  were  left  as  controls  (SHM).  Graphs  represents  
the  A)  Number  of  axons;  B)  myelin   sheath   thickness;  C)   axon  perimeter;  D)   g-­‐ratio;  E)   representative  
micrographs.   Representative  microphotographs   are   observed   in   the   left.   Bars   represent  mean±SEM.  
Scale  bar:  Scale  bar:  10µm.  *  p<0.05  vs  SHM;  #  p<0.05  vs  HV),  by  ANOVA.  
Results  
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MBP   signal   in   corpus  
callosum   (Fig.   29C).  At   the  
same   time,   memory  
impairment   was   positively  
correlated   with   cortex  
hypomyelination  (Fig.  29D).  
Although  no  changes  could  
be   observed   between   HV  
and   HC   in   the   correlation,  
CBD   administration   was  
able   to   hamper   both  
hemiparesis   and   cognitive  
impairment-­‐HI   induced  







To  summarize  the  results  of  this  goal,  HI  induced  a  significant  hypomyelination  and  axonopathy  
observable  one  month  after  the  damage.  Myelination  impairment  was  observed  in  both  corpus  
callosum  and  parieto-­‐temporal  cortex,  although  only  in  the  cerebral  cortex  a  reduction  in  the  
population   of   mature   oligodendrocyte   could   be   observed.   Remarkably,   hypomyelination  
correlated   with   the   long-­‐term   motor   and   cognitive   deficits   detected.   By   contrast,   CBD  
administration   prevented   mature   oligodendrocyte   decrement   in   cortex   as   well   as  
hypomyelination  and  axonopathy  in  both  areas.  In  agreement  with  those  results,  HC  group  did  





























































Figure   29.      Relationship   between   immunohistochemical   and  
neurobehavioral   studies.   Neurobehavioral   studies   and   its   linear  
correlation   with   MBP   staining   intensity   performed   30   days   after   a   HI  
insult.  A)   Preference   for   the   use   of   the   ipsilateral   paw   in   the   cylinder  
rearing   test   (CRT);  B)   Time   percentage   of   the   time   exploring   the   new  
object  versus  total  exploring  time  in  the  NOR  test;  C)  Correlation  between  
hemiparesis  as  assessed  by  the  CRT  and  MBP  intensity   in  white  matter  
(Spearman’s   correlation:   R=   0.396,   t=   2.58,   p=0.013.   D)   Correlation  
between  memory  impairment  as  assessed  by  NOR  and  MBP  intensity  in  
cortex;  Spearman’s  correlation:  R=  0.443,  t=  2.57,  p=0.015).  *  p<0.05  vs  
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3.  ASSESSING  IF  CBD  HYPOMYELINATION  PREVENTION  IS  RELATED  
WITH   BRAIN   CELL   PROLIFERATION   ACTIVATION   AND   GLIAL  
RESPONSE  MODULATION    
After  demonstrating  the  prevention  of  hypomyelination  by  CBD,  the  next  step  was  to  elucidate  
how   that   effect   of   CBD   could   be   achieved.   Since   it   is   known   that   HI   triggers   a   proliferative  
response  in  brain  in  order  to  substitute  the  cell   loss  (Brégère  et  al.,  2017;  Plane  et  al.,  2004;  
Segovia  et  al.,  2008),  we  started  by  studying  the  proliferative  response  induced  by  HI  and  its  
modification  by  CBD  administration.  
3.1  Cell  proliferative  response  and  cell  death  
First  at  all,  proliferating  cells  rates  were  studied  on  both  corpus  callosum  and  parieto-­‐occipital  
cortex,  24  hours  and  seven  days  after  HI.  No  differences  were  observed  at  24  hours  in  any  region  
(Fig.  30).  Seven  days  after  the  insult  HC  group  showed  increased  Ki67+  cell  population  in  White  
Matter  as  compared  to  SHM,  an  effect  not  observed  in  HV  (Fig.  30A).  By  contrast,   in  parietal  
cortex  the  HI-­‐induced  potent  proliferative  response  was  not  statistically  different  in  HV  and  HC,    
although  such  response  tended  to  be  lower  in  HC  group  seven  days  after  the  insult  (Fig.  30B).  
This  proliferative   response  was  associated  with   an   increase  of  mature  and  proBDNF  protein  
levels   seven   days   after   the   HI   insult   with   no   significative   differences   between   HV   and   HC,  
although  proBDNF  levels  tended  to  be  lower  in  HC  group  (Fig.  31A)  .  No  changes  were  detected  
in  the  protein  levels  of  GDNF  and  IGF-­‐1  (Fig.  31B  and  D).  
Then,  proliferative  response  was  studied  in   the  SVZ   (Fig.  32A).  HI   led  to  a  quick  proliferative  
response  in  the  SVZ,  observable  just  one  day  after  damage  in  both  HI  groups.  Seven  days  after  
HI,  HV  showed  a  non-­‐significant  reduction  of  Ki67+  cell  density  in  SVZ,  an  effect  not  detected  in  







   73  
  
Figure   30.   Proliferation  
characterization   in   corpus  
callosum  and   cerebral   cortex.  
Representative  
microphotographs   and  
graphical   representation   of  
proliferation   studies  
performed  24  hours  and  7  days  
after   a   neonatal   HI   insult  
induced  Wistar  rat  pups  which  
were  then  treated  with  vehicle  
(HV)   or   cannabidiol   (HC),   and  
its   control   littermates   (SHM).  
The  regions  represented  are  A)  
external   capsule   of   corpus  
callosum   and   B)   parieto-­‐
occipital   cerebral  cortex.  Scale  
bar:  50μm.    
**  p<0.01  vs  SHM  by  ANOVA.  
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Figure  32.  Ki67  immunohistochemical  study  in  SVZ.  Ki67-­‐positive  cells  quantification  performed  in  SVZ  
24   hours   and   1  week   after   a   neonatal   hypoxic-­‐ischemic   insult   induced   in   PND7-­‐10  Wistar   rats   then  
receiving   vehicle   (HV)   or   cannabidiol   (HC),   or   a   similar   period   in   control   rats   (SHM).   Representative  
images  (right)  and  graphical  representation  of  Ki67-­‐positive  cells  (left).  Scale  bar:  50μm.  *  p<0.05  vs  SHM  
by  ANOVA.  


































Figure   31.  
Neurotrophins  
quantification   at  
cerebral   cortex.  
Western   blot   studies  
performed   in   cerebral  
cortex  of  Wistar  rats  one  
week  after  a  neonatal  HI  
insult.   A)   Quantitative  
determination   of   the  
precursor  (proBDNF)  and  
mature   (mBDNF)  
isoforms  of  brain  derived  
neurotrophic   factor  
(BDNF)   expression;   B)  
Quantitative  
determination   of   glia  
derived   neurotrophic  
factor   (GDNF)  
expression;   C)  
Representative   images  
of   western   blot;   D)  
Quantification   of   insulin  
growth   factor-­‐1.   Bars  
represent   mean±SEM*  
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Besides,  HI   led  to  increased  cell  death  in  parietal  cortex,  as  observed  by  TUNEL  staining  (Fig.  
33A).  In  this  case  no  significative  differences  were  observed  between  HC  and  HV  groups  (Fig.  
33B).  
3.2  Oligodendrocyte  response  
For  a  better  understanding  of  CBD  effects  on  hypomyelination  induced  by  HI,  oligodendrocyte  
population   was   studied   by   immunohistochemistry   in   the   regions   involved:   cortex,   corpus  
callosum   and   SVZ.   When   SVZ   was   analyzed,   no   differences   among   groups   in   Olig2+   cell  
quantification  was  observed  at  any  time  (Fig.  34A).  SOX10+  cell  density  was  decreased  24  hours  
after  the  insult.  Seven  days  after  the  insult  SOX10+  cell  density  was  restored  (Fig.  34B)  with  even  
a   non-­‐significant   increase   in   both   HI   groups   (Fig.   34B).   By   contrast,   in   corpus   callosum   a  
significant  decrease  of  both  Olig2  (Fig.  35A)  and  SOX10  (Fig.  35B)  positive  cell  population  was  
observed  24  hours  after  damage  with  no  differences  between  HV  y  HC.  Olig2+  and  SOX10+  cell  
density  was  restored  one  week  after  HI  (Fig.  35)  with  a  non-­‐significant  reduction  of  SOX10+  cell  
density  in  HC  (Fig.  35B).  
The  analysis  of  oligodendrocyte  linage  cells  on  cortex  proved  that,  similarly  to  that  observed  in  
corpus  callosum,  HI  induced  a  rapid  decrease  of  Olig2  (Fig.  36A)  and  SOX10  (Fig.  36B)  positive  
cell  population  that  was  restored  one  week  after  the  insult.  While  CBD  had  no  effect  24  hours  
after   HI,   an   increase   of   Olig2+   cells   was   observed   one   week   later   (Fig.   36A).   However,   no  
difference  was  seen  in  SOX10+  cell  density,  with  both  HV  and  HC  showing  similar  levels  than  SHM  





Figure  33.  Cell  death  quantification  in  parieto-­‐occipital  cortex.    Staining  for  TUNEL-­‐positive  cells  in  the  
cerebral  cortex  of  rat  pups  seven  days  after  a  HI  insult  and  its  treatment  with  vehicle  (HV)  or  CBD  (HC).  
Graphical  representation  of  TUNEL-­‐positive  cells  (left)  and  illustrative  microphotrographs  (right).  Bars  
represent  mean±SEM.    
Results  
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Figure  34.  Quantification  of  oligodendrocyte  lineage  population  in  the  subventricular  zone.  Illustrative  
microphotographs  and  graphs  of  the  immunohistochemical  studies  performed  24  hours  and  7  days  after  
a  HI  in  the  different  groups.  A)  Olig2  and  B)  SOX10  staining  in  corpus  callosum.  Bars  represent  mean±SEM.    
Scale  bar:  50μm.  *  p<0.05  vs  SHM  by  ANOVA.  
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Figure   35.   Quantification   of   oligodendrocyte   lineage   population   in   white   matter.  
Immunohistochemical  quantification  of  oligodendrocyte  lineage  were  performed  24  hours  and  7  days  
after  a  HI  in  the  different  groups.  Illustrative  images  could  be  also  observed  at  the  right  of  the  figure.  A)  
Olig2  and  B)  SOX10.  Bars  represent  mean±SEM.    Scale  bar:  50μm.  *  p<0.05  vs  SHM;  **  p<0.01  vs  SHM  
by  ANOVA.  
  



















Figure  36.  Analysis  of  oligodendrocyte  lineage  population  in  parieto-­‐occipital  cortex.    Representative  
microphotographs  (right)  and  graphical  representation  (left)  of  Olig2  and  Sox10  immunohistochemical  
studies  in  parietal-­‐occipital  cortex  of  rat  brain  24  hours  and  7  days  after  damage.  A)  Olig2  and  B)  SOX10  
staining.  Bars  represent  mean±SEM.    Scale  bar:  50μm.  *  p<0.05  vs  SHM  24h  ;  **  p<0.01  vs  SHM  24h  ;  ***  
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Since  cell  density  changes  were  mainly  observed  in  cortex  subsequent  studies  were  focused  in  
this  region.  To  further  understand  the  discrepancies  between  Olig2  and  SOX10  analysis  different  
experiments  were  performed.  First,  BrdU  was  injected  at  fourth,  fifth  and  sixth  day  after   the  
insult  and  then  pups  were  sacrificed  at  the  seventh  day.  Labelling  the  new  cells  developed  during  
that  period  with  different  oligodendrocyte  markers  would  facilitate  the  characterization  of  the  
proliferative  and  maturative  response  induced  by  HI  and  how  it  could  have  been  modified  by  
CBD.   The   first   step  was   to   look   for   some   differences   in   the   number   of   new   cells   produced  
between  the  fourth  and  the  sixth  days  after  the  insult.  Surprisingly,  the  HI  insult  did  not  result  
in  a  different  density  of  newly  formed  cells  as  studied  one  week  after  the  insult,  no  matter  the  
treatment  with  VEH  or  CBD  (Fig.  37A).  The  same  lack  of  statistically  significant  differences  was  
observed   in   the   density   of   newly   formed   (BrdU+)  Olig2+   or   SOX10+   cells   (Fig.   37B   and   37C),  
although  a  non-­‐statistically  significant  increase  of  BrdU+/Olig2+  cells  was  observed  in  HC  animals  
(Fig.  37B)  whereas  a  non-­‐statistically  significant  decrease  of  BrdU+/SOX10+  cells  was  observed  in  
HV  animals.    
Figure  37.  BrdU  study  in  cerebral  cortex  seven  days  after  damage.  Representative  microphotographs  
and  graphs  of  BrdU  analysis  and  colocalization  with  oligodendrocyte  markers  in  parieto-­‐occipital  cortex  
one  week   after   damage.  A)  BrdU-­‐positive  cell   quantification;  B)  BrdU+  /Olig2+quantification;  C)   BrdU+  
/SOX10+  quantification.  Scale  bar:  50μm.      
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In  order  to  get  more  insights  into  those  differences,  co-­‐localization  of  Ki67  and  Olig2  marker  was  
analysed.  Since  Olig2+  cells  could  also   label  astrocytes,   the  co-­‐localization  of  GFAP  and  Olig2  
markers  was  also  performed.  In  agreement  with  the  aforementioned  results  from  BrdU  studies,  
no   differences   were   detected   among   groups   after   double-­‐immunostaining   studies   were  
conducted  with  Olig2  and  Ki67  antibodies   (Fig.  38A).  By   contrast,  a  dramatic   increase   in   the  
number  of  cells  expressing  both  GFAP  and  Olig2  markers  were  found  in  HV  group  (Fig.  38B).  That  
effect  was  reversed  by  CBD  so  that  HC  rats  showed  similar  colocalization  rates  to  SHM  (Fig.  38B).    
  
The  analysis  of  BrdU+/NeuroD+  cells  showed  a  non-­‐significant  decrease  in  HV  group  as  compared  
to  SHM  (Fig.  39A),  in  contrast  with  the  increased  proliferation  observed  by  Ki67  in  HV  group  (Fig.  
30B).  Further  analysis  confirmed  that  HI  induced  a  significant  reduction  of  the  new  immature  
neurons  seven  days  after  damage  while  CBD  administration  led  to  a  newly  formed  immature  cell  
density  similar  to  that  of  SHM  at  that  timepoint  (Fig.  39B).  








Figure  38.  Study  of  Olig2  colocalizations  in  cerebral  cortex.    Representative  microphotographs  of  Olig2  
colocalization   with   the   proliferative   marker   Ki67   or   the   astroglial   marker   GFAP,   and   its   graphical  
quantification  in  parieto-­‐occipital  cortex  one  week  after  damage.  A)  Olig2+/Ki67+;  B)  Olig2+/GFAP+.  Scale  
bar:  50μm.  *  p<0.05  vs  SHM  by  ANOVA.  
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3.3  Astroglial  response  
In   order   to   further   study   if   the   increment   of   Olig2+/GFAP+   cell   proliferation   in   HV   rats   was  
associated   with   an   enhanced   gliotic   response,   astrocytes   and   microglial   population   were  
analyzed  separately.    As  expected,  a  noteworthy  rise  of  GFAP+  cells  was  observed  in  HV  animals  
as  compared  to  SHM,  an  effect  reduced  by  CBD  administration  (Fig.  40A).  That  enhancement  
was  associated  to  a  gain  of  GFAP  fluorescence  intensity  (Fig.  40B),  which  corresponds  with  an  
active  astrocyte  (Cengiz  et  al.,  2014;  Diaz  et  al.,  2017).  HC  group  reduced  astrocyte  activation,  
with  a  non-­‐significant  reduction  in  GFAP  fluorescence  intensity  (Fig.  40C).    
Figure   39.   BrdU+/NeuroD+    
colocalization   analysis   in  
cerebral   cortex   one   week  
after   HI.      Representative  
images  and  graphs  of  BrdU  
colocalization   with  
immature   neuronal  
markers  NeuroD  in  parieto-­‐
occipital   cortex  seven  days  
after  HI.  A)  Number  of  cells  
which   co-­‐express   both  
markers;   B)   Percentage   of  
BrdU+   cells   which   are   also  
positive   for   NeuroD  
marker.  Scale  bar:  50μm.  *  
p<0.05  vs  SHM  by  ANOVA  
  
SHM HV HC 
GFAP/DAPI 
B   A Figure   40.   Astrogliosis  
analysis  in  parieto-­‐occipital  
cortex.      Graphical  
representation   (up)   and  
illustrative   images   (down)  
of   immunohistochemical  
studies   of   the   astroglial  
marker  GFAP  performed   in  
the   parieto-­‐occipital   cortex  
7   days   after   a   HI   insult.  A)  
GFAP-­‐   positive   cells  
quantification;   B)   GFAP  
intensity   signal  
quantification.   Bars  
represent   mean±SEM.    
Scale  bar:  50μm.  *  p<0.05  vs  
SHM;   **   p<0.01   vs   SHM;   #  
p<0.05  vs  HV  by  ANOVA.  
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3.4  Microglial  response  
HI  insult  led  a  remarkable  microgliotic  response  that  was  not  affected  by  CBD  administration,  
(Fig.    41A).  Regarding  microglia  morphology  there  were  no  statistically  significant  differences  in  
microglial  cell  soma  size  among  the  different  groups  (Fig.  41B),  although  in  HV  animals  microglial  
cells   showed   shorter   ramifications   and  an  ameboid   shape   (Fig.   41C),   corresponding  with  an  
active   microglia   phenotype.   HC   and   SHM   groups   had   similar   microglia   soma   size   and  
ramifications  lengths  (Fig.  41B  and  C).    
3.5  “Deadly  triad”  analysis  
To  get  more  insights  into  the  gliotic  response,  TNFα  levels  were  analysed  by  western  blot.  As  
predicted,  brain  TNFα  concentration  was  increased  in  HV  group  one  week  after  the  HI  insult  (Fig.  
42A).   Such   increase  was  prevented  by  CBD  administration,  with  TNFα  protein   concentration  
reaching  similar  levels  to  those  observed  in  SHM  (Fig.  42A).  
A 




Figure  41.  Microgliosis  study  in  parieto-­‐occipital  cortex.    Characterization  of  microglial  response  by  cell  
quantification   and   morphological   studies   performed   seven   days   after   damage.      Illustrative  
microphotographs  of  microglia  population  with  cell  augmentation  of  the  main  cell  morphology  found  
are   represented  at  bottom  right.  A)   Iba1-­‐  positive  cells  quantification;  B)   Soma  area  of   Iba-­‐1  positive  
cells;  C)  Average  of  dendrite  length  of  Iba-­‐1  positive  cells.  Bars  represent  mean±SEM.    Scale  bar:  50μm.  
*  p<0.05  vs  SHM;  **  p<0.01  vs  SHM  by  ANOVA  
Results  
  
   82  
Due  to  the  potent  CBD  antioxidant  effect,  HI-­‐induced  increase  of  oxidative  stress  was  studied  in  
brain   samples   by   quantifying   both   carbonyl   groups   in   oxidized   protein   by  western-­‐blot   and  
glutathione   by   H+-­‐
MRS.   By   using   both  
techniques   a  
dramatic   increase   of  
oxidative   stress  
markers   was  
observed  in  HV  group  
one   week   after  
damage,  as  expected  
(Fig.  42B  and  C).  CBD  
administration   fully  
prevented   the   HI-­‐
induced   increase   of  
oxidative   stress   (Fig.  






The  third  axis  of  the  “deadly  triad”  is  excitotoxicity.  An  increased  concentration  of  glutamate  
was  observed  by  H+-­‐MRS  one  week  after  the  HI  insult  in  HV  animals  (Fig.  43),  an  effect  blunted  







Figure   42.   Inflammation  and  oxidative  stress   analysis   in  parieto-­‐occipital  
cortex.     Western  and  H+-­‐RMS  studies  performed  in   the  ipsilateral   cerebral  
cortex   one   week   after   HI.   A)   TNFα   quantification   by      western-­‐blot   and  
representative  bands  of  TNFα   (50KDa)  and  b-­‐actina  (42KDa)   ;  B)  Graphical  
representation  of  OxyBlot  analysis  and  illustrative  lanes  of    carbonyl  groups  
in   oxidize;   C)  Glutathione   (GSH/Cr)   analyzed   by   H+-­‐RMS   .   Bars   represent  
mean±SEM.  *  p<0.05  vs  SHM  by  ANOVA.  
        
Figure  43.  Glutamate  quantification  in  parieto-­‐occipital  cortex.  
Glutamate   quantification   by   H+-­‐RMS   in   the   parieto-­‐occipital  
cortex  seven  days  after  HI   insult.  Bars  represent  mean±SEM.  *  
p<0.05  vs  SHM  by  ANOVA.  
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3.6  Summary  
To  sum  up  the  most  important  results  of  this  goal,  HI  induced  early  death  of  oligodendrocytes  
in  both  areas  of  damage  resulting  in  reduced  cell  density;  oligodendrocyte  density  was  restored  
seven  days  after  the  insult.  Besides,  CBD  administration  led  to  increased  Olig2+  population  in  
cortex   at   that   timepoint;   BrdU   studies   showed   that   HC   group   had   more   new   cells   Olig2+  
produced  between  the  fourth  and  the  sixth  day  after  the  insult.  Furthermore,  CBD  prevented  
the  decrease  of  SOX10+  cell  density  observed  at  that  timepoint.  In  agreement  with  these  results,  
a  more  actively  differentiation  of  Olig2+  population  into  astroglial  lineage  was  observed  in  HV  
but  not  in  HC  group.  This  was  also  observed  after  studying  astrocyte  and  microglial  cells.  In  this  
case  CBD  administration  decreased  both  astrogliosis  and  microgliosis  in  a  manner  linked  to  the  
modulation  of  oxidative   stress   and   inflammation.   Finally,   CBD  administration   led   to   reduced  
excitotoxicity  in  cortex  seven  days  after  the  insult.  
4.INVOLVEMENT   OF   CB2   RECEPTOR   ACTIVATION   IN   CBD  
PROTECTIVE  EFFECTS   IN  A  NEWBORN  RAT  MODEL  OF  HYPOXIC-­‐
ISCHEMIC  BRAIN  DAMAGE  
We  then  aimed  to  characterize  if  CB2  receptors  could  be  involved  in  CBD  neuroprotection.  We  
chose  CB2  since  astro-­‐  and  microglia  modulation  seemed  to  be  a  key  part  of  such  effect,  and  
both  are  known  to  express  CB2  in  a  pathological  or  stressful  situations  (Espejo-­‐Porras  et  al.,  2018;  
Fernández-­‐Ruiz  et  al.,  2007;  López  et  al.,  2018;  Robertson  et  al.,  2017;  Sagredo  et  al.,  2009;  Tolón  
et  al.,  2009).  Moreover,  the  involvement  of  CB2  activation  in  CBD  protective  effect  in  a  piglet  
model  of  HI  was  previously  observed  by  our  group  (Pazos  et  al.,  2013).    
The   first   step   was  
optimizing  the  dose  of  the  
CB2  agonist  used,  HU-­‐308,  
in  the  HI  model  in  newborn  
rats.  From  the  three  doses  
tested   of   HU-­‐308   only  
1mg/Kg   reduced   the  
histological   damage  
induced   by   HI   in   parietal  
B A 
Figure  44.  HU-­‐308  dose  optimization  in  a  HI  model   in  newborn  rat.    
Semi-­‐quantitative  score  of  cell  death  by  Nissl  staining  performed  in:  A)  
parieto-­‐occipital   cortex   and  B)   CA1  of   hippocampus.   Bars   represent  
mean±SEM.  *  p<0.05  vs  SHM;  #  p<0.05  vs  HV)  by  ANOVA.  
.  
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cortex  (Fig.  44A)  and  hippocampus  (Fig.  44B),  while  0.1  and  10mg/Kg  did  not  show  any  protective  
effect.  Thereby,  1mg/kg  was  the  dose  selected  for  the  experiment.  
HI   led   to   an  
impairment   of   motor  
reflexes   as   observed  
one   week   after   the  
insult   in   negative  
geotaxis,   grip   and  
grasp   reflex   (Fig.   45).  
CBD   administration  
reduced   HI-­‐induced  
impairment   in   grasp  
test   with   no   effect  
observable   in   the  
other   tests   (Fig.   45C).    
HU-­‐308   showed   no  
beneficial  effect  in  any  
reflex   test   performed  
(Fig.45).   Surprisingly,  
the   co-­‐administration  
of  CBD  and  the  CB2  agonist  led  to  an  additive  protective  effect    in  the  grip  reflex  test  (Fig.  45B).    
To  further  assess  the  role  of  CB2  receptor  in  CBD  protection,  the  specific  antagonist  SR2  was  
administrated  along  with  the  previous  treatment.  The  CB2  antagonist  administration  prevented  
the  protective  effect  showed  by  CBD  (Fig.  46).  
Figure  45.  Motor  reflex  evaluation  of  CBD  and  HU-­‐308  prevention  of  HI-­‐
induced  motor  impairment.  Motor  reflexes  tests  conducted  in  Wistar  rats  
one  week  after  they  were  submitted  at  PND7-­‐9  to  sham  operation  (SHM)  or  
to  HI,  and  were  treated  whether  with  CBD,  VEH  or  with  the  CB2  agonist  HU-­‐
308.  A)  Negative  geotaxis;  B)  Grip  reflex  and  C)  Grasp  reflex.  Bars  represent  
mean±SEM.  *  p<0.05  vs  its  SHM;  #  p<0.05  vs  HI+VEH;  $  p<0.05    vs  HI+CBD;  
&  p<0.05  vs  HI+HU-­‐308  by  Anova  and  t-­‐test.  
B                    A 
C 
B A C 
Figure  46.  SR2  effect  on  motor  disability-­‐induced  by  HI.    Analysis  of  motor  impairment  seven  days  after  
HI,   after   what   animals   were   treated  with   CB2   antagonist   SR2,   SR2   plus   CBD  or   SR2   plus   HU-­‐308.  A)  
Negative  geotaxis;  B)  Grip  reflex  and  C)  Grasp  reflex  Bars  represent  mean±SEM.  *  p<0.05  vs  its  SHM;  δ  
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CBD   reduced   both   the   volume   of   brain   damage   and   the   hyperintense   area,   an   effect   not  
observable  after  HU-­‐308  administration  (Fig.  47A  and  C).  In  this  case  the  administration  of  HU-­‐
308   together   with   CBD   did   not   significantly   reduce   neither   the   volume   of   lesion   nor   the  
hyperintense   area   (Fig.   47A   and   C).   CB2   antagonism   had   no   effect   on   brain   damage   or  
hyperintense   area   volume   (p=0.123   and   p=0.938   vs   HI+VEH,   respectively)   (Fig.   47B   and   D).  





























Figure  47.  Volume  brain  damage  evaluation.  MRI  Studies  conducted   in  Wistar   rats   seven  days  after  
PAIS  in  animals  treated  either  with  CBD  or  HU-­‐308  (A  and  B)  or  with  SR2  (C  and  D).  Both  the  total  brain  
volume  lesion  and  hyperintense  are  were  analyzed.  Bars  represent  mean±SEM.  #  p<0.05  vs  HI+VEH;  δ  
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of   lesion   (p=0.023   vs   HI+VEH)   (Fig.   47C)   but  
blunted  the  effects  of  CBD  on  the  hyperintense  
area  volume  (p=0.474  vs  HI+VEH)  (Fig.  47D).    
Finally,   similar   results  were  obtained  when   the  
protein  levels  of  TNFα  were  studied  by  western-­‐
blot.  CBD  prevented  the  increase  of  this  cytokine  
induced  by  HI;  that  protective  effect  was  reduced  
by  CB2  antagonist  co-­‐administration  (p=0.533  vs  
HI+VEH)  (Fig.  48A).  The  administration  of  HU-­‐308  
did  not  reduced  the  TNFα  increase  induced  by  HI  
(Fig.  48A)  an  effect  that  was  not  modified  by  the  
co-­‐administration  of  CBD  and  HU-­‐308  (Fig.  48A).    
No   oxidative   stress   differences   were   observed  







Figure   48.   CBD   and   HU-­‐308   effect   on  
inflammatory   and   oxidative   stress   response  
in   cortex   after   HI.   Western-­‐blot   tests  
performed   in   the   ipsilateral   cortex   of  Wistar  
rats      one   week   after   PAIS.   A)   TNF⍺/GAPDH  
quantification   and   representative   bands   of  
TNF⍺   trimer   (50KDa)  and  GAPDH  (37KDa);  B)  
Oxyblot   quantification   normalized   by   total  
protein  loaded.  Bars  represent  mean±SEM.    
*  p<0.05  vs  SHM;  #  p<0.05  vs  HI+VEH;  $  p<0.05    








Figure   49.   Analysis   of   inflammatory   and  
oxidative  stress  in  cortex  after  a  HI  event  and  
the   SR2   administration.   Western-­‐blot   assay  
performed   in   the   ipsilateral   cortex   of  Wistar  
rats   seven   days   after   PAIS   and   posterior  
treatment   with   SR2,   SR2+CBD   and   SR2+HU-­‐
308.   A)   TNF⍺/GAPDH   quantification;   B)  
Oxyblot   quantification   normalized   by   total  
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4.1  Summary  
Only   CBD   administration   was   able   to   reduce   motor   impairment,   brain   volume   damage,   as  
observed  by  MRI,  and  brain  TNFα  concentration  increase.  The  administration  of  HU-­‐308  only  
showed  some  protective  effect   in  motor   test  but  not   in  MRI  or  biochemical  studies.  The  co-­‐
administration  of  HU-­‐308  with  CBD  potentiated  the  CBD  protective  effects  in  motor  test  but  not  
as  long  as  brain  damage  volume  or  brain  TNFα  levels  was  concerned.  The  administration  of  both  
CBD  and  SR2  reversed  some  CBD  protective  effects,  which  might  indicate  that  this  receptor  is  
somehow  involved  in  CBD  neuroprotective  actions.  
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Neonatal  hypoxic-­‐ischemic  brain  injury  is  a  severe  pathology  with  deleterious  consequences  like  
cerebral  palsy,  which  lasts  for  the  rest  of  the  life  of  the  individual  and  the  family  (Adhikari  and  
Rao,   2016;   Martinez-­‐Biarge   et   al.,   2011;   Nelson   and   Lynch,   2004).   Unfortunately,   the   only  
treatment  currently  used,  hypothermia,  is  only  partially  effective  in  cases  of    moderate  to  severe  
NHIE  and  with  a  very  short  therapeutic  window;  for  PAIS  current  treatment  is  only  symptomatic  
(Armstrong-­‐Wells   and  Ferriero,   2014;  Cnossen  et   al.,   2009;   Sagredo  et   al.,   2018).   Therefore,  
there  is  an  actual  need  for  new  drugs  that  can  improve  neonatal  hypoxic-­‐ischemic  brain  injury  
outcome;  in  this  regard,  CBD  has  risen  as  a  promising  therapeutic  drug  (Fernández-­‐Ruiz  et  al.,  
2015;  Martínez-­‐Orgado  et  al.,  2007;  Sagredo  et  al.,  2018).  Different  works  from  our  group  have  
already  proven  that  CBD  is  neuroprotective  in  in  vitro  and  in  vivo  models  of  global  HI  (Castillo  et  
al.,  2010;  Lafuente  et  al.,  2016,  2011,  Pazos  et  al.,  2013,  2012),  with  remarkable  beneficial  effects  
in  functional/  neurobehavioral  studies  (Lafuente  et  al.,  2011;  Pazos  et  al.,  2012).  
1.   CBD   NEUROPROTECTIVE   EFFECTS   IN   A   FOCAL   MODEL   OF  
HYPOXIC-­‐ISCHEMIC  BRAIN  INJURY  IN  NEWBORN  RATS  
  
In  this  work  we  have  demonstrated  that  the  induction  of  HI  or  MCAO  in  newborns  rat  pups  of  
PND7-­‐10,  led  to  brain  injury  with  long-­‐lasting  sequelae  as  analyzed  seven  or  thirty  days  after  the  
insult   that   were   mostly   prevented   by   CBD   administration   ten   minutes   after   the   insult.  
Surprisingly  CBD  was  neuroprotective  at  such  a  low  dose  as  1  mg/kg  in  both  models,  differently  
to  what  has  been  reported  in  adult  chronic  neurodegenerative  disease  models  (Cheng  et  al.,  
2014;  Sagredo  et  al.,  2007).  Hayakawa  et  al.  have  reported  that  two  doses  of  at  least  3  mg/Kg,  
one  of   them  during  occlusion,  are  needed  to  obtain  CBD  neuroprotective  effects   in  an  adult  
model  of  MCAO  (Hayakawa  et  al.,  2007b,  2007a).    By  contrast,  in  our  neonatal  MCAO  model  we  
obtained  neuroprotective  effects  with  CBD  single  dose  administered  only  post-­‐stroke.  In  that  
neonatal  model  better  results  were  obtained  with  a  dose  of  5mg/Kg  than  with  1mg/Kg:  higher  
doses   did   not   significantly   improve   neurobehavioral   tests   or  MRI   analysis   of   brain   damage  
results.  In  fact,  the  dose  of  100mg/Kg  increased  the  mortality  rate.  Conceivably,    since  CBD  at  
high  doses  can  induce  hypotension  (Jadoon  et  al.,  2017)  the  administration  at  such  a  high  dose  
in  our  model  might  have  potentiated  the  blood  pressure  decrease  due  blood  loss  often  observed  
during  the  surgical  procedure.  
  
Both  global  and  focal  ischemic-­‐brain  damage  induced  motor  reflex  impairment  seven  days  after  
damage,  which  was  prevented  by  post-­‐insult  CBD  administration  in  MCAO  but  not  in  HI  models,  
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where  only  a  reduction  in  the  grasp  reflex  was  observed.  That  could  be  explained  not  only  by  
the  higher  dose  used  in  MCAO  model  but  also  for  the  severity  and  the  different  areas  affected  
by  the  HI  damage.  While  focal  HI,  i.e.  MCAO,  led  to  damage  circumscribed  to  the  MCA  territory  
affecting  cerebral  cortex  and  caudate  nucleus  (Derugin  et  al.,  2000,  1998),  global  HI  induced  a  
diffuse  wide  lesion  involving  cerebral  cortex,  subcortical  and  periventricular  White  Matter,  deep  
Grey  Matter  structures  like  basal  ganglia  and  thalamus,  striatum  and  hippocampus  (Vannucci  
and  Vannucci,  2005).  Therefore,  the  lower  dose  administrated  in  HI  model  might  have  not  been  
effective  enough  to  reduce  the  motor  impairment  observed  early  after  the  insult,  whereas  in  
the  model  of  MCAO  CBD  could  have  been  more  effective  taking  into  account  that  the  dose  was  
higher  and  the  brain  damage  area  smaller.  
In  agreement  with  the  different  brain  areas  affected,   results   from  the  neurobehavioral   tests  
observed  thirty  days  after  damage  were  also  different.  Both  models  induced  a  long-­‐lasting  motor  
impairment  showed  by  hemiparesis  and  motor  coordination  loss,  as  previously  reported  in  HI  
models  (Vannucci  and  Vannucci,  2005).  This  motor  disability  correlates  with  the    disruption  of  
M1  motor   cortex   connectivity   (Gharbawie  et   al.,   2008)  which   could  have  happened   in  both  
models.  By  contrast,  HI   led  to  a  cognitive   impairment  which  was  not  observed   in   the  MCAO  
model.  As  explained  before,  HI  causes  great  damage  on  hippocampus  (Vannucci  and  Vannucci,  
2005)   which   could   affect   the  memory-­‐related   performance   as   explored   using   the   NOR   test  
(Antunes   and   Biala,   2012).   However,   since   Middle   Cerebral   Artery   does   not   irrigates  
hippocampus  (Gharbawie  et  al.,  2008,  2005),  MCAO-­‐induced  insult  are  not  inducing  the  same  
effects  on  memory.  Mechanisms  of  CBD   long-­‐term  neuroprotective  effects  will   be  discussed  
later  in  this  section.    
In  our  MCAO  model  early  poor  motor  reflex  performance  demonstrated  a  good  correspondence  
with  the  definitive  adult  motor  impairment,  as  previously  reported  (Ten  et  al.,  2003).  In  the  HI  
model,  however,  CBD  protective  effects  were  more  apparent  one  month  than  one  week  after  
the  damage.  That  effect  can  be  related  to  the  well-­‐known  evolution  in  space  and  time  of  the  
more  diffuse  damage  observed  in  HI  models  (Mehta  et  al.,  2007;  Uria-­‐Avellanal  and  Robertson,  
2014).  In  agreement,  the  relative  brain  volume  loss  area  induced  by  HI  as  observed  by  MRI  in  
rats  decreases  from  one  week  to  one  month  after  the  insult  (Pazos  et  al.,  2012).  By  contrast,  the  
MCAO-­‐induced  relative  brain  volume  loss  area  observed  in  our  experiment  was  not  only  smaller  
than  in  HI  but  it  also  remained  similar  one  week  and  one  month  after  the  insult.  
Despite  a  similar  degree  of  brain  volume  loss  in  MCAO-­‐VEH  and  MCAO-­‐CBD,  CBD  administration  
significantly  decreased  the  hyperintense  area  as  compared  to  MCAO-­‐VEH,  at  both  time-­‐points.  
Discussion  
  
   91  
This  hyperintense  area  corresponds  at  least  in  part  to  vasogenic  and  cytotoxic  oedema  during  
the   first   days   after   the   stroke   (Allen   et   al.,   2012;   Qiao   et   al.,   2007),   but   subsequently   it  
correspondes   to   an   area   of   gliotic   scar   and   cell   debris   accumulation   (Justicia   et   al.,   2008;  
Velthoven   et   al.,   2017).   This   hyperintense   area   correlates  with   the   increased  GFAP   staining  
observed  one  week  but  mainly  one  month  after  the  insult.  Indeed,  it  has  been  described  that  
astrogliosis   induced  shortly  after  a  HI   insult  will  eventually  produce  the  so-­‐called  “glial   scar”  
(Shrivastava  et  al.,  2012;  Wang  et  al.,  2012)  which  corresponds  to   that  observed  by  MRI  one  
month  after  MCAO  and  that  was  decreased  by  CBD  administration    Noteworthy,    although  the  
purpose  of  this  biological  response  is  undoubtedly  to  delimitate  brain  damage  (Bush  et  al.,  1999;  
Wanner   et   al.,   2013),   the   composition   and   dimension   of   this   glial   scar   has   been   inversely  
correlated  with  the  survival  of  perilesional  neuron  networking;  being  one  of  the  main  differences  
between   adult   and   neonatal   positive   outcome   after   stroke   (Teo   et   al.,   2018).   Thus,   CBD  
reduction  of  hyperintense  area  and  glial  scar  observed  one  month  after  MCAO  might  be  a  factor  
contributing  to  neuron  loss  prevention  and  better  neurobehavioral  outcome.  
As  previously  reported  HI  brain  injury  induced  a  strong  inflammation  response  characterized  by  
a   remarkable   micro-­‐   and   astrogliosis.   In   both   models,   a   sharp   increase   of   astrocytes   and  
microglia   cellularity   was   observed   after   the   insult,   as   described   before   (Buser   et   al.,   2012;  
Hellström  Erkenstam  et  al.,  2016;  Huang  et  al.,  2017;  Liu  and  McCullough,  2013;  McRae  et  al.,  
1995;  Shen  et  al.,  2012).   Those  glial  cells  also  presented  an  activated  morphology.  This  pro-­‐
inflammatory  state  of  glia  was  confirmed  by  the  significant  increase  of  inflammatory  cytokine  
TNFa  in  HI  model  as  well  as  the  high  oxidative  stress  levels  observed.    The  increase  of  both  TNFa  
and  oxidative  stress  were  dramatically  blunted  by  CBD  administration.  
In  astrocytes  the  activated  state  is  characterized  by  the  increase  of  GFAP  intensity  staining  and  
a  morphological  change  with  shorten  and  engrossed  processes  (Cengiz  et  al.,  2014;  Diaz  et  al.,  
2017).  We  observed  that  response  mainly  in  the  HI  model.  These  activated  astrocytes  are  known  
to  promote   inflammation  by   releasing   cytokines   and  other  products   triggering  death   signals  
(Faustino   et   al.,   2011;   Hagberg   et   al.,   2015;   Jin   et   al.,   2009;   Kichev   et   al.,   2014;   Liu   and  
McCullough,  2013).  MCAO  astrogliosis  was  rather  characterized  by  a  loss  of  astrocyte  function,  
as   reflected   by   the   decrease   of   mI/Cr   ratio   (Harris   et   al.,   2015).   This   is   important   because  
astrocytes  play  a  protective  role  after  HI   reducing  the  volume  of  damage  (L.  Li  et  al.,  2008),  
promoting   neurites   growth   (Wang   et   al.,   2012)   and   keeping   glutamate   uptake   and   thus  
decreasing  excitotoxicity   (Cengiz   et   al.,   2014;   L.   Li   et   al.,   2008).   CBD  administration   reduced  
astrogliosis  in  both  HI  and  MCAO  models,  not  only  reducing  the  number  of  astrocytes  but  also  
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reducing   its   pro-­‐inflammatory   state   or   preserving   its   function.   To   our   knowledge,   this   glio-­‐
protective  effect  has  not  been  reported  in  other  treatments.    
HI  and  MCAO  insult  led  to  an  increase  in  microglia  cell  number.  Those  cells  showed  an  ameboid  
phenotype  with  reduced  ramification  length,  a  phenotype  corresponding  to  activated  microglia  
(Kaur  et  al.,  2013).  Although  CBD  administration  only  partially  reduced  microglia  proliferation  in  
the  MCAO  model,  that   treatment  was  associated  with  a  reduction  of  the  presence  of  a  non-­‐
amoeboid   microglia   phenotype,   suggesting   a   reduction   of   microglial   activation.   CBD   anti-­‐
inflammatory  effect  has  been  largely  described  (Khaksar  and  Bigdeli,  2017;  Mukhopadhyay  et  
al.,   2011;   Vilela   et   al.,   2017),   including   neonatal   hypoxia-­‐ischemia   and   adult   stroke  models  
(Khaksar  and  Bigdeli,  2017;  Lafuente  et  al.,  2011;  Pazos  et  al.,  2012).    Microglia  plays  a  chief  role    
containing  brain  damage  after  stroke  (Faustino  et  al.,  2011;  Fernandez-­‐López  et  al.,  2016).  Thus,  
indiscriminate  microglial  inhibition  produces  a  more  intense  pro-­‐inflammatory  response,  higher  
levels  of  brain  volume  damage  and  haemorrhages  post-­‐stroke  (Faustino  et  al.,  2011;  Fernandez-­‐
López   et   al.,   2016).   Noteworthy,   CBD   promotes  microglial   phagocytosis   via   TRPV1   receptor  
activation   (Hassan   et   al.,   2014),   thus      contributing   to   damage   reduction.   Summarizing,   CBD  
administration  post-­‐damage  would  promote  a  repairing  microglia  phenotype  which  would  have  
a   role   in   the   neuroprotective   effect   of   CBD   and,   consequently,   in   the  motor   improvement  
observed  in  the  MCAO-­‐CBD  or  HC  group.  
The  fact  that  CBD  was  effective  in    modulating  microglial  cells  in  MCAO  but  no  in  HI  model  could  
be  to  the  different  role  of  macrophage  infiltration  in  those  conditions,  a  factor  that  deserves  
consideration   since   Iba-­‐1   labels   both   microglia   and   macrophage   (Matsumoto   et   al.,   2008;  
Ohsawa  et  al.,  2000).  Whereas  early  BBB  break  after  HI  damage  is  a  well-­‐known  phenomenon  
(Ek  et  al.,  2015),  recently  it  has  been  proved  that  BBB  remains  stable  after  a  neonatal  stroke  
(Fernández-­‐López  et  al.,  2012).  Thus  the  macrophage  infiltration  component  might  be  different  
in  MCAO  and  HI  (Fernández-­‐López  et  al.,  2012;  Moretti  et  al.,  2015;  Vexler  and  Yenari,  2009).  
Another   very   interesting   feature   was   that   microgliosis   was   still   observed   one   month   after  
damage   in   the   MCAO   model.   Although   it   has   been   proposed   that   this   prolonged   immune  
response   is   mainly   an   adaptive   mechanism   (Hagberg   et   al.,   2015;   Shrivastava   et   al.,   2012;  
Winerdal   et   al.,   2012),   such  a   long-­‐term  microgliosis   could  be  particularly  harmful,   not  only  
because   of   the   deleterious   effect   of   ROS   and   cytokine   release,   but   also   because   “resting”  
microglia   plays   a   physiological   role   of   pruning   neuronal   contact   and   define   neuron   circuitry  
during  development  (Low  and  Ginhoux,  2018;  Mallard  et  al.,  2018;  Schafer  et  al.,  2012),  an  effect  
potentially  lost  when  microglia  changes  into  an  activated  state.    
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Another  important  factor  of  CBD  neuroprotection  was  the  decrease  of  excitotoxicity  induced  by  
MCAO   or   HI   as   observed   short-­‐term   after   the   damage.   HI/MCAO-­‐induced   excitotoxicity   is  
increased   by   neuron   delayed   death,   still   observed   one   week   after   insult,   but   also   by   the  
enhanced    glutamate  release  by  reactive  astrocytes  and  microglia  (Cengiz  et  al.,  2014;  Hagberg  
et  al.,  2015;  Socodato  et  al.,  2018)  as  well  as  an  impaired  astrocyte  re-­‐uptake  (Cengiz  et  al.,  2014;  
Swanson  et  al.,  1995).  CBD  excitotoxicity  modulation  after  hypoxic-­‐ischemic   insults  has  been  
previously   reported   (Castillo   et   al.,   2010;   Pazos   et   al.,   2013,   2012)   and   would   be   likely  
contributing  to  the  brain  damage  reduction  observed  in  MCAO-­‐CBD    or  HC.  
In   agreement   with   CBD   reduction   of   inflammation,   oxidative   stress   and   excitotoxicity,   CBD  
administration   reduced   cell   death,  blunting  neuronal   loss   in  perilesional   cerebral   cortex   and  
modulated  post-­‐insult   increase  of  the  levels  of  Lac/NAA,  a  marker  of  metabolic  derangement  
and   tissue   damage   (Li   et   al.,   2010;   Pazos   et   al.,   2013,   2012;   Penrice   et   al.,   1997b).   Similar  
neuroprotective  results  were  previously  obtained  in  HI  model  (Pazos  et  al.,  2012),  although  CBD  
was  not  able  to  reduce  the  number  of  dead  cells  one  week  after  such  a  diffuse  damage.    
2.  HI-­‐INDUCED  LONG-­‐LASTING  HYPOMYELINATION  IN  WHITE  AND  
GREY  MATTER  AND  ITS  PREVENTION  BY  CBD  
Beside  the  neuronal  loss,  hypomyelination  was  also  detected  one  month  after  the  insult  in  both  
models,  correlating  with  the  early  loss  of  myelin  fibers  and  the  accumulation  of  myelin  debris  
reported  in  the  first  weeks  after  neonatal  stroke  (Velthoven  et  al.,  2017;  Villapol  et  al.,  2011).    
This  would  be  particularly   important  since  several  studies  have  pointed  out   that  myelin   loss  
might  also  been  important  in  HI  and  PAIS  motor  and  cognitive  impairment  development  (Choi  
et  al.,  2018;  de  Vries  and  Jongmans,  2010;  Groeschel  et  al.,  2017;  Martinez-­‐Biarge  et  al.,  2011;  
Stewart  et  al.,  2017).  By  contrast,  CBD  administration  post-­‐insult  reduced  hypomyelination  as  
well  as  prevented  motor  and  cognitive  impairment.  
  
The   relationship   between   long-­‐lasting   sequelae   and   hypomyelination   can   be   explained   by  
several   factors.   Firstly,   by   the   hypomyelination   itself.   In   both   corpus   callosum   and   parieto-­‐
temporal  cortex  we  could  observe  an  increase  of  the  g-­‐ratio  due  to  a  smaller  myelin  thickness;  
that  thinner  myelin  sheath  has  lower  conduction  velocity  (Clayton  et  al.,  2017;  Drobyshevsky  et  
al.,  2014).  In  fact,  a  promising  theory  has  stablished  that  myelination  is  another  kind  of  brain  
plasticity,   promoting   those  mostly   activated   circuits   (Mitew  et   al.,   2016;   Stedehouder  et   al.,  
2018).      Secondly,   by   the   loss   of   axons   observed   in   both   areas,   probably   due   to   the   higher  
sensitivity  of  poorly  myelinated  axons  to  damage  (Lee  et  al.,  2012;  Nave,  2010).    Actually,  human  
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newborns  showing  a  similar  myelin  damage  in  cortex  and  watershed  White  Matter  develops  
hemiplegia   or   cognitive   impairments   (de   Vries   and   Jongmans,   2010;  Martinez-­‐Biarge   et   al.,  
2011),   consequences   comparable   to   those   observed   in   our   experiment.   In   our   experiment,  
White   Matter   hypomyelination   correlated   with   hemiparesis,   in   agreement   with   the  
correspondence   of   lower   fractal   anisotropy   and   volume   of   corpus   callosum   tracts   with  
hemiplegia  in  humans  after  adult  or  neonatal  stroke  (Groeschel  et  al.,  2017;  Stewart  et  al.,  2017).  
Besides,  the  long-­‐lasting  cognitive  impairment  observed  in  our  rats  was  directly  related  to  low  
myelin   levels   in  parieto-­‐temporal  cortex,  a   region   involved   in     working  memory  (Yoon  et  al.,  
2008)  and  which  damage  induces  spatial  memory  impairment  (Zhou  et  al.,  2016).  
HI-­‐induced  axonopathy  in  both  areas  deserves  more  deeply  studies.  In  cortex,  axon  diameter  
was  similar  in  all  groups  despite  the  fact  that  HV  animals  showed  oligodendrocyte  loss  and  axon  
density  reduction  likely  because  of  the  aforementioned  higher  sensibility  of  unmyelinated  axon  
to  damage  (Lee  et  al.,  2012;  Nave,  2010).  By  contrast,  in  White  Matter  the  specific  loss  of  bigger  
diameter  axons  could  be  caused  by  its  particular  sensitiveness  to  excitotoxicity  and  therefore  to  
HI-­‐induced  damage  (Alix  et  al.,  2012).  In  this  scenario,  glutamate  reduction  by  CBD  would  help  
to  protect  axons  from  direct  damage  by  HI.  Consequently,  CBD  would  help  to  maintain  a  proper  
myelination   and   oligodendrocyte   maturation   since   axon-­‐oligodendrocyte   interaction   is  
necessary  for  some  axon  myelination  (Lundgaard  et  al.,  2013;  Mitew  et  al.,  2016;  Shen  et  al.,  
2012).  
Although  we  did  not  obtain  a  statistically  significant  correlation  between  MBP  signal   in  both  
areas  and  the  improvement  observed  in  HC  group  in  the  neurobehavioral  tests,  it  is  conceivable  
that  CBD  beneficial  effects  on  motor  and  cognitive  impairment  might  rely  at  least  in  part  on  a  
protective   effect   on  myelination.   Supporting   that   suggestion   is   the   fact   observed   in  MCAO  
experiments,  in  agreement  with  that  previously  reported  for  HI  (Pazos  et  al.,  2012),  that  CBD  
was   far   more   effective   on   preventing   post-­‐insult   long-­‐term   functional   disabilities   than   on  
reducing  the  volume  of  brain  damage  or  hyperintense  area  or  neuronal  loss.  Other  treatments  
like  hypothermia,  melatonin  or  erythropoietin  also  reduce  the  MBP  loss  (Fan  et  al.,  2011;  Kida  
et   al.,   2013;   Lee  et   al.,   2016;  Reinboth  et   al.,   2016;  Villapol   et   al.,   2011;  Xiong  et   al.,   2013),  
although  only  hypothermia  given  immediately  after  HI  was  able  to  prevent  hypomyelination  as  
observed    in  both  White  Matter  (Reinboth  et  al.,  2016;  Xiong  et  al.,  2013)  and  cortex  (Kida  et  al.,  
2013).  However,   comparisons   should  be  done   cautiously   since   results   from  all   those   studies  
might  be  influenced  by  the  different  species,  strains  and  gender.    
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Myelination  studies  performed  in  the  HI  model  point  out   that  HI  affects  differently  Grey  and  
White  Matter.  While  HI  led  to  the  reduction  of  myelin  sheath  thickness  and  number  of  axons  in  
both   areas,   the  more   dramatic   loss   of  myelin   and  mature   oligodendrocyte  was   observed   in  
cerebral  cortex.  Different   responses  depending  on   the  specific  area  can  be  explained  by  the  
different  characteristics  displayed  by  oligodendrocytes  in  White  or  Grey  Matter  (Lentferink  et  
al.,  2018;  Viganò  et  al.,  2013).  Those  cells  respond  differently  to  astrocytic  cues  or  inflammatory  
cytokines  depending  on  the  area  (Lentferink  et  al.,  2018)  and  differentiation  of  OPC  in  White  
Matter  is  more  intense  and  quicker  than  in  Grey  Matter  (Lentferink  et  al.,  2018;  Viganò  et  al.,  
2013).  Several  studies  point  to  the  different  maturational  stage    of  oligodendrocyte  in  Cortex  
and  White  Matter  at  term  (Buser  et  al.,  2010;  Segovia  et  al.,  2008;  Tomassy  and  Fossati,  2014)  
as   the  main   reason   for   those   regional   differences.  Whereas  White  Matter   oligodendrocyte  
maturation   from  preOL  to   iOL  triggers  between  18  and  27  postconceptional  week   in  human  
(equivalent  to  PND2-­‐PND3  in  rats)  (Back  et  al.,  2002a,  2002b),  cortex  preOL  maturation  happens  
around  birth  at   term  (equivalent   to  PND7-­‐PND10   in  rats)   (Segovia  et  al.,  2008;  Tomassy  and  
Fossati,  2014).  Therefore,  due  to  the  special  sensitivity  of  preOL  but  not  iOL  to  the  “deadly  triad”  
characteristically  observed  after    HI  (Alix,  2006;  Back  et  al.,  2007;  Back  and  Rosenberg,  2014;  
Fragoso  et  al.,  2004;  Volpe,  2011),  the  deleterious  effects  of  HI  occurring  at  term  (or  equivalent  
period  in  rats)  on  OL  maturation  should  take  place  mainly  in  cortex  but  not  in  White  Matter.  In  
agreement,  studies  on  very  preterm  babies,  whose  White  Matter  is  populated  mainly  by  preOL  
(Back   et   al.,   2002a;   Buser   et   al.,   2010),   have   revealed   that   severe   preterm   White   Matter  
pathology  such  as  periventricular  leukomalacia,  originated  by  brain  insults  occurring  before  the  
27th  postconceptional  week,    is  characterized  by  myelin  loss  in  the  White  Matter  with  reduced  
numbers  of  mature  oligodendrocyte  (Segovia  et  al.,  2008).  Hence,  effects  on  White  Matter  of  
brain  insults  occurring  over  the  period  of  preOL  maturation  in  that  area  in  humans  were  similar  
to  those  observed  in  our  experiments  in  cortex  after  brain  insults  occurring  over  the  time  point  
where  maturating  preOL  are   the  main  oligodendrocyte  population      in   this   area   (Back  et   al.,  
2002a;  Dean  et  al.,  2011).  
PreOL  particular  sensitivity  to  HI  damage  is  caused  at  least  in  part  by  the  activation  of  AMPA  
receptors  localized  in  soma  (Follett,  2004;  Salter  and  Fern,  2005).  The  over-­‐activation  of  AMPA  
receptors   by   the   high   levels   of   glutamate   observed   after   HI   together   with   the   increased  
permeability  of  the  receptor  in  neonatal  brain  (D  M  Talos  et  al.,  2006;  Delia  M  Talos  et  al.,  2006),  
induces  a  remarkable  increase  of  intracellular  calcium  leading  to  cell  death  (Follett,  2004;  Shen  
et   al.,   2012).   PreOL   are   also   quite   vulnerable   to   oxidative   stress   because   of   the   low  
concentrations  of  GSH  associated  with  a  high  intracellular  concentration  of  iron  (Thorburne  and  
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Juurlink,  1996),  required  for  myelin  synthesis  (Connor  and  Menzies,  1996),  whose  homeostasis  
is  impaired  after  HI  (Buonocore  et  al.,  2001).  Inflammation  is  also  very  harmful  to  preOL.  PreOLs  
have  TNFa  receptors  in  the  soma  (Deng  et  al.,  2008;  Su  et  al.,  2011)  whose  activation  induces  
preOL  death  or  inhibits  its  maturation  (Su  et  al.,  2011)  by  a  mechanism  mediated  by  astrocytes  
(Kim  et  al.,  2011).  Besides,  they  are  particularly  sensitive  to  HI-­‐induced  astro-­‐  and  micro-­‐gliosis  
that  inhibit  oligodendrocyte  maturation  by  modifying  neurotrophic  factor  secretion  (Wang  et  
al.,  2011).  Moreover,  iron  accumulation  in  activated  microglial  cells,  like  the  ones  observed  in  
our   model,   induces   a   decrease   of   glutathione   and   potentiates   lipid   peroxidation   in  
oligodendrocytes   (Rathnasamy   et   al.,   2011).   Reactive   astrocytes   secretes   hyaluronic   acid,   a  
potent  inhibitor  of  both  myelination  and  OPC  maturation,  to  create  the  gliosis  scar  described  in  
our  experiments  (Buser  et  al.,  2012).  
Despite  the  fact  that  White  Matter  was  populated  mainly  by  iOL  at  the  moment  of  the  HI  insult  
in  our  experiments,  and  that   iOL  are  more  resistant   to  HI  effects   than  preOL,  myelination  at  
White  Matter  was  also  affected.  This  was  probably  happening  because  myelination   is  still   in  
progress  in  White  Matter  at  the  time  when  birth  takes  place  at  term  with  iOL  extending  their  
processes  to  axons  and  forming  the  myelin  sheath  (Back  et  al.,  2002a).  This  process  could  be  
affected  by  excitotoxicity  and  neurotrophic  factors,  among  others  (Jantzie  et  al.,  2015;  Miron  et  
al.,  2013a).  Noteworthy,   iOL  express  NMDA  receptors  in  their  processes   to  get  axonal   inputs  
(Salter  &  Fern,  2005;  Follett,  2004).  Those  NMDA  receptors  are  also  highly  sensitive  to  glutamate  
(Ewald  and  Cline,  2009;  Kirson  et  al.,  1999).  Because  of  that,  the  high  levels  of  glutamate  that  
last   even   a   week   after   the   insult   will   be   particularly   harmful   for   those   oligodendrocytes  
processes.   Intracellular   calcium   concentration   would   rise   exponentially   in   iOL   processes,  
inducing  local  excitotoxicity  which  can  damage  the  processes  without  affecting  the  viability  of  
the  cell  (Follett,  2004;  Salter  and  Fern,  2005;  Volpe,  2009).  That  would  explain  the  myelin  defects  
observed   in   in   the   second   goal   of   our   experiments   in   spite   of   the   preservation   of   mature  
oligodendrocyte  cell  density.    
Summarizing,  because  of  the  increase  oxidative  stress,  glutamate  and  inflammation  observed  
seven  days   after   the   insult,   preOL  population  was   reduced   in  Grey  Matter   after  HI  whereas  
White  Matter  iOL  oligodendrocyte  survived  after  the  insult,  although  with  reduced  myelinating  
activity.  CBD  administration  was  able  to  prevent  both  myelination  impairment  in  White  Matter  
and  hypomyelination  and  mature  oligodendrocyte  loss  in  cortex.  This  work  demonstrates  by  the  
first   time   that   CBD   has   beneficial   effect   on   oligodendrocytes   and   myelination   after   acute  
neonatal   brain   injury,   an  effect   in  which  CBD   reduction  of   the   “deadly   triad”   as  well   as   the  
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modulation  of  astro-­‐  and  microglial  activation  are  likely  playing  key  roles.  CBD  has  proven  to  
protect  both  astrocyte  and  neuron  after  neonatal  damage  in  this  work  and  others  (Lafuente  et  
al.,  2016,  2011;  Pazos  et  al.,  2013)  and  shows  oligoprotective  properties  in  animal  models  of  
Multiple  Sclerosis  (Mecha  et  al.,  2012;  Rahimi  et  al.,  2015).    
3.  ASSESSING  IF  CBD  HYPOMYELINATION  PREVENTION  IS  RELATED  
WITH   BRAIN   CELL   PROLIFERATION   ACTIVATION   AND   GLIAL  
RESPONSE  MODULATION  
  
Beside   its   effects   on   cell   death   signals,   HI   also   triggers   a   proliferative   response   (Kido   and  
Matsumoto,  2016;  Ong  et  al.,  2005;  Plane  et  al.,  2004;  Zhu  et  al.,  2009).  Actually,  enhanced  OPC  
proliferation   has   been   characterized   in   models   of   preterm   brain   damage,   although   the  
maturation  process  of   those  cells   is   interrupted,   remaining  in  an  “arrested  preOL  stage”  and  
eventually  leading  to  hypomyelination  (Buser  et  al.,  2012,  2010;  Segovia  et  al.,  2008).  
The  proliferative  response  was  strong  in  the  SVZ,  one  of  the  main  proliferative  niches  of  brain  
and  responsible  for  generating  OPC  that  lately  migrate  and  differentiate  in  the  different  White  
Matter  areas  (Mao  et  al.,  2013).  Puzzling,  we  observed  that  HI  induced  an  increase  in  the  number  
of  proliferating  cell  24  hours  after  the  insult  in  the  SVZ,  as  has  been  reported  (Ong  et  al.,  2005;  
Plane  et  al.,  2004),  but  in  our  experiments  that  number  was  restored  and  even  decreased  in  HV  
group  one  week  later.  It  has  been  described  that  HI-­‐induced  proliferation  is  localized  in  specific  
areas  of   the  SVZ,  so   that   the  effect   can  be  overlooked  when  the  entire  SVZ  area   is  analyzed  
(Felling  et  al.,  2006).    However,  we  cannot  rule  out  the  possibility  that  our  different  results  were  
due   to   different   species   and   HI   protocol   used.   The   oligo-­‐proliferative   response   was   also  
observed   in  our  model   in  both  corpus  callosum  and  SVZ:      the  population  of  OPC  and  preOL,  
reduced  24  h  after  the  HI  insult,  was  restored  seven  days  later.    The  increase  in  preOL  population  
observed  in  HV  as  compared  to  SHM  group  agreed  with  the  well-­‐known  compensatory  increase  
of  preOL  described  in  models  of  preterm  White  Matter  injury  (Back  et  al.,  2002a;  Buser  et  al.,  
2012;  Segovia  et  al.,  2008).  By  contrast,  the  increment  of  OPC  in  corpus  callosum  is  not  observed  
after  HI  damage  in  models  of  term  brain  injury  (Dizon  et  al.,  2010).  Altogether  those  features  
suggest   that   the   kind   of   proliferative   response   of   oligodendrocyte   is   dependent   on   the  
developmental  stage.    
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Surprisingly,  no  CBD  effects  on  oligodendrocyte  progenitor  or  proliferation  itself  were  observed  
that  could  explain  CBD  prevention  of  hypomyelination,  with  the  exception  made  for  the  increase  
of  Ki67-­‐positive  cell  density  observed  one  week  after  the  insult  in  HC  group.    Similar  results  has  
been  observed   in  HI  newborn  rats   treated  with  hypothermia  after  co-­‐localizing  KI67  with  an  
oligodendrocyte  precursor  marker  (Xiong  et  al.,  2013).  Since  no  differences  were  observed  in  
the   number   of   Olig2   or   Sox10   among   the   different   groups,   it   is   unlikely   that   HC-­‐induced  
proliferative  enhancement   in  White  Matter   corresponded   to   increased  proliferation  of  OPC.  
Rather,  other  cellular  types  should  contribute  to  this  CBD-­‐induced  increased  proliferation.  Some  
candidates   are   astrocytes   or   immune   cells   whose   proliferative   response   as   has   been  
characterized  in  other  brain  regions  (Domowicz  et  al.,  2018;  Kido  and  Matsumoto,  2016;  Zhu  et  
al.,  2009).  Nevertheless,  a  more  detailed  study  of  oligodendrocyte  maturation  stages  and   its  
origin,  as  well  as  other  White  Matter  lesion  area  characterization  should  be  performed  to  further  
characterize  this  response.    
Also  in  agreement  with  what  has  been  previously  reported  (Kido  and  Matsumoto,  2016;  Zhu  et  
al.,  2009),   the  quantification  of  Ki67-­‐positive  population  in  cerebral  cortex  showed  increased  
proliferation  seven  days  after  HI.  However,  when  BrdU  studies  were  performed  in  perilesional  
cortex  no  difference  was  observed  among  groups  seven  days  after  the  insult.  This  divergence  
between  Ki67  and  BrdU  studies  might  be  explained  because  these  techniques  label  different  cell  
populations:  Ki67  is  a  nuclear  protein  which  is  mainly  expressed  during  cell  division  phases,  so  
that  its  antibody  labels  actual  proliferating  cells  (Boddaert  et  al.,  2018;  Gerdes  et  al.,  1991).  By  
contrast,    BrdU  is  an  analogue  nucleotide  which  is  used  to  track  cells  which  were  created  during  
BrdU  injection  period  (Fernández-­‐López  et  al.,  2010;  Magavi  and  MacKlis,  2008).  According  to  
this,   the   aforementioned   results   would   suggest   that   although   there   was   an   increased  
proliferative  activity  exactly  seven  days  after  the  insult,  no  increased  proliferation  took  place  
during  the  fourth,  fifth  and  sixth  days  post-­‐insult.  The  lack  of  increased  proliferation  during  the  
first  days  after  the  HI  episode  might  be  due  to  increased  cell  death  that  would  limit  the  survival  
of  these  new  cells.  In  agreement  with  this  hypothesis,  a  remarkable  rise  of  TUNEL-­‐positive  cells  
was  observed  in  HV  and  HC  groups.  Similar  results  were  found  an  in  vitro  model  of  HI,  where  the  
number  of  BrdU+  cells  were  significantly  lower  in  OGD  than  in  the  control  group  (Ziemka-­‐Nalecz  
et  al.,  2018).    The  double-­‐edged  effect  of  HI  on  proliferation  was  also  observed  in  BDNF  studies,  
in  which  an  increase  of  both  pro  and  mature  isoforms  of  BDNF  was  observed  one  week  after  HI  
independently  of   the   treatment.   The  positive  effects  of  BDNF,   like  neuron  proliferation  and  
protection,      are   associated   to   the  mature   form   (Jiao   et   al.,   2016;   Li   et   al.,   2017);  while   the  
precursor  one,  proBDNF,  is  known  to  limit  neuron  proliferation  and  migration  (Li  et  al.,  2017).    
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Similar  results  to  that  obtained  in  White  Matter  was  observed  in  cortex,  in  which  a  normalization  
of  Olig2+  and  SOX10+  population  was  observed  seven  days  after  HI.  At  this  time-­‐point  no  changes  
in   IGF-­‐1   or   GDNF   brain   concentration   was   found.   Those   molecules   have   well-­‐known  
oligodendrocyte  proliferating  and  maturating  effects  (Broughton  et  al.,  2007;  Li  et  al.,  2015;  Shi  
et   al.,   2014).   The   quantification   of   Ki67+/Olig2+   cells,   corresponding   to   proliferating   OPC,  
confirmed   that   oligodendrocyte   lineage  was   not   being   promoted   seven   days   after   damage,  
despite   the   observed   increase   of   proliferating   cells.   These   results   might   suggest   that   a  
compensatory  oligodendrocyte  proliferative  response  took  place  early  after  the  insult  to  restore  
oligodendrocyte  cell  density,  resulting  in  no  more  oligodendrocyte  proliferation  happening  one  
week   after   damage.   Supporting   this   hypothesis,   a   reduction   of   BrdU+/SOX10+   cells  was   also  
observed  in  HV  animals  despite  of  SOX10+  population  normalization  implying  that  HI  induced  
not   only   an   early   proliferative   but   also   a   quick   differentiation   of   OPC.   That   is   particularly  
interesting  because  the  “arrested  preOL  state”  has  been  correlated  to  an  early  exit  of  the  cycle  
in   OPC   that,   somehow,   affects   the   capacity   of   survival   and   maturation   of   preOL   into   a  
myelinating  oligodendrocyte  (Back  et  al.,  2002a)  (Fig.  50).      
The  aforementioned  results  also  suggest  that  
HI-­‐induced   proliferation   observed   in   HV  
group   seven   days   after   the   insult   might  
involve  other  cellular  lineages.  In  agreement,  
HV   group   showed   higher   Olig2+/GFAP+   cell  
density   that   correspondence   with  
astrogliosis.   Thus,   it   seems   that   astrocyte  
lineage   proliferation   was   promoted   over  
oligodendrocyte   proliferation   seven   days  
after   the  HI   event,   an  effect   similar   to   that  
reported   after   adult   spinal   cord   damage  
(Wang  et  al.,  2011)  (Fig.  50).    
As  opposite  to  the  lack  of  effect  of  CBD  on  
oligodendrocyte  lineage  cell  proliferation  in  
White  Matter,  in  cortex  CBD  administration  
induced   a   rise   of   BrdU+/Olig2+   population  
that   leads   to   the   increase   of   Olig2+   cell  
Figure  50.  Oligodendrocyte  proliferative   response  
induced   by   HI   hypothesis   and   possible   effect   of  
CBD   in   cortex.   Oligodendrocyte   progenitors  
proliferation  is  induced  after  HI  but  its  maturation  is  
impaired,   eventually   leading   to   hypomyelination.  
The  administration  of  CBD  post-­‐HI  is  able  to  prevent  
this  oligodendrocyte  arrested  state  and  consequent  
hypomyelination.  OPC,  oligodendrocyte  progenitor  
cell;   preOL,   pre-­‐oligodendrocyte;   iOL,   immature  




density   seven   days   after   HI.   These   newly   formed   OPC   cells   seems   to   be   driven   into   an  
oligodendrocyte  lineage  as  suggested  by  the  reduction  of  Olig2+/GFAP+  and  increase  BrdU+/Sox+  
ratios   to   levels   similar   to   SHM.   Therefore,   CBD   seems   to   promote   and   sustain   the  
oligodendrocyte  proliferation  response,  limiting  the  pro-­‐astroglial  fate  of  OPCs  induced  by  HI.  
This  can  result  eventually    in  the  protection  of  a  physiological  maturation  of  oligodendrocytes,  
thus   avoiding   the   premature   differentiation   that   might   contribute   to   the   HI-­‐induced    
oligodendrocyte  “arrested  state”  and  subsequent  hypomyelination  (Fig.  50).    
We  observed  that  HI  led  to  a  reduction  of  the  density  of  BrdU+/NeuroD+  cell  density.  Since  global  
density  of  BrdU+  cells  were  similar  in  all  groups,  this  means  that  HI  increased  the  proportion  of  
glial  cells  among  the  BrdU+  cell  population.  In  other  words,  it  means  that  HI  induced  a  pro-­‐glial  
response,   affecting   normal   cortical   maturation.   Such   effect   of   HI   was   prevented   by   CBD  
administration,  suggesting  that  the  beneficial  effect  of  CBD  was  also  affecting  the  proliferation  
of  non-­‐glial  cells  as  neurons.    
Summarizing   those   results,   the   HI   insult   increases   excitotoxicity,   oxidative   stress   and  
inflammation   leading   to   astro-­‐   and   micro-­‐gliosis   that   was   associated   with   increased   preOL  
death.  Likely,  due  to  this  “deadly  triad”  prolonged  feedback  the  reparative  response  after  HI  was  
also  affected,  with  astroglial  lineage  being  preferentially  promoted.  Similarly  to  what  observed  
in  MCAO  model,  CBD  administration  post-­‐HI  was  able  to  reduce  the  three  components  of  the  
deadly  triad  as  well  as  modulate  both  astroglial  and  microglial  response,  resulting  in  a  more  anti-­‐
inflammatory   or   repairing   glia   phenotype,   which   is   involved   in   OPC   protection   and  
oligodendrocyte   differentiation   (Miron   et   al.,   2013b).   Interestingly,   the   switch   of   glial   sate  
towards  an  anti-­‐inflammatory  or  rested  state  is  associated  with  re-­‐  and  myelination  processes  
(Miron  et  al.,  2013b;  Moore  et  al.,  2011).    
Then,  on  the  one  hand,  CBD  would  be  promoting  oligodendrocyte  survival  and  maturation  in  
cerebral  cortex  and  protecting  myelination  in  White  Matter  by  reducing  these  detrimental  HI  
events.  On  the  other  hand,  CBD  would  be  preserving  the  success  of  the  repair  response  induced  
by  HI   promoting   the   proper  maturation   and  myelination   of   the   new   oligodendrocytes.   This  
would  explain   the  protective  effect  of  CBD  on  hypomyelination  and  axonopathy  observed   in  





4.   INVOLVEMENT   OF   CB2   RECEPTOR   ACTIVATION   IN   CBD  
PROTECTIVE  EFFECTS   IN  A  NEWBORN  RAT  MODEL  OF  HYPOXIC-­‐
ISCHEMIC  BRAIN  DAMAGE  
CB2   agonists   have   proved   neuroprotective   effects   in   different  models   of   neurodegenerative  
diseases,  by  similar  glia-­‐modulating  and  anti-­‐inflammatory  effects  to  those  described  for  CBD  in  
this  work  (Espejo-­‐Porras  et  al.,  2018;  Fernández-­‐Ruiz  et  al.,  2007;  López  et  al.,  2018;  Sagredo  et  
Figure   51.   CBD   prevents   hypomyelination   induced   by   HI.   At   PND7-­‐10   cortex   and  White   Matter   are  
populated   by   oligodendroctyes   at   different   maturational   stages   (A).      During   HI   the   “death   triad”,   a  
combination   of   excitotoxicity,   inflammation   and   oxidative   response,   will   damage   oligodendrocytes   of  
both   areas   (B).   In   corpus   callosum,   the   iOL   processes   failed   to   reach   and  myelinated   axon  while   HI  
induceds  cortical  preOLs  death.  Eventually,  this  will  lead  to  a  decrease  hypomyelination  and  axon  loss  in  
both  areas  (C).  By  contrast,  CBD  administration  is  able  to  reduce  these  three  components  of  the  death  
triad  (D),  eventually  allowing  a  correct  oligodendrocyte  maturation  and  myelination  and  therefore,  also  




al.,  2009;  Tolón  et  al.,  2009).  These  facts,  together  with  previous  reports  stating  that  some  of  
the  protective  effects  of  CBD  are  mediated  by  CB2  receptor  activation  (Pazos  et  al.,  2013;  Vilela  
et  al.,  2017),  prompted  us  to  analyze  the  role  of  CB2  receptor  in  CBD  neuroprotection  after  a  
global  hypoxic-­‐ischemic  insult  in  newborn  rats.  
After   testing   the   neuroprotective   effects   of   HU-­‐308,   we   observed   that   CBD   showed   better  
neuroprotective   effects   than   HU-­‐308,   which   might   be   explained   by   the   greater   number   of  
targets  driven  by  CBD.  CB2  expression  is  thought  to  be  limited  to  immune    cells  (Galiègue  et  al.,  
1995;  Núñez  et   al.,   2004;   Turcotte  et   al.,   2016),   such  as  microglia   (Núñez  et   al.,   2004)      and  
monocytes   (Turcotte   et   al.,   2016),   which   are   the   first   infiltrating   cells   to   become   the  
predominant  cell  type  present  in  brain  in  the  first  24  hours  post-­‐insult  (Hagberg  et  al.,  2015;  
Winerdal   et   al.,   2012).      Therefore,  HU-­‐308  effects   shall   be   restricted   to   these   immune   cells  
activation.    The  expression  of  CB2  receptor  in  astroglial  cells  is  more  controversial  as  long  as  the  
physiological  state  is  concerned  (Dowie  et  al.,  2014;  Fernández-­‐Trapero  et  al.,  2017b),  although  
CB2   receptor   expression   has   been   detected   in   activated   astrocytes   in   neurodegenerative  
conditions  (Benito  et  al.,  2007;  Espejo-­‐Porras  et  al.,  2018;  Sagredo  et  al.,  2009).  In  any  case,  in  
our  experiments  HU-­‐308  was  unable  to  reduce  neither  the  hyperintense  area,  which  is  at  least  
in   part   due   to   the   astroglial   response   one  week   after   damage   (Justicia   et   al.,   2008)   nor   HI-­‐
induced  TNFa  production  increase.  Overall,  these  results  suggest  that  CB2  agonism  would  have  
a  low  effect  on  astroglia  in  a  neonatal  model  of  HI.    
CB2   receptor  activation  may  be  also   involved   in   the  anti-­‐inflammatory  effects  of  CBD.   In   this  
work,  the  administration  of  the  CB2  antagonist  SR2  prior  CBD  injection  reversed  some  of  the  CBD  
neuroprotective  effects,  in  particular  those  related  with  motor  reflex  performance,  brain  volume  
of  damage  and  hyperintense  area.  Since  those  results  were  associated  to  the  reversal  of  CBD-­‐
induced  TNFa  release  reduction  by  the  pre-­‐administration  of  SR2,  it  can  be  suggested  that  CB2  
receptor   activation   was   somehow   involved   in   the   anti-­‐inflammatory   effect   of   CBD   in   the  
neonatal  model  of  HI.    Previous  works  of  our  group  reported  that  CB2  receptor  activation  was  
involved  in  CBD  neuroprotection  in  a  piglet  model  of  acute  HI  brain  damage  (Pazos  et  al.,  2013).    
There  are  several  explanations  that  might  explain  CBD  and  CB2  interaction.  A  direct  binding  to  
the  canonical  site  of  CB2  receptor  can  be  ruled  out  since  the  concentration  peak  of  CBD  in  brain  
after  subcutaneous  injection  did  not  achieve  the  micromolar  range  needed  for  this  interaction  
(McPartland  et  al.,  2014;  Pazos  et  al.,  2012).  However,  binding  studies  are  usually  performed  
using  human  CB2  receptor  but  binding  characteristics  of  rodent  and  human  receptor  might  be  




et   al.,   2002;   Shire  et   al.,   1996).   This  direct   action  on  CB2   receptor   is   very  unlikely,   however,  
because  if  CBD  would  act  as  a  direct  agonist  of  CB2  receptor  a  similar  neuroprotective  effect  
would  have  been  expected  after  HU-­‐308  administration,  particularly  having  into  account  the  key  
role  of  the  conversion  of  microglia  cells  and  astrocytes  into  anti-­‐inflammatory  or  non-­‐activated  
states   in   the  neuroprotective  effects  of  CBD,  as   it  has  been  extensively  demonstrated   in   the  
present  work.  
Another   possible  mechanism   could   be   the   recently   published   activity   of   CBD   as   a   negative  
allosteric  modulator  of  the  cannabinoid  receptor  (Laprairie  et  al.,  2015;  Martínez-­‐Pinilla  et  al.,  
2017).    That  would  be  particularly  interesting  since  the  levels  of  AEA  and  2-­‐AG,  which  activate  
CB2   receptor,   are   remarkably   increased   after   a   HI   insult   (Pazos   et   al.,   2013),   and   2-­‐AG  
overexpression  after  stroke  has  been  associated  to  a  poorer  outcome  and  microgliosis  (Jalin  et  
al.,  2015;  Shearer  et  al.,  2018).  Another  hypothesis  is  that  CB2  and  5-­‐HT1A  receptors  could  form  
an   heteromer,   like   several   other   G   protein-­‐coupled   receptors.   The   physical   union   of   both  
receptors,  which  constitute  the  basis  of  an  heteromer,  has  been  proved  in  cells  transfected  with  
both  receptors  (Pazos  et  al.,  2013).  If  such  heteromer  existed  and  was  functional   in  newborn  
brain,  the  involvement  of  CB2  on  CBD  actions  might  actually  be  the  expression  of  a  cross-­‐agonism  
between  CB2  and  5-­‐HT1A  receptors  in  the  heteromer  after  CBD  activated  the  5-­‐HT1A  (Russo  et  al.,  
2005).    Nevertheless,  further  experiments  are  warranted  to  assess  the  role  of  CB2  receptors  in  
CBD  neuroprotection.   Those  experiments   should   include   the  glial   characterization,   since  glia  
modulation  seems  to  play  a  pivotal  role  in  CBD  effect  and  CB2  is  highly  expressed  in  those  cells  
(Fernández-­‐Trapero  et  al.,  2017a;  Núñez  et  al.,  2004),  as  well  as  the  study  of  other  important  
immune  cells  involved  like  monocytes/macrophages,  which  infiltrate  the  brain  after  the  insult  
and   participate   in   damage   evolution   (Hagberg   et   al.,   2015;   Winerdal   et   al.,   2012).   Finally,  
another  very  interesting  option  will  be  to  use  a  knock-­‐out  mouse  model  for  CB2  receptor.  
CBD  is  also  activating  other  receptors.  Firstly,  CBD  shows  a  great  affinity  for  5-­‐HT1A  receptors  
(Russo  et  al.,  2005),  whose  activation  by  specific  agonists  after  HI  insults  has  been  associated  to  
a  reduced  brain  volume  of  damage  (Johansen  et  al.,  2014)  by  reducing  reactive  astrocytes  and  
limiting  neuronal  damage  after  the  insult  (Ramos  et  al.,  2004)  as  well  as  by  inducing  hypothermia  
(Johansen  et  al.,  2014).  5-­‐HT1A    activation  is  involved  in  CBD  positive  hemodynamic  effects  (Pazos  
et  al.,  2013)  and  CBD  protection  of  blood  brain  barrier  stability  (Hind  et  al.,  2016).  The  latter  
results  in  a  reduction  of  HI-­‐induced  brain  oedema,  an  effect  which  could  explain  why  CBD  but  
not  HU-­‐308  reduced  the  hyperintense  area  as  observed  in  MRI  one  week  after  damage.  CBD  




effect   for   post-­‐HI   insult   recover   of   the   newborn   (Fogaça   et   al.,   2014).   Another   important  
receptor  probably  involved  in  CBD  neuroprotective  effects  is  the  adenosine  receptor  A2A  (Carrier  
et  al.,  2006),  which  is  expressed  in  microglia  (Carrier  et  al.,  2006),  in  neurons  (Kerkhofs  et  al.,  
2018)  and  in  astrocytes  (Cervetto  et  al.,  2018)  and    participates  in  the  regulation  of  glutamatergic  
synapses  (Cervetto  et  al.,  2018;  Kerkhofs  et  al.,  2018).  In  an  in  vitro  model  of  HI  brain  damage  
CBD   A2A   receptor   activation   is   involved   in   CBD-­‐induced   reduction   of   excitotoxicity   and  
inflammation  (Castillo  et  al.,  2010).    Also,  CBD  is  a  potent  agonist  of  PPARg  (Hegde  et  al.,  2015;  
O’Sullivan  et  al.,  2009)  which  could  explain  an  even  stronger  anti-­‐inflammatory  effect  than  CB2  
agonists.  PPARg  is  expressed  in  astrocytes  (Chistyakov  et  al.,  2015),  microglia  (Wen  et  al.,  2018)  
and   macrophages   (Heming   et   al.,   2018),   neurons   (Warden   et   al.,   2016)   and   neural  
stem/progenitor  cells  (Yuan  et  al.,  2017).     PPARg  activation  decreases  inflammation  (Villapol,  
2018;  Wen  et  al.,  2018),  promotes  phagocytosis  (Heming  et  al.,  2018),  stimulates  that  progenitor  
cells  differentiate  into  oligodendrocytes  or  neurons  instead  astrocytes  (Villapol,  2018;  Yuan  et  
al.,  2017)  and  promotes  the  M2  phenotype  in  microglia  (Wen  et  al.,  2018),  effects  that  could  
explain  some  of    the  results  obtained  in  this  study.  Besides,    PPARg  activation  plays  a  key  role  in  
CBD  effects  on  maintaining  BBB  stability  after  hypoxic-­‐ischemic  insult  (Hind  et  al.,  2016).    
In  this  set  of  experiments  no  differences  were  observed  regarding  oxidative  stress,  which  was  
probably  due  to  the   intrinsic  variability  of   the  experiment  having  into  account   that  oxidative  
stress  was  reported  in  other  experiments  in  this  work  as  well  as  in  previously  reported    similar  
HI  neonatal  models  (Blanco  et  al.,  2017;  Pazos  et  al.,  2013).    
In  conclusion,  in  a  neonatal  rat  model  of  HI  CBD  administration  was  more  effective  than  a  direct  
CB2   receptor   agonist,   with   no   additive   effects   after   combining   both   substances.   CBD  
neuroprotective  effects  were  at  least  in  part  mediated  by  CB2  receptor  activation,  which  seems  
to  be  somehow  involved  in  the  CBD  anti-­‐inflammatory  effects.  The  participation  of  CB2  receptors  
in  CBD  effects  has  been  already  suggested   in  previous  reports  on  neonatal  HI  brain  damage,  
although  the  exact  mechanisms  involved  has  not  been  elucidated.  Some  hypothesis  to  explain  
why  CB2  receptors  are  involved  in  the  effects  of  a  substance  like  CBD,  which  is  not  considered  a  
direct  agonist  of   those  receptors,   include  the  existence  of  CB2-­‐5HT1A   receptor  heteromers   in  
neonatal   brain   tissue   after   HI   or   the   activity   of   CBD   as   an   allosteric   modulation   of   the  
cannabinoid  receptor.
  
     
















1.   Neonatal  hypoxic-­‐ischemic  (HI)  insult  led  to  brain  injury  resulting  in  long-­‐lasting  motor  
and  cognitive  sequelae,  dependent  on  the  areas  affected  by  the  insult.  As  observed  one  
week  after  the  insult  HI  events  led  to  brain  volume  loss  that  correlated  with  acute  cell  
death   in   a   manner   related   with   excitotoxicity,   increased   oxidative   stress   and  
inflammation.  Therefore,  HI  led  to  a  remarkable  decrease  on  neuronal  population  and  
myelin  content  that  were  not  recovered  one  month  after  the  insult.  
2.   Global  HI  brain  insult  led  to  hypomyelination  in  White  and  Grey  Matter,  associated  to  
axonal   loss,   which   correlated   with   motor   and   cognitive   disabilities.   Myelination  
impairment   was   region-­‐specific,   probably   because   of   the   different   oligodendrocyte  
maturational  stage  in  the  different  regions.  
3.   Neonatal   HI   brain   insult   triggered   a   strong   inflammatory   response   characterized   by  
micro-­‐  and  astrogliosis   lasting  for  weeks  after  the  insult.   In  both  cases  cell  responses  
were  characterized  by  the  increase  in  the  number  of  cells  and  the  transformation  of  cells  
into   an   activated   state.   Activation   of   astrocytes   led   to   a   functional   impairment   and  
eventually   led   to   the   development   of   a   glial   scar,   corresponding   to   an   increased  
hyperintense  area  as  observed  by  MRI  one  month  later.  
4.   Post-­‐insult  CBD  administration  blunted  the  short-­‐  and  long-­‐term  motor  and  cognitive  
impairment  induced  by  either  the  global  or  the  focal  hypoxic-­‐ischemic  brain  insult.  CBD  
neuroprotective   effects   were   linked   to   the   preservation   of   neuronal   population   by  
reducing  HI-­‐induced  cell  death  in  a  manner  related  with  the  reduction  of  excitotoxicity,  
oxidative  stress  and  inflammation.  
5.   Post-­‐HI  administration  of  CBD  also  modulated  the  astroglial  and  microglial   response,  
decreasing  the  gliosis  and  promoting  a  non  pro-­‐inflammatory  state  in  both  cell  types  as  
observed  in  the  short-­‐  and  long-­‐term  after  the  insult.  Furthermore,  CBD  prevented  the  
astroglial  function  impairment  and  the  preferential  development  of  glial  precursors  into  
astroglial  instead  of  oligodendroglial  lineage  cells  induced  by  the  HI  insult.  
6.   Post-­‐insult   CBD   administration   blunted   the   HI-­‐induced   hypomyelination   and  
axonopathy   in   a   region-­‐specific  manner.   In   all   regions   CBD   treatment   prevented  HI-­‐
induced  axonal   loss   and  preserved   the  normal  myelination  of   axons.   In  Grey  Matter  
those  effects  were  associated  with  the  preservation  of  a  proper  maturation  of  immature  
glial  cell  whereas  in  White  Matter  they  were  associated  with  the  preservation  of  the  
proper  axon  myelination  by  oligodendrocytes.  
7.   CB2  receptor  activation  was   involved   in  CBD  neuroprotection  after  neonatal  hypoxic-­‐




CBD  by  CB2  receptor  antagonist.  However,  the  comparison  with  the  effects  of  pure  CB2  
receptor  agonists   indicates   that   it   is  unlikely   that  CBD  neuroprotection  was  due   to  a  
direct  CB2  activation  and  that  the  activation  of  such  receptors  cannot  be  the  only  way  
to  explain  CBD  neuroprotective  effects.  
     















1.   El   daño   hipóxico-­‐isquémico   neonatal   indujo   un   daño   cerebral   asociado   a   secuelas  
motoras  y  cognitivas  a  largo  plazo,  que  van  a  depender  de  la  zona  afectada.  Como  se  
observó,  el  daño  HI  condujo  a  una  pérdida  de  volumen  cerebral  asociada  a  una  muerte  
celular  aguda  relacionada  con  la  excitotoxicidad,  el  incremento  del  estrés  oxidativo  y  la  
inflamación.  En  consecuencia,  la  HI  produjo  una  disminución  de  la  población  neuronal  y  
del  contenido  de  mielina  que  aún  pudo  ser  observado  un  mes  después  de  la  lesión.  
2.   El  daño  HI  global  indujo  una  hipomielinización  en  la  Sustancia  Blanca  y  Gris,  asociada  a  
la   pérdida   axonal   y   que   se   correlaciona   directamente   con   la   discapacidad  motora   y  
cognitiva.  La  alteración  de  la  mielinización  se  produjo  de  manera  distinta  en  cada  región,  
probablemente   por   el   diferente   estado  madurativo   de   los   oligodendrocitos   en   cada  
área.  
3.   El  daño  HI  neonatal  promovió  una  fuerte  respuesta  inflamatoria  caracterizada  por  una  
astro-­‐   y   microgliosis   que   se   prolongó   durante   semanas   tras   la   lesión.   En   ambas  
poblaciones  esta  respuesta  estuvo  caracterizada  por  un  aumento  del  número  de  células  
y  por  un  fomento  del  estado  activado.  La  activación  astrocitaria  condujo  a  una  pérdida  
de   función  y,   finalmente,  al  desarrollo  de   la  cicatriz  glial,  que  se  correspondió  con  el  
incremento   del   volumen   del   área   hiperintensa   observado   por   resonancia  magnética  
nuclear  un  mes  después  de  la  lesión.  
4.   La   administración   del   CBD   tras   el   daño   previno   el   desarrollo   de   secuelas  motoras   y  
cognitivas  a  medio  y  largo  plazo.  Los  efectos  protectores  del  CBD  se  relacionaron  con  la  
preservación   de   la   población   neuronal   mediante   la   reducción   de   la   muerte   celular  
causada  por  la  HI,  al  reducir  la  excitotoxicidad,  el  estrés  oxidativo  y  la  inflamación.  
5.   La  administración  post-­‐HI  del  CBD  también  moduló  la  respuesta  astroglial  y  microglial,  
disminuyendo  la  gliosis  y  promoviendo  el  estado  no  pro-­‐inflamatorio  en  ambos  tipos  
celulares  como  pudo  observarse  a  corto  y  largo  plazo.  Es  más,  el  CBD  previno  la  pérdida  
de   la   función   astrocitaria   y   el   fomento   preferencial   del   linaje   astrocitario   sobre   el  
oligodendrocítico,  como  consecuencia  de  la  HI.  
6.   La  administración  de  CBD  tras  el  daño  previene   la  hipomielinización  y  axonopatía  de  
manera  específica  en  cada  región.  En  ambas  áreas  el  tratamiento  con  CBD  previno  la  
pérdida   axonal   y   permitió   la   correcta   mielinización   axonal.   En   Sustancia   Gris   estos  
efectos  estuvieron  asociadas  a   la  preservación  de   la  maduración  de   la  glia   inmadura  
mientras   que   en   Sustancia   Blanca   se   relaciono   principalmente   con   el   proceso   de  
mielinización.  
7.   Se  puede  concluir  que   la  activación  del   receptor  CB2  participó  en   la  neuroprotección  




protectores  del  CBD  por  la  administración  del  antagonista  del  receptor.  Sin  embargo,  la  
comparación   con   el   agonista   puro   de   CB2   indica   que   es   poco   probable   que   la  
neuroprotección  del  CBD  se  deba  a  una  activación  directa  del  receptor  y  que  debe  haber  
más  dianas  o  mecanismos  implicados  en  la  neuroprotección  ofrecida  por  el  CBD.
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